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Summary 
Ochratoxin A (OTA) is a mycotoxin produced by certain fungal species of the genera 
Aspergillus and Penicillium. OTA is well known as a contaminant of a large variety of 
foods, feeds and beverages worldwide. Cereal-based foodstuffs are the most important 
OTA-contaminated foods for human consumption. Wine has been shown to be frequently 
contaminated with OTA and thus contributes significantly to human exposure to this 
mycotoxin. Studies in rodents show that exposure to OTA promotes the development of 
kidney and liver tumours. The International Agency for Research on Cancer (IARC) 
classified OTA in the group 2B (possibly carcinogenic to humans), because there are 
insufficient data about its carcinogenicity to humans. 
 
This PhD thesis had two general objectives: i) to assess the bioaccessibility of OTA in red 
wine, and ii) to assess OTA cytotoxicity, genotoxicity and gene expression modulation. 
 
With regard to OTA bioaccessibility, a study was conducted with red wine at three 
contamination levels (1.0-4.0 µg/L) using an in vitro dynamic digestion model. The results 
showed that OTA is highly bioaccessible in the gastric chyme (103-128%) but much less 
bioaccessible in the intestinal chyme (<26%). The digestion system was also used to 
evaluate the transformation of OTA to OTα; the amount of OTα generated in gastric 
digestion was found to range from 5.1% to 19.1%, while the amount generated in 
intestinal digestion did not exceed 5%. 
 
OTA cytotoxicity was evaluated by means of different in vitro assays with two human cell 
lines (Caco-2 and HepG2 cell lines) and primary human lymphocytes. Viability assays 
showed that low doses of OTA (0.075-45 µM) did not cause viabilities below 65%. At the 
same doses, significant damage was observed in the membrane integrity of differentiated 
Caco-2 cells and a cytostatic effect in lymphocytes treated with 15 µM OTA. 
 
In Caco-2 cells, the effect of exposure to low OTA doses, alone and in combination with 
the mycotoxin deoxynivalenol (DON), was evaluated, as was the apparent protective 
effect of the antioxidant resveratrol (RES), a natural compound found in red wine. Co-
exposure to both mycotoxins significantly increased the cytotoxicity of both compounds in  
vi 
Caco-2 cells, without an increase in the generation of reactive oxygen species (ROS). Co-
exposure to OTA or DON with RES did not diminish the cytotoxicity; on the contrary, an 
increase in the cytotoxicity was observed that was not associated with an increase in ROS 
production. 
 
OTA doses lower than 45 µM were used to assess the gene expression modulation of the 
xenobiotic transformation system (CYP P450 system genes), as well as of the COX-2, LOX-
5, and MRP2 genes. To this end, the gene expression level was investigated in a co-
culture system of Caco-2 and HepG2 (transwell culture plates) to simulate intestinal 
absorption and hepatic metabolism. The results suggest that OTA was able to strongly 
modulate gene expression over time, and that the time of exposure to OTA had a greater 
effect on expression gene and membrane integrity (as measured by transepithelial 
electrical resistance) than the dose of toxin used in the treatments. 
 
With regard to the OTA genotoxicity assessment, OTA was shown to be a genotoxic 
mycotoxin, because it was able to induce micronucleus (MN) formation in human 
lymphocytes. Moreover, in a comet assay, OTA increased the percentage of DNA in the 
comets and caused an accumulation of DNA in the comets’ tails by delaying the DNA 
repair pathway. 
 
Our results show that further research is needed to understand the mode of action of 
OTA, especially considering its possible association with human cancer development. Our 
findings on OTA cytotoxicity and genotoxicity at low doses support the theory that OTA 
should be considered a non-threshold carcinogen. 
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Resumen 
La ocratoxina A (OTA) es una micotoxina producida por varias especies de mohos de los 
géneros Aspergillus y Penicillium. Es bien conocido que la OTA es una de las micotoxinas 
más ubicuas, ya que se ha encontrado a nivel mundial en una gran variedad de alimentos 
tanto de origen vegetal como animal. Los productos para consumo humano elaborados a 
base de cereales son el grupo de alimentos que presenta una mayor contaminación por 
OTA. El vino es un alimento que se encuentra contaminado con frecuencia con OTA y que 
puede tener una importante contribución a la exposición humana a esta micotoxina. 
Estudios en roedores han demostrado que la OTA es capaz de promover el desarrollo de 
tumores renales y hepáticos. La Agencia Internacional para la Investigación del Cáncer 
(IARC) ha clasificado a la OTA en el grupo 2B (posible compuesto carcinógeno para el 
hombre), porque los datos que demuestran la carcinogenicidad de la OTA en humanos 
aún son insuficientes.  
 
Esta tesis doctoral tuvo dos objetivos generales: i) evaluar la bioaccesibilidad de la OTA en 
vino tinto, y ii) evaluar la citotoxicidad, genotoxicidad y la modulación de la expresión 
génica por la OTA. 
 
En el caso de la bioaccesibilidad de la OTA, se llevó a cabo un estudio en vino tinto con 
tres niveles de contaminación de OTA (1,0-4,0 µg/L) en un sistema in vitro de digestión 
dinámica simulada. Los resultados de este estudio mostraron que la OTA es altamente 
bioaccesible en jugo gástrico (103-128%), pero es poco bioaccesible en el jugo intestinal 
(<26%). Adicionalmente, en este sistema se evaluó también la transformación de la OTA 
a OTα, encontrando que la cantidad de OTα generada en la digestión gástrica varió entre 
el 5,1-19,1%, mientras que en el compartimento intestinal no excedió del 5%. 
 
La evaluación de la citotoxicidad de la OTA fue llevada a cabo usando varios ensayos in 
vitro, y tres tipos de cultivos celulares (linfocitos humanos, y las líneas celulares Caco-2 y 
HepG2). Los ensayos de viabilidad mostraron que bajas dosis de OTA (0,075-45 µM) no 
causan viabilidades por debajo del 65%. Aplicando estas mismas dosis, tras 24 h de 
exposición se detectó un daño significativo en la integridad de la membrana celular de las 
células Caco-2 diferenciadas y un efecto citostático en linfocitos humanos tratados con 15 
µM de OTA. 
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En el caso de las células Caco-2, se estudió el efecto de la exposición a bajas dosis de 
OTA, sola o de forma conjunta con la micotoxina deoxinivalenol (DON), y se evaluó el 
presunto efecto protector del antioxidante resveratrol (RES), compuesto naturalmente 
presente en el vino tinto. La co-exposición a ambas micotoxinas aumentó 
significativamente la citotoxicidad de ambos compuestos en las células Caco-2, sin 
aumentar por ello la producción de especies reactivas del oxígeno (ERO). La co-exposición 
de OTA o DON con RES no disminuyó la citotoxicidad, más bien al contrario, se observó 
un aumento de la citotoxicidad no asociado con un aumento en la producción de ERO. 
 
Se usaron dosis bajas de OTA, inferiores a 45 µM, para evaluar la expresión de genes del 
sistema biotransformador de xenobióticos (genes del grupo CYP P450), así como la de los 
genes COX-2, LOX-5, y MRP2. Para ello se empleó un sistema de co-cultivo de células 
Caco-2 y HepG2 (placas de cultivo transwell) para simular la absorción intestinal y el 
metabolismo hepático. Los resultados indican que la OTA es capaz de modular 
fuertemente la expresión de los genes estudiados a lo largo del tiempo, teniendo, por lo 
general, el tiempo de exposición a la OTA un mayor efecto sobre la modulación de los 
genes y la integridad de la membrana (medida por la resistencia eléctrica transepitelial) 
que las diferentes dosis de toxina utilizadas en los tratamientos. 
 
En cuanto a la evaluación de la genotoxicidad de la OTA, se ha demostrado que la OTA es 
un micotoxina genotóxica capaz de inducir formación de micronúcleos en linfocitos 
humanos, así como de, en un ensayo cometa, incrementar el porcentaje de ADN en el 
cometa, y causar la acumulación del mismo en las colas de los cometas mediante un 
retraso en el sistema de reparación del ADN.  
 
Los resultados obtenidos indican que se deben realizar mayores esfuerzos para entender 
el modo de acción de la OTA, especialmente teniendo en cuenta su posible relación con el 
desarrollo del cáncer en los seres humanos. Los hallazgos sobre la citotoxicidad y 
genotoxicidad de la OTA a bajas dosis apoyan la teoría de que la OTA debería de ser 
considerada un carcinógeno sin umbral. 
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Resum 
L’ocratoxina A (OTA) és una micotoxina produïda per vàries espècies de fongs del gènere 
Aspergillus i Penicillium. L’OTA és una de les micotoxines més ubiques, ja que a nivell 
mundial s’ha trobat en una gran varietat d’aliments tant d’origen vegetal com d’animal. Els 
productes per a consum humà elaborats a base de cereals són el grup d’aliments que 
presenta una major contaminació d’OTA. El vi és un altre aliment que freqüentment es 
troba contaminat amb OTA i que pot tenir una important contribució en quan a l’exposició 
humana d’aquesta micotoxina. Estudis realitzats en rosegadors  han demostrat que l’OTA 
és capaç de promoure el desenvolupament de tumors renals i hepàtics. L’Agència 
Internacional per a la Investigació del Càncer (IARC) ha classificat l’OTA dins el grup 2B 
(possible compost carcinogen per als humans), ja que les dades que demostren la 
carcinogenicitat de l’OTA en humans encara són insuficients.   
Aquesta tesi doctoral consta de dos objectius generals: i) avaluar la bioaccessibilitat de 
l’OTA en vi negre i, ii) avaluar la citotoxicitat, genotoxicitat i la modulació de l’expressió 
genètica per a l’OTA.  
En el cas de la bioaccessibilitat de l’OTA, es va dur a terme un estudi en vi negre amb tres 
nivells de contaminació d’OTA (1,0-4,0 µg/L) en un sistema in vitro de digestió dinàmica 
simulada. Els resultats d’aquest estudi van demostrar que l’OTA és altament bioaccessible 
en suc gàstric (103-128%) però és poc bioaccessible en el suc intestinal (<26%). 
Addicionalment, en aquest mateix sistema es va avaluar la transformació de l’OTA a OTα i 
es va observar que la quantitat de OTα generada durant la digestió gàstrica va variar 
entre el 5,1-19,1%, mentre que en el compartiment intestinal no va excedir el 5%. 
L’avaluació de la citotoxicitat de l’OTA es va dur a terme mitjançant diversos assajos in 
vitro i tres tipus de cultius cel·lulars (els limfòcits humans i les línies cel·lulars Caco-2 i 
HepG2). Els assajos de viabilitat van demostrar que baixes dosis d’OTA (0,075-45 µM) no 
causen viabilitats per sota del 65%. Aplicant aquestes mateixes dosis, després de 24 hores 
d’exposició, es va detectar un dany significatiu en la integritat de la membrana cel·lular de 
les cèl·lules Caco-2 diferenciades i un efecte citostàtic en els limfòcits humans tractats 
amb 15 µM d’OTA. 
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En el cas de les cèl·lules Caco-2, es va estudiar l’efecte de l’exposició a baixes dosis 
d’OTA, sola o de forma conjunta amb la micotoxina deoxinivalenol (DON), i es va avaluar 
el presumpte efecte protector de l’antioxidant resveratrol (RES), el qual es troba 
naturalment present en el vi negre. La co-exposició a ambdues micotoxines va augmentar 
significativament la citotoxicitat de tots dos compostos en les cèl·lules Caco-2, sense 
produir un augment de les espècies reactives de l’oxigen (ERO). La co-exposició de l’OTA 
o el DON amb el ROS no va disminuir la citotoxicitat, al contrari, es va observar un 
augment de la citotoxicitat no associat a un augment en la producció de les ERO. 
Es van utilitzar dosis baixes d’OTA, inferiors a 45 µM, per avaluar l’expressió dels gens del 
sistema biotransformador de xenobiòtics (gens del grup CYP P450), així com la dels gens 
COX-2, LOX-5 i MRP2. Amb aquest objectiu es va utilitzar un sistema de co-cultiu de 
cèl·lules Caco-2 i HepG2 (plaques de cultiu transwell) per a simular l’absorció intestinal i el 
metabolisme hepàtic. Els resultats indiquen que l’OTA té gran capacitat per modular 
l’expressió dels gens estudiats al llarg del temps. En general es va observar que el temps 
d’exposició a l’OTA tenia un major efecte sobra la modulació dels gens i la integritat de la 
membrana (mesurada mitjançant la resistència elèctrica transepitelial) que no pas les 
diferents dosis de toxina utilitzades en els tractaments. 
En relació a l’avaluació de la genotoxicitat de l’OTA, s’ha demostrat que l’OTA és una 
micotoxina genotòxica capaç d’induir la formació de micronuclis en els limfòcits humans, 
així com, en un assaig cometa, incrementar el percentatge d’ADN en el cometa i provocar 
la seva acumulació en les cues dels cometes mitjançant un retràs en el sistema de 
reparació de l’ADN. 
Els resultats obtinguts indiquen que s’han d’invertir més esforços per tal d’entendre el 
mode d’acció de l’OTA, especialment tenint en compte la seva possible relació amb el 
desenvolupament del càncer en humans. Les troballes en referència a la citotoxicitat i la 
genotoxicitat de l’OTA a baixes dosis recolzen la teoria que l’OTA hauria de ser 
considerada carcinogènica sense llindar. 
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1.1 Introduction to mycotox ins 
Mycotoxins are secondary metabolites produced by filamentous fungi that are capable of 
causing disease and death in humans and animals. The term “mycotoxin” derives from the 
Greek word mycos, meaning mould, and the Latin word toxicum, meaning poison. Of 
natural origin, limited taxonomic distribution and, usually, relatively low molecular weight, 
mycotoxins are not considered to have an obvious function in the producer species, 
although it is generally accepted that their production could provide an ecological 
advantage. Mycotoxin production often occurs under stressful conditions for the mould, 
and they are sometimes produced by growing colonies approximately at the time of 
sporulation (Bennett and Bentley, 1989; Calvo et al., 2002). Most of the known 
mycotoxins are produced by various species in the fungal genera Aspergillus, Penicillium, 
Fusarium and Alternaria. A single mycotoxin can be produced by multiple fungal species, 
and a single fungal strain can produce multiple types of mycotoxins. If conditions are 
favourable, moulds can grow in crops and produce mycotoxins directly in the field, as well 
as during the harvest, drying and storage. Because certain chemical, physical and 
biological conditions affect fungal growth and mycotoxin production, the distribution of 
mycotoxins in foodstuffs is expected to vary from year to year, depending on the 
production processes used (FAO, 2001; Richard, 2007). 
 
Exposure to mycotoxins is primarily through ingestion, although it can also occur through 
other pathways, such as inhalation and contact. Mycotoxins can produce both acute and 
chronic toxicities, with symptoms ranging from deleterious effects on the gastrointestinal 
tract, the cardiovascular, pulmonary or central nervous systems, or other internal organs 
to death (FAO, 1991; FAO, 2001). Diseases and symptoms caused in humans or animals 
by exposure to mycotoxins are known as mycotoxicoses. Chronic toxicity is of special 
concern for human health since human mycotoxicoses are both less understood and less 
clearly defined than animal mycotoxicoses, most of which have been experimentally 
confirmed (Bennett and Klich, 2003; Smith et al., 1995). 
 
By the early twenty-first century, more than 300 mycotoxins had been identified, produced 
by approximately 350 species of fungi (Betina, 1989; Richard, 2003). Today, the number 
is even higher. In 2003, Bennett and Klich estimated that the number of mycotoxins is 
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closer to 400, and many have since been identified, although the exact number has yet to 
be accurately determined. The International Agency for Research on Cancer (IARC) has 
evaluated the toxicity of the most important of these toxins (Table 1) (IARC, 1993), and 
the European Union (EU) has implemented regulations on the maximum allowable limits of 
the main mycotoxins in foods and feeds (Commission Regulation, 2006ab; 2010). 
Scientific attention has tended to focus on those mycotoxins that have proven to be 
carcinogenic and/or toxic in other ways, such as aflatoxins (mainly the aflatoxins B1, B2, 
G1, G2 and M1), fumonisins (mainly fumonisins B1 and B2), ochratoxin A, patulin, 
trichothecenes (mainly deoxynivalenol and the T-2 and HT-2 toxins), and zearalenone. 
As this PhD thesis is focused on ochratoxin A, the following sections will provide a more 
detailed description of this toxin. 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
Table 1. Carcinogenic risk of some mycotoxins evaluated by the IARC (IARC, 2003). 
Mycotoxin Evidence of carcinogenicity Overall 
evaluation of 
carcinogenicity 
to humans 
In humans In animals 
    
Naturally occurring mixtures of 
aflatoxins  
S S Group 1 
Aflatoxin B1 S S Group 1 
Aflatoxin B2  L  
Aflatoxin G1  S  
Aflatoxin G2  I  
Aflatoxin M1 I S Group 2B 
Ochratoxin A I S Group 2B 
Toxins derived from F. 
moniliforme 
I S Group 2B 
Naturally occurring mixtures of 
fumonisins 
I   
Fumonisin B1  S Group 2B 
Fumonisin B2  I  
Fusarin C  L  
T-2 toxin  L  
Toxins derived from F. 
verticillioides 
I S Group 2B 
Toxins derived from F. 
graminearum, F. culmorum, F. 
crookwellense 
I  Group 3 
Zearalenone  L  
Deoxynivalenol  I  
Nivalenol   I  
Fusarenone-X  I  
Patulin I  Group 3 
Degrees of evidence: S = sufficient, I = inadequate; L = limited; N = negative. Group 1: 
carcinogenic to humans; Group 2A: probably carcinogenic to humans; Group 2B: possibly 
carcinogenic to humans; Group 3: not classifiable as to its carcinogenicity to humans; 
Group 4: probably not carcinogenic to humans. 
 
 
1.2 Ochratoxins 
Ochratoxins are a small group of chemically related toxic fungal metabolites produced by 
several species of the Aspergillus and Penicillium genera. Chemically, ochratoxins are weak 
organic acids consisting of dihydroisocoumarin linked to β-phenylalanine (Figure 1). There 
are three major ochratoxins, designated as ochratoxin A, B and C. According to the 
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literature, ochratoxin A (OTA) and ochratoxin B (OTB) occur frequently in mouldy products 
(Li et al., 1997; K J van der Merwe et al., 1965). OTB is the dechlorinated analogue of 
OTA. The major metabolite of OTA is ochratoxin alpha (OTα), and the dechlorinated 
isocoumarin of OTB is ochratoxin β (ΟΤβ); neither metabolite is linked to phenylalanine. 
The ethyl ester of OTA is ochratoxin C (OTC) (Moss, 1996; Xiao et al., 1995). The most 
important, toxic and economically significant ochratoxin is OTA (Li et al., 1997; K J van der 
Merwe et al., 1965). 
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Structure  Compound  R identity 
R1 R2 R3 R4 R5 
a OTα Cl H H H - 
a OTβ H H H H - 
b OTA Cl H H H H 
b OTB H H H H H 
b OTC Cl H H H CH3CH3 
b 4R-OH-OTA Cl H H OH H 
b 4S-OH-OTA Cl H OH H H 
b 4-OH-OTA H H H OH H 
b 10-OH-OTA Cl OH H H H 
Figure 1. Molecular structure of the major ochratoxins naturally produced by filamentous 
fungi. a) isocoumarin structure of ochratoxins and b) general structure of ochratoxins. 
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1.3 Ochratoxin A 
1.3.1 Physicochemical properties and stability of ochratox in A 
OTA (C20H18CINO6) has a molecular mass of 403.83 g/mol. The systematic chemical IUPAC 
name for OTA is (2S)-2-{[(3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-
benzopyran-7-yl]formamido}-3-phenylpropanoic acid. OTA is a colourless, crystalline 
compound that is soluble in polar organic solvents (chloroform, ethanol, methanol, xylene) 
in acid and neutral pH, slightly soluble in water, and soluble in 0.1 M sodium bicarbonate 
(van der Merwe et al., 1965a; van der Merwe et al., 1965b). OTA has a melting point of 
about 90 °C when it was crystallised from benzene as a solvate. After drying for 1 h at 60 
°C, it has a melting point in the range of 168-173 °C, and the molecule is optically active 
([alpha]21D: -46.8 °C (c = 2650 µmol/L)) in chloroform (van der Merwe et al., 1965b). 
OTA is a weak acid, a dissociable molecule with a dissociation constant (pKa) 
approximately equal to 4 for the carboxyl group of phenylalanine and 7 for the phenolic 
groups (Bredenkamp et al., 1989). OTB has a higher pKa value (pKa 7.8), suggesting that 
the presence of the electron-withdrawing chlorine (isocoumarin ring) and carboxyl 
(phenylalanine) enhance the dissociation of the phenolic hydroxyl group, in contrast with 
the higher pKa of OTα (pKa 11-11.6) (Chu et al., 1972; Gillman et al., 1999). 
 
OTA shows an intense green fluorescence under UV light in an acidic medium and a blue 
fluorescence in alkaline conditions (Eppley, 1968). In a basic medium (0.5 N NaOH, pH 
13), the dissociated form of OTA (dissociation of the phenolic hydroxyl group) shows a 
high fluorescence with a red shift from 333 to 380 nm, followed by a time-dependent blue 
shift from 380 to 345 nm (deprotonated form). The blue shift in the UVmax of OTA is 
attributed to the hydrolysis of its lactone (Gillman et al., 1999). In a solution of 0.5 M 
Na2CO3 (pH 10-11), OTA shows the same red shift from 333 to 381 nm but not the time-
dependent blue shift (Gillman et al., 1999). Thus, under the different conditions described 
above, three forms of OTA can occur (Figure 2). 
 
OTA is a very stable mycotoxin; gamma irradiation (up to 7.5 Mrad) does not affect the 
OTA molecule, although it suffers photolysis during exposure to fluorescent light, and 
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degradation in an excess of sodium hypochlorite (Castegnaro et al., 1991; Neely and 
West, 1972). 
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Figure 2. Oxidation of OTA at basic pH. 
 
 
OTA can be stored in ethanol under refrigeration and can resist up to 3 h of high-pressure 
steam sterilisation (121 °C) (Neely and West, 1972; Trivedi et al., 1992). Cooking under 
normal conditions, and even at 170-250 °C, does not completely destroy it (Müller, 1982; 
Vidal et al., 2014). 
 
1.4 OTA producers and occurrence in foods and feeds 
1.4.1 OTA producers 
In a large screen of fungal metabolites, van der Merwe et al. (1965a) isolated OTA from 
Aspergillus ochraceus and found it to be the most abundant and toxic ochratoxin. OTA 
was first reported as a contaminant of corn by Shotwell et al. (1969). Since then, several 
members of the Aspergillus genus, common in warm and temperate climates, have been 
described as ochratoxin producers. Aspergillus section Nigri is the largest section with 
species showing ability to produce OTA, including five OTA producers: A. awamori 
(Perrone et al., 2011), A. carbonarius (García-Cela et al., 2014; Frisvad et al., 2011; 
Samson et al., 2007), A. niger (Perrone et al., 2011; Samson et al., 2004; Varga et al., 
2007), A. sclerotioniger (Frisvad et al., 2011; Samson et al., 2007; Serra et al., 2006), and 
A. tubingensis (Medina et al., 2005; Varga et al., 2007). 
 
 9 
The most important OTA producer species are A. ochraceus, A. westerdijkiae and A. 
steynii, which are members of Aspergillus section Circumdati, due to their occurrence in 
foods. Other species belonging to the Aspergillus genus have also shown the ability to 
produce OTA. Likewise, in addition to Aspergillus, other species in the Penicillium genus 
have been shown to produce OTA (Table 2). 
 
Table 2. Main OTA-producing species. 
 Aspergillus section Candidi 
 A. taichungensis 
 A. campestris 
Aspergillus section Circumdati 
 A. cretensis  
 A. flocculosus  
 A. melleus  
 A. ochraceus*  
 A. ostianus  
 A. persii  
 A. petrakii  
 A. pseudoelegans  
 A. roseoglobulosus  
 A. sclerotiorum  
 A. steynii*  
 A. sulphureus  
 A. westerdijkiae*  
Aspergillus section Flavi 
 A. albertensis (Petromyces albertensis)  
 A. alliaceus (Petromyces alliaceus) 
 A. lanosus 
Aspergillus section Nigri 
 A. carbonarius*  
 A. niger*  
 A. sclerotioniger  
Aspergillus section Wentii 
 A. sepultus and  
 A. dimorphicus 
Penicillium  
 P. nordicum  
 P. verrucosum§ 
*The most economically important OTA producers and §the 
most important OTA producer in northern Europe, which is 
associated with the cooler, damper conditions in the post-
harvest. Adapted from Abrunhosa et al. (2010) and García-Cela 
et al. (2014). 
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1.4.2 Occurrence of OTA in foods and feeds 
OTA has been detected worldwide in several cereals and cereal by-products, such as  
(Ibáñez-Vea et al., 2012), bran (Vidal et al., 2013), maize (Saleemi et al., 2012; Serrano 
et al., 2012), oats (Nguyen and Ryu, 2014; Vidal et al., 2013), rice (Nazari et al., 2014; 
Nguyen and Ryu, 2014), rye (Serrano et al., 2012), sorghum (Serrano et al., 2012) and 
wheat (Nguyen and Ryu, 2014; Serrano et al., 2012; Streit et al., 2013). From an 
economic point of view, the occurrence of OTA in other important foodstuffs, such as 
coffee (Drunday and Pacin, 2013; Galarce-Bustos et al., 2014; Vladimir. Ostry et al., 
2013), cocoa (Brera et al., 2011; Copetti et al., 2010) and beverages like wine (Coronel et 
al., 2012; Ostry et al., 2013) and beer (Coronel et al., 2012), is also notable. OTA has 
additionally been detected in dried fruits (Coronel et al., 2012; Ostry et al., 2013) and 
spices (Prelle et al., 2014; Waśkiewicz et al., 2013). 
 
Deleterious effects of mycotoxins have been documented in different animals due to the 
intake of contaminated feeds. In a global survey conducted with feed samples from 
America, Europe, and Asia, OTA was present up to 31% of the time (Rodrigues and 
Naehrer, 2012). In other worldwide studies (with samples from Asia, Europe, Africa, the 
Middle East, Oceania and America), the percentage of OTA-contaminated samples was as 
high as 28% (Streit et al., 2013). The highest percentage (50%) of contaminated samples 
was reported for wheat/wheat bran samples from North America (Rodrigues and Naehrer, 
2012). The consumption by animals of feed contaminated with OTA leads to the presence 
of this toxin in animal-derived food products and, therefore, to its chronic ingestion by 
humans. In this regard, OTA has been detected in tissues from healthy pigs (20-100%), 
chickens (69.2%), ducks (57.8%) and geese (41.7%) (Duarte et al., 2012). OTA has also 
been found in the blood (Bernardini et al., 2014; Grajewski et al., 2012; Perši et al., 
2012), eggs (Hassan et al., 2012; Iqbal et al., 2014; Piskorska-Pliszczyńska and 
Juszkiewicz, 1990) and milk (Boudra et al., 2013; Huang et al., 2014; Muñoz et al., 2014) 
of exposed animals. 
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1.5 Socio-economic impact and legislation 
Millions of tonnes of agricultural and food products are produced each year. The 
occurrence of mycotoxins in a large percentage of them is thus a public health issue, due 
to their deleterious effects. International regulations on mycotoxins are most often 
concerned with agricultural products such as cereals. In countries where agricultural 
commodities, such as cereals, account for a high percentage of total national exports, high 
mycotoxin levels take on economic importance and can affect to international trade (APS, 
2015; FAO, 1991; FAOSTAT, 2014). There are no accurate figures on the worldwide 
economic losses resulting from mycotoxin contamination of foods, as in addition to the 
direct losses of food and feed due to fungal or mycotoxin contamination, there are a 
variety of indirect losses, including those due to: lower productivity, losses in foreign 
exchange earnings, inspection, sampling and testing costs before and after shipment, the 
need to purchase insurance, farm subsidies to cover production losses, research costs and 
project support, training costs, the costs of mycotoxin decontamination, etc (APS, 2015). 
 
It is thus essential for mycotoxin concentrations to be kept at toxicologically acceptable 
levels. Toxin regulations are a compromise, and regulations on mycotoxins have been put 
into place and are strictly enforced. Today, many countries have regulations or 
recommendations for mycotoxins, such as the EU member states, the USA and Canada. 
Table 3 shows the allowable levels of OTA in foods in the EU, and Table 4 shows the EU’s 
recommendations on OTA levels in feedingstuffs.  
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Table 3. Maximum allowable levels of OTA in foodstuffs in the EU. 
Foodstuff Maximum 
level (μg/kg) 
Enactment* 
Dietary foods for special medical purposes intended 
specifically for infants 
0.5 2006 
Green coffee, dried fruit other than dried vine fruit, 
beer, cocoa and cocoa products, liqueur wines, meat 
products, spices and liquorice 
0.5 2006 
Wine 2 2006 
Processed cereal-based foods and baby foods for 
infants and young children 
2 2006 
All products derived from unprocessed cereals, 
including processed cereal products and cereals 
intended for direct human consumption 
3 2012 
Unprocessed cereals 5 2006 
Roasted coffee beans and ground roasted coffee, 
excluding soluble coffee 
5 2006 
Wheat gluten not sold directly to the consumer 8 2012 
Dried vine fruit (currants, raisins and sultanas) 10 2006 
Soluble coffee (instant coffee) 10 2006 
Various species of spices, including  Piper spp 
(pepper), Myristica fragrans (nutmeg), Zingiber 
offinale (ginger), Curcuma longa (turmeric) and 
Capsicum spp. (chili pepper), and mixtures of spices 
containing any one of them  
15 2012 
*By Commission Regulation (EC) No. 1881/2006 and Commission Regulation (EU) No. 
594/2012. 
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Table 4. Recommended OTA levels in feedingstuffs in the EU. 
Feedingstuff Maximum 
level 
(mg/kg)§ 
Enactment* 
Feed materials  2006 
 Cereals and cereal products 0.05  
Complementary and complete feedingstuffs  2006 
 Complementary and complete feedingstuffs for pigs 0.05  
 Complementary and complete feedingstuffs for 
poultry 
0.1  
§Concentration in a feedingstuff with a moisture content of 12%. *Commission 
Recommendation (EC) No.576/2006. 
 
 
1.6 Bioavailability and in vitro bioaccessibility 
The oral bioavailability (F) of a mycotoxin has been defined as the fraction of an orally 
ingested mycotoxin, in a given food matrix, that ultimately reaches the systemic circulation 
and is distributed throughout the body to exert its toxic effect (Versantvoort, 2004). 
Bioaccessibility (B) determination is the first step to consider when the bioavailability of a 
molecule in a given food matrix needs to be calculated. The bioavailability of an ingested 
mycotoxin depends on three different, sequential steps (Brandon et al., 2006): 
 
a) the release of the mycotoxin from the food matrix during digestion in the 
gastrointestinal (GI) tract. It is in this step that the bioaccessible mycotoxin (FB) is 
measured. 
b) the absorption of the bioaccessible mycotoxin through the intestinal epithelial cells of 
the GI tract (FA) and its subsequent transport to the blood (or lymph) stream. 
c) the metabolism of the mycotoxin prior to systemic circulation (i.e. its biotransformation 
and excretion by the intestinal epithelium or liver). This is the so-called first-pass effect 
(FM). 
 
In light of these steps, Equation 1 defines the bioavailable fraction of an ingested 
mycotoxin, i.e. the fraction reaching the systemic circulation: 
14 
 
F = FB x FA x FM                                         [Equation 1] 
 
In vitro bioaccessibility has become important because it represents the amount of the 
mycotoxin that could reach the blood after intestinal absorption. Bioaccessibility is given in 
percentages and calculated with the following equation (Equation 2): 
 
B (%) = [mycotoxinchyme] after GI digestion / [mycotoxinfood matrix] before GI digestion 
[Equation 2] 
 
It is worth noting that bioaccessibility has only been calculated in in vitro systems. The 
concept is only applicable to oral exposure. 
 
1.6.1 In vitro bioaccessibility of OTA 
To date, few studies have been conducted on the bioaccessibility of OTA and its 
relationship to different food matrices. Using the Dutch National Institute for Public Health 
and the Environment (Dutch name: Rijksinstituut voor Volksgezondheid en Milieu) model 
(Dutch acronym: RIVM model), Versantvoort et al. (2004) determined the OTA 
bioaccessibility in two lots of buckwheat and found that a considerable amount of OTA 
was released from the food matrix, from over 45% (in a buckwheat batch contaminated at 
20 µg/kg) to 84% (in a buckwheat batch contaminated at 7 µg/kg). In 2005, the same 
authors, using the same experimental design, reported considerably higher OTA 
bioaccessibilities (from 86 to 116%), although the amount of mycotoxin used in the 
digestion model was lower in the second study (Versantvoort et al., 2005). Those data 
agree with the results later reported by Avantaggiato et al. (2007), who, using the TIM-1 
model (TNO gastro-intestinal model-1) with artificially OTA-contaminated corn feed, found 
absorption levels of around 88%. In contrast, Kabak et al. (2009) once again reported 
much lower values for OTA bioaccessibility (22-32%) using the RIVM model with naturally 
OTA-contaminated buckwheat and low- and highly contaminated spiked infant foods. The 
bioaccessibilities found did not seem to depend on the contamination level; however, 
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bioaccessibility seemed to increase when spiked contamination was employed, as in such 
cases the toxins may not be tightly bound to the food matrix. Table 5 shows a summary of 
the OTA bioaccessibility studies published to date. 
 
 
Table 5. Gastrointestinal in vitro models used for bioaccessibility or absorption 
determination of OTA. 
Food 
matrix 
Contami
-nation 
Matrix 
contamina-
tion range 
 (µg/kg) 
Bioaccessibility/ 
Absorption 
(%) 
In vitro 
model 
used* 
Reference 
Buckwheat N 7-20 45-84 RIVM Versantvoort 
et al., 2004 
Food mix N 3.3-3.5  60-6 RIVM Versantvoort 
et al., 2004 
Buckwheat N 11-11.3  86-100 RIVM Versantvoort 
et al., 2005 
Food mix N 1.83-2.0  114-116 RIVM Versantvoort 
et al., 2005 
Corn feed S 11 88 
(73 jejunum; 
15 ileum) 
TIM-1 Avantaggiato 
et al., 2007 
Buckwheat N 24.9  22 RIVM Kabak et al., 
2009 
Infant food S 3.2-13.1  29-32 RIVM Kabak et al., 
2009 
N: natural; S: spiked. RIVM model: The Dutch National Institute for Public Health and the 
Environment. TIM-1 model: TNO (gastro-intestinal model-1) 
 
 
 
1.7 Toxicokinetics of OTA 
1.7.1 Absorption  
In the gastrointestinal tract, the highest levels of OTA absorption are found in the small 
intestine, mainly in the proximal jejunum. The absorption mechanism for OTA is passive 
and increases over time, and it is affected by changes in pH. A decrease in pH results in 
an increase in OTA uptake (Berger et al., 2003; Kumagai, 1988); therefore, pKa values in 
the range of 4.2-4.4 (carboxylic group) and 7.0-7.3 (phenolic hydroxyl group) play an 
important role in OTA absorption (Galtier et al., 1979; Roth et al., 1988). In rats, the 
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highest OTA concentration is found in portal blood and the rate of appearance in the 
venous plasma increases in keeping with increases in the luminal concentration of OTA 
(Kumagai and Aibara, 1982); in contrast, the lymphatic route only contributes to low-dose 
levels of OTA (Roth et al., 1998). 
 
1.7.2 Tissue distribution and bioavailability 
Once OTA crosses the intestinal epithelium and reaches the bloodstream, it is bound to 
plasma proteins, mainly albumin. This fact favours the passive absorption of OTA, 
especially in mammalian species (more than 97% of OTA in plasma) as compared to fish 
(22%) (Hagelberg et al., 1989). In humans, up to 84% of OTA binds to plasma proteins 
within a period of 8 h (Studer-Rohr et al., 2000). In contrast, in rats the maximum OTA 
level is reached within 3 h; this concentration then remains unchanged before beginning 
to decline on day 4 and until day 14 (Mantle, 2008). The highest bioavailability values of 
OTA in animal species have been reported in mice (92%) and pigs (65.7%), followed by 
rats (61%), monkeys (57%), rabbits (55.6%), chickens (40%) and fish (1.6%) (Galtier et 
al., 1981; Hagelberg et al., 1989). OTA or its metabolites are mainly distributed in the 
blood, kidney and liver, but they are also found in the lungs, heart, spleen and bile 
(Aoudia et al., 2008; Fuchs and Hult, 1986; Han et al., 2013). 
 
Interestingly, OTA levels in blood appear to be gender-dependent (Castergnaro et al., 
2006; Coronel et al., 2011; Heussner et al., 2002). In rats, females have been shown to 
have higher blood OTA levels than males (Castegnaro et al., 2006; Mantle, 2009; Zepnik 
et al., 2003). In humans, blood OTA levels have also been shown to be slightly higher in 
females (0.81 ng/mL) than in males (0.71 ng/mL) (Coronel et al., 2011). These findings 
can be explained by the fact that OTA binds to α-2u-globulin protein in blood and is 
rapidly delivered to the renal proximal tubule epithelium. This delivery of OTA to the 
kidney occurs more quickly in males than females, increasing the OTA concentration in the 
target organ and, consequently, nephrotoxicity in males (Haighton et al., 2012; Mantle 
and Nagy, 2008).  
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With regard to age, of the different human age groups studied, the group over the age of 
45 had the highest mean (0.55 ng/mL) and maximum OTA levels (10.92 ng/mL) in blood 
(Coronel et al., 2011). 
In vivo and in vitro inhibition of organic anion transport with probenecid (a uricosuric drug 
that increases uric acid excretion in the urine) prevents OTA renal clearance, suggesting 
that the OTA reabsorption/excretion mechanism occurs via a transcellular organic anion 
transport system and, thus, that glomerular filtration of OTA is negligible and the organic 
anion transport system must be the specific renal mechanism associated with OTA-
induced toxicity (Stein et al., 1985; Tsuda et al., 1999). The OTA clearance mechanism is 
related to the MRP2 transporter (Berger et al., 2003; Leier et al. 2000). MRP2 (or ABCC2; 
173.681 kD) is a second member of the human multidrug resistance-associated protein 
(MRP) subfamily, a membrane protein implicated in the active efflux of drugs and 
xenobiotics. MRP2 transport is highly expressed at the apical side of the enterocytes and 
in other organs such as the kidney, liver, brain, etc. MRP2 plays an important role as a 
xenobiotic outward transporter, reducing oral bioavailability and, in the liver, contributing 
to bile formation and to toxin elimination via this pathway (Dietrich et al., 2003; 
Jedlitschky et al., 2006). 
 
1.7.3 Half-life and excretion  
OTA half-life has not been clearly defined and several factors, such as exposure time, diet, 
health status and the degree of serum binding, can affect the rate at which it is removed 
from the body. The high affinity of OTA for serum proteins partially explains its long half-
life in the body and high bioavailability (Hagelberg and Hult, 1989; Kumagai, 1985). In 
rats, the OTA half-life is 5.93 days (Mantle, 2008). Experimental OTA half-life in humans is 
35.5 days, and the elimination half-life of OTA is generally longer in blood than in tissue, 
due to its high affinity to bind to blood proteins (Studer-Rohr et al., 2000). 
 
OTA, as well as its metabolites OTα and hydroxylated OTAs (4R-4-OH-OTA and 4S-4-OH-
OTA), are mainly excreted in urine (Klapec et al., 2012). 4R-4-OH-OTA has been detected 
at higher concentrations than 4S-4-OH-OTA in the urine of rats (Stormer et al., 1980). 
OTA is also excreted in faeces (Kumagai and Aibara, 1982) and the OTα metabolite has 
been detected in the caecum and large intestine of rats, which suggests that OTα may 
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also be found in faeces (Storen et al., 1982; Suzuki et al., 1977). Reabsorption of OTA 
occurs in the proximal tubules and via enterohepatic circulation and results in the 
redistribution of the toxin to the body (Stein et al., 1985). OTα is not accumulated in the 
body and has an elimination rate of up to 90% following intraperitoneal administration in 
rats (Storen et al., 1982). 
 
1.7.4 Metabolism/ Biotransformation of OTA  
OTA may undergo hydrolysis as a first-pass effect during the GI digestion by 
carboxypeptidase A, trypsin, α-chymotrypsin and cathepsin C. Digestive enzymes break 
the peptide bond, giving rise to a phenylalanine molecule and the non-toxic metabolite 
OTα, a chlorinated dihydroisocoumarin (Doster and Sinnhuber, 1972; Kumagai, 1988; 
Pitout, 1986). This is the main metabolic pathway by which OTA is biotransformed into a 
less toxic compound. OTα is also produced in in vitro reactions by several cell types 
(Faucet-Marquis et al., 2006; Han et al., 2013; Jennings-Gee et al., 2010). 
 
In ruminant species, such as sheep (Hohler et al., 1999), goats (Nip and Chu, 1979; 
Ribeling et al., 1978), cows (Ribeling et al., 1978) and Holstein calves (Hult et al., 1976; 
Ribeling et al., 1978), intestinal microbiota enzymes are also capable of degrading the 
OTA. The hydrolysis reaction by microbial enzymes mainly occurs in the large intestine, 
although some hydrolysis can also occur in the stomach. However, the microbial enzymes 
involved in OTA hydrolysis have not been identified. 
 
Peptidases are not the only enzymes involved in the detoxification of OTA, and several 
metabolites have been characterised in vitro and/or in vivo. OTA can be metabolised in a 
non-specific manner by several enzymes of the cytochrome P450 system (CYP450). The 
CYP450 enzymes (e.g. CYP2A6, 2B6, 2C9, 2C18, 2C19, 3A4, and 3A5) metabolise 
compounds to hydroxylated products (de Jonge et al., 2005; Xie et al., 2003). In the case 
of OTA, three different hydroxylated metabolites have been identified: 4R-4-OH-OTA, 4S-
4-OH-OTA and 10-OH-OTA (Creppy et al., 1983; Stormer et al., 1983; Syvertsen and 
Størmer et al., 1983). The 10-OH-OTA metabolite is only produced in rabbits (Stormer et 
al., 1983) and the OH-OTA is not produced by sheep (Hohler et al., 1999). Figure 4 shows 
some metabolic reactions and the OTA metabolites produced. The biotransformation of 
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OTA has not been elucidated in detail and the contribution of each metabolic enzyme is 
still unclear; few studies have been conducted on this aspect. For example, in recombined 
HIH/3T3 cells (P450/LacZ) the mutagenicity of OTA increases in the presence of a stable 
expression of P450 enzymes 1A1, 1A2, 2C10 or 3A4 (de Groene et al., 1995; de Groene et 
al., 1996). 
 
To date, several OTA metabolites have been identified in vitro and in vivo as OP-OTA, OTA 
methyl and ethyl ester, OTA-GSH, OTHQ, OTHQ-GSH, OTHQ-NAC, etc. (Faucet-Marquis et 
al., 2006; Han et al., 2013; Li et al., 1998; Malaveille et al., 1991; Tozlovanu et al., 2012). 
Some had been previously described in in situ chemical reactions (Dai et al., 2002; 
Frenette et al., 2008; Xiao 1995; Xiao 1996). Other OTA metabolites have yet to be 
defined (Faucet-Marquis et al., 2006; Jennings-Gee et al., 2010). 
 
With regard to the metabolism of recognised OTB and OTC, the OTB is biotransformed to 
OTβ and OH-OTB and subsequently excreted in urine (Mally et al., 2005). The affinity of 
metabolising enzymes for OTB is high, since the hydrolysis and the elimination rate of this 
metabolite is faster than for the transformation of OTA to OTα. This fact favours the OTB 
elimination and its low toxicity (Mally et al., 2005; Pitout, 1986). On the other hand, OTC 
(the ethyl ester of OTA), has been transformed in vivo into OTA by an esterase and 
chymotrypsin. The ratio of appearance of OTA (from OTC) in blood is as fast as the 
absorption of OTA from the gastrointestinal tract (Fuchs et al., 1984; Hult, 2006). These 
findings support the fact that OTC is just as toxic as OTA (Fuchs et al., 1984; Hult, 2006; 
Li et al., 1997; Xiao et al., 1996). 
 
1.7.5 Action mechanism of OTA  
OTA toxicity has been attributable to its isocoumarin moiety in the structure. Several 
mechanisms of OTA toxicity have been proposed; the first mechanism of toxicity described 
in literature was the inhibition of protein synthesis by competition with phenylalanine in 
the phenylalanine-tRNA aminoacylation reaction (Baudrimont et al., 1997; Creppy et al., 
1984). A study of microarray analysis showed that genes encode proteins of cytoskeleton 
were downregulated and the protein content of plasma membrane was decreased 
(Hundhausen et al., 2008). 
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Figure 4. Proposed pathway of OTA metabolism in animals and humans. 
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Experimental evidence supports an important role for reactive oxygen species in the 
cancer development through modulation of cell signals such as the mitogen-activated 
protein (MAP) kinases.  Protein kinases are involved in proliferation, differentiation, and 
apoptosis, and the intracellular calcium modulation (calcium homeostasis) (Klaunig and 
Kamendulis, 2004). In this regard, the results of in vitro studies showed that OTA has 
ability to inhibit the calcium (Ca2+) uptake and cause a depletion of intracellular calcium 
stores means of an inhibitory effect on store-operated Ca2+ channels (SOCs) (Berndt et 
al., 1984; Hundhausen et al., 2008; Khan et al., 1989). The oxidative stress process was 
investigated on the flavoprotein NADPH-cytochrome P450 reductase, where OTA 
enhanced the reduction of ferric ions (Fe3+) to ferrous ions (Fe2+), results in initiation of a 
lipid peroxidation reaction (Omar et al., 1990). In contrast, Manderville and Pfohl-
Leszkowicz (2006) reported a increase in the hydroxyl radicals level in presence of NADPH 
and OTA without Fe2+.  
 
OTA has also been able to alter genes involved in cell transport, immune response and 
inflammation, coagulation, antioxidative defence, DNA repair and mitotic regulation (Cavin 
et al., 2007; Gagliano et al., 2006; Luhe et al., 2003; Marin-Kuan et al., 2006). The 
overexpression of these mitotic regulators suggest that these may play a key role in 
tumour formation by OTA. Studies suggest that the metabolic activation of OTA plays an 
essential role in its genotoxic capacity. In case of DNA mutation assays, OTA did not cause 
mutation in Salmonella typhimurium using the Ames assay either with or without 
metabolic activation (Bendele et al., 1985; Kuczuk et al., 1978), but posteriorly Hennig et 
al. (1991) and Obrecht-Pflumio et al. (1999) identified mutations caused by OTA using the 
same Ames assay and bioactivated OTA metabolites by hepatic cells and kidney 
microsomal fraction. 
 
The Sister Chromatid Exchange (SCE) assay (Anninou et al., 2014; Bendele et al. 1985; 
Föllmann et al., 1995; Lioi et al., 2004; Mosesso et al., 2008) and induction of 
micronucleus (MN) (Ali et al., 2011; Corcuera et al., 2015; Dönmez-Altuntaş et al., 2003; 
Ehrlich et al., 2002) have also been reported both positive and negative. In  addition, the 
C8-guanine adduct of OTA (C8 dG-OTA) was detected in liver, kidney and testis of mice 
and pig following activation by cytochrome P450 enzymes and peroxidase enzymes 
(Faucet et al., 2004; Jennings-Gee et al., 2010; Mantle et al., 2010a). Results obtained 
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using the comet assay have been positive, which support the oxidative stress theory 
caused by OTA as an action mechanism (Cariddi et al., 2015; Klarić et al., 2010; Russo et 
al., 2005), (Ali et al., 2014; Arbillaga et al., 2007; Cariddi et al., 2015; Kamp et al., 2005; 
Lebrun and Follmann, 2002). 
 
Controversial results of in vitro studies have been obtained and the studies have provided 
evidence that OTA toxicity is a plausible epigenetic mechanism, nerveless, direct 
genotoxicity versus epigenetic mechanism is a key question to classify to OTA as direct or 
indirect genotoxic (FAO/WHO, 2001, EFSA, 2010; IARC, 1993). 
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2.1 Objectives 
This thesis focused on the determination of the bioaccessibility of ochratoxin A (OTA) in a 
food matrix and on the in vitro assessment of this toxin’s cytotoxicity and genotoxicity on 
three lines of human cells. 
 
With regard to bioaccessibility, we chose to use wine as the food in this study because 
previous research by our group (Belli et al., 2004; Coronel et al., 2009, 2012; Valero et al., 
2008) had determined that it is one of the most OTA-contaminated matrices. To select the 
most suitable cytotoxic and genotoxic assays, we followed the recommendations of the 
OECD and the EFSA. 
 
The objectives of this thesis fall within the objectives of the Spanish national research 
project ”Integrated approach to simultaneous human exposure to ochratoxin A and 
deoxynivalenol” (project AGL2011-24862) and, more specifically, within its objective of ”in 
vitro evaluation of the bioaccessibility of OTA in several food matrices, the effect of 
absorption and the cytotoxicity induced”. 
 
To meet this general objective, the following specific objectives were defined: 
 
▪ To assess the bioaccessibility of OTA in a single food matrix (red wine) at different 
levels of contamination using an in vitro digestion model. 
▪ To determine the in vitro cytotoxicity and genotoxicity of OTA in three human cell 
types. This objective, in turn, included the following sub-objectives: 
• To determine the bioaccessibility of OTA from red wine. 
• To investigate the in vitro cytotoxicity and genotoxicity of OTA in human cell 
cultures. 
• To determine the oxidative stress induced by OTA (and, complementarily, by 
DON) in human cell cultures. 
• To assess the modulation of the expression of some important genes in human 
cell cultures in the presence of OTA. 
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Figure 1. Work plan to perform the in vitro OTA bioaccessibility and toxicity studies. 
2.2 Work plan 
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Study I. 
Bioaccessibility of ochratoxin A from red wine in an in vitro dynamic 
gastrointestinal model. 
 
 
González-Arias, C.A., Piquer-Garcia, I., Marin, S., Sanchis, V. and Ramos, A.J.* 
 
Food Technology Department. Lleida University. UTPV-XaRTA, Agrotecnio Center. Av. 
Rovira Roure, 191. 25198 Lleida. Spain. 
 
 
Abstract 
Ochratoxin A (OTA) is a mycotoxin produced by Aspergillus and Penicillium species with 
immunosuppressive, teratogenic, and carcinogenic properties. It has been determined that 
wine is the second largest source of OTA (10% of total OTA intake) in the European diet 
and that its presence, even in small doses, can be a problem in terms of long-term 
toxicity. In this paper, we evaluated the bioaccessibility of OTA in a spiked red wine 
sample under human fasting conditions using an in vitro dynamic digestion model that 
includes a continuous-flow dialysis system to simulate intestinal passage. To the best of 
our knowledge, this report is the first examining the bioaccessibility of OTA in wine. A 
liquid-liquid method was used to extract the OTA and ochratoxin alpha (OTα) from 
gastrointestinal juices, and the extracts were analysed by HPLC-FD. The bioaccessibility of 
OTA from the spiked red wine (1.0, 2.0 and 4 µg/L) was high in the gastric compartment 
(102.8%, 128.3% and 122.3%, respectively), whereas in the simulated intestine, it did not 
exceed the 26%, and the amount of OTA that crossed the dialysis membrane was very 
low (< 3.3%). The amount of OTα in gastric chyme ranged from 5.1 to 19.1% of the 
spiked OTA, whereas in the intestinal compartment it did not exceed 5%. In conclusion, in 
the in vitro system assayed, OTA exhibited a high bioaccessibility in the simulated 
stomach, but it decreased after the intestinal digestion and passage through the dialysis 
membrane. 
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1.1 Introduction 
Ochratoxin A (OTA) is a toxic secondary metabolite produced naturally by certain fungal 
species belonging to the Aspergillus and Penicillium genera. OTA is a potent nephrotoxin 
(IARC 2B group) that also exhibits immunosuppressive, teratogenic, and carcinogenic 
properties. OTA can be found in different raw materials (such as cereals, grains, and 
coffee beans) and foodstuffs, such as grape juice and wine (IARC, 1993). Several studies 
have reported that the OTA levels in wine can be reduced, but that OTA is not fully 
degraded or extracted during the main stages of wine making, during the fermentation 
process (Cecchini et al., 2006; Esti et al., 2012), wine ageing (Anli et al., 2011), or 
through physical treatments, e.g., wine clarification and decontamination with adsorbents 
(Castellari et al., 2001; Var et al., 2008). 
 
Due to the adverse effects that OTA can have on health, the Commission Regulation 
1881/2006 set a maximum level of 2 μg of OTA/L for wine and 10 mg of OTA/kg for dried 
vine fruit (currants, raisins, and sultanas) (EC, 2006a). Although OTA is usually detected in 
wine at levels below 1 μg/L, concentrations exceeding the legal limits are frequently found 
(EC, 2002). This is concerning because wine is the second most significant source of OTA 
(13-10% of the total intake) in the European diet (EC, 2002) and wines are the second 
most consumed alcoholic drink after beer (WHO, 2013). 
 
It is known that OTA exposure occurs mostly by ingestion, however, a given intake of 
mycotoxin through food does not always reflect the amount of toxin that is able to cross 
the intestinal membrane. Some in vitro models have been developed to determine the 
amount of contaminant released (bioaccessible fraction) from food during its 
gastrointestinal passage. Release of the toxin from food in the gastrointestinal tract is a 
prerequisite for uptake (and bioavailability) in the body. The bioaccessible fraction is 
defined as the amount of free contaminant that may become available for absorption 
because it has been released from the matrix and solubilised in the gastrointestinal fluid 
(Versantvoort et al., 2004). Ochratoxin alpha (OTα) is a derivative of OTA formed in the 
gastrointestinal tract by the action of carboxypeptidase A and chymotrypsin (Kumagai and 
Aibara, 1982). 
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To date, no studies on the bioaccessibility of OTA have been performed in wine, a 
beverage consumed regularly by adults. The aim of this study was to estimate the 
bioaccessibility of OTA in spiked red wine through a dynamic in vitro gastrointestinal 
model simulating the digestion process, as well as the formation of OTα in the 
gastrointestinal juice. 
 
1.2 Materials and Methods 
1.2.1 Chemicals, reagents, and equipment 
Ochratoxin A (OTA) (CAS: 303-47-9) (purity 98%) was supplied by Sigma-Aldrich (St. 
Louis, MO, USA), while ochratoxin alpha (OTα) (CAS: 16281-39-3) was from Romer Labs 
Diagnostic (Tulln, Austria). All salts used to prepare the gastrointestinal solutions and the 
hydrochloric acid (HCl, 37%) were supplied by Panreac, Chemical S.A. (Barcelona, Spain) 
or Fisher Bioreagents (Fair Lawn, NJ). Orthophosphoric acid and sodium sulphide were 
from Scharlau Chemical S.A. (Barcelona, Spain). Organic solvents and HPLC grade 
reagents were from Fisher Scientific (Leicestershire, UK). The simulated digestive system 
was designed with an adapted Liebig-West condenser, endfitting fluid connectors, silicone 
tubing (12 mm diameter) and dialysis tubing cellulose membrane from Sigma-Aldrich 
(D9277) with a molecular mass cut-off of 12400 Da and 32.8 mL/m of capacity (10 mm of 
flat width x 6 mm of diameter). A D-21FT peristaltic pump from Dinko Instruments 
(Barcelona, Spain) and a thermostat bath Tectron-bio-100 from J.P. Selecta, S.A. 
(Barcelona. Spain) were also used. 
 
1.2.2 Wine 
In this study, we used a commercial Spanish red wine made from a Tempranillo grape 
variety harvested in 2011 from the Castilla-La Mancha region. The initial OTA and OTα 
contamination in this wine was evaluated using the method described by Muñoz et al. 
(2009). In-house validation of the method was performed at three OTA and OTα 
contamination levels (1.0, 2.0, and 4.0 μg/L) to determine the recovery of the toxins from 
the matrix. Recoveries ranged from 92.4 to 100.0% (repeatability Relative Standard 
Deviation, RSDr: 1.30-11.54%) for OTA and 63.7-66.9% (RSDr: 15.9-20.1%) for OTα. The 
amount of OTA found in this wine, considering the mean recovery of the method, was 
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0.103 μg/L, whereas, as expected, no OTα was detected. This amount of OTA was taken 
into account for bioaccessibility calculations. 
 
1.2.3 In vitro digestion procedure 
The digestion model used was a slightly modified version of the technique developed by 
Gil- Izquierdo et al. (2002), including a continuous-flow dialysis system to simulate 
intestinal passage. The model describes a three-step procedure mimicking the digestive 
process in the mouth, stomach (gastric digestion), and small intestine (intestinal 
digestion). The constituents and concentrations of the simulated saliva, gastric juice, 
duodenal juice and bile juice employed were those described in Versantvoort et al. (2005). 
Digestion assays were carried out with 5 mL of red wine (spiked at 1.0, 2.0, or 4.0 μg 
OTA/L, with 5, 10 and 20 ng OTA). The digestion began with the addition of 6 mL of 
salivary juice to 5 mL of the assayed red wine, adjustment of the pH to 6.8 using 10% 
NaHCO3 and incubation at 37 ºC for 5 min. at constant orbital movement. After this 
treatment, gastric or gastric+intestinal digestions were developed. The gastric and 
intestinal mixtures were incubated for 2 h. The intestinal mixture was introduced into the 
dialysis tube in a continuous-flow dialysis system simulating the intestine. 
 
The dialysis system was designed with an adapted Liebig-West condenser and end-fitting 
fluid connectors. The first chamber contained the dialysis tube, through which the 
intestinal mixture flowed during the intestinal digestion step using a peristaltic pump with 
a flow rate of 1 mL/min, and a phosphate buffer solution (PBS, pH 7.4) that bathed the 
dialysis tube. A temperate water solution was pumped from a bath through a water jacket 
to keep the system’s temperature constant at 37 ºC (Figure 1). Once the gastric and 
gastric+intestinal digestions were completed, the fluids (gastric, intestinal, and the 
dialysate) were collected and analysed. The fluids were centrifuged for 10 minutes at 100 
rpm and 10 ºC, yielding a supernatant that was analysed for OTA and OTα content. 
Overall, for each spike level, six parallel experiments were carried out, from which three 
were interrupted for analysis after the gastric phase, and the remaining three underwent 
the intestinal phase before analysis. 
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Figure 1. Schematic diagram of the simulated in vitro intestinal digestion system. PBS = 
phosphate buffered saline. 
 
 
1.2.4 Sample analysis 
1.2.4.1 Liquid-l iquid extraction of OTA and OTα from the simulated 
physiological fluids 
The extraction of OTA and OTα, was performed using the method described by Muñoz et 
al. (2009), with slight modifications. The gastric chyme was diluted 1:1 with NaHCO3 
(1%), and the pH adjusted to 3 with 6 M H3PO4; the intestinal chyme and dialysis samples 
were diluted 1:4 in H3PO4/NaCl (0.5 M:2 M) and the pH was adjusted to 1.6 using 10% 
NaHCO3 (Zimmerli and Dick, 1995). Liquid-liquid OTA and OTα extractions were carried 
out by adding 5 mL of chloroform/isopropanol (97:3) and shaking using a magnetic stirrer 
for 20 min, at which time the mixture was centrifuged for 10 minutes at 1000 rpm. The 
organic phase was recovered and dried under a gentle stream of nitrogen at 40 ºC. 
Samples were stored at 4 ºC until HPLC analysis. To determine if the physiological fluids 
caused chromatographic interference, two digestions free from wine were performed 
following the previously described digestion procedure. After the incubation period for 
each digestion phase, the obtained juices were directly subjected to liquid-liquid extraction 
as previously described or were spiked with OTA and OTα (at 1.0, 2.0, and 3.0 μg/L) and 
then extracted, and the toxin was immediately analysed (Figure 2). 
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Figure 2. HPLC chromatogram of ochratoxin α (OTα) and ochratoxin A (OTA) in (a) spiked 
red wine, (b) spiked intestinal juice, (c) spiked gastric juice, (d) non-spiked gastric juice 
and (e) non-spiked intestinal juice. 
 
 
1.2.4.2 High Performance Liquid Chromatography (HPLC) analysis 
The HPLC analysis of OTA and OTα was performed using a Waters 2695 Separations 
Module coupled to a Waters 2475 Multi λ fluorescence detector. The integration software 
used to manage the chromatographic data was Empower 2 (2006 Waters Corporation, 
Database Version 6.10.00.00). Retention times were 10 min (OTα) and 27 min (OTA). 
Figure 2 shows the chromatograms of the extracted physiological fluids (spiked or 
unspiked with OTA and OTα) and a sample of the spiked wine post-digestion. The method 
performance was evaluated in terms of linearity, limit of detection, limit of quantification, 
inter-day repeatability, and recovery rates. 
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1.2.5 Statistical analysis 
Validation to estimate the inter-day repeatability was performed with runs in triplicate. 
Results are shown as the means ± standard deviations. Analysis of variance (ANOVA) was 
used to test if there were significant differences (p < 0.05) in the calculated bioccessibility 
and for the values of mycotoxin that crossed the dialysis membrane at the various tested 
OTA concentrations. 
 
1.3 Results and Discussion 
1.3.1 Method validation for OTA and OTα analysis 
The detection (LOD) and the quantification (LOQ) limits for the two toxins were 
experimentally determined from the calibration curve of a set of two-fold serial dilutions of 
the toxin standards (from 100 to 0.006 ng/mL), which was linear in the range of 0.012 to 
100 ng/mL (r2=0.995). The LOD and LOQ determined for OTA were 0.012 and 0.036 
ng/mL, whereas for OTα these were 0.024 and 0.072 ng/mL, respectively. The method 
was repeatable for the two toxins at the three assayed spike levels, with an RSDr below 
5% in most cases. OTA and OTα recoveries from the dialysis fraction were similar and 
usually greater than 80%. In the gastric and intestinal fractions, recoveries were lower for 
OTα (62-78%), although the RSDr percentages were similar to those obtained with OTA 
(Table 1). OTA recoveries fit the performance criteria established in the EU Regulation 
401/2006 (EC, 2006b) for its official control in foodstuffs. Although there are no 
established performance criteria for OTα, all of the recovery percentages were 
homogeneous at the three spike levels. The bioaccessibility results and the amount of 
mycotoxin that crossed the dialysis membrane were corrected using the recovery rates. 
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Table 1. Recovery rates and inter-day repeatability for ochratoxin alpha (OTα) and 
ochratoxin A (OTA) in the digestion juices. 
Digestion 
step 
Spike 
level 
(ng/mL) 
 OTα  OTA 
Recovery* 
(%)1 
RSDr 
(%)2 
 Recovery* 
(%) 
RSDr 
(%) 
Gastric 1.0  62.40 2.04  89.19 2.21 
 2.0  65.58 5.99  84.57 3.83 
 3.0  62.76 4.17  86.12 1.56 
        
Intestinal 1.0  78.45 3.98  78.28 11.1 
 2.0  72.20 2.94  75.57 2.88 
 3.0  77.11 4.74  87.58 3.32 
        
Dialysis  1.0  83.76 2.32  85.91 3.41 
 2.0  83.65 0.61  79.44 1.30 
 3.0  89.55 0.88  85.07 2.56 
1Mean of three measurements. 2RSDr = relative standard deviation, calculated from 
results generated under repeatability conditions. 
 
 
 
1.3.2 Bioaccessibility of OTA in w ine 
The extractable compounds from the physiological fluids did not interfere with the 
chromatographic analysis of OTA (Figure 2). In our study, OTA levels detected in the 
gastric chyme were quite high, representing a bioaccessibility of 102.81, 128.26, and 
122.25% in each of the tested contamination levels (Table 2). No significant differences 
were determined for the three bioaccessibility values (p > 0.05). Our results demonstrate 
that, in the tested OTA concentration range, the food matrix did not affect the 
bioaccessibility of OTA in the gastric chyme. 
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Table 2. Bioaccessibility of ochratoxin A (OTA) from wine in an in vitro human digestion 
system. 
 OTA spiked amount  
(ng OTA) 
Fraction Average 
(ng OTA) 
Bioaccessibility 
(% ± SD) 
 5 Gastric 5.14 102.81 ± 11.26 
  Intestinal 1.215 24.24 ± 11.98 
  Dialysis <LOQ1  
 10 Gastric 12.83 128.26 ± 18.01 
  Intestinal 2.60 25.99 ± 9.00 
  Dialysis <LOQ  
 20 Gastric 24.45 122.25 ± 15.03 
  Intestinal 4.27 20.80 ± 1.38 
  Dialysis 0.22  
1LOQ = limit of quantification: 0.036 ng/mL. 
 
 
High bioaccessibility levels (86 to 116%) were determined by Versantvoort et al. (2005) in 
buckwheat, peanuts, and mixtures of these cereals (4, 11, 51 ng OTA in the digestion 
model). Avantaggiato et al. (2007) also described a high bioaccessibility of OTA (88%) 
from the stomach to the small intestine in a corn food at one contamination level (11 μg 
OTA/kg). Our results and the results of studies mentioned above are consistent with the in 
vivo data reported by Galtier (1978) and Roth et al. (1988). The authors attributed this 
behaviour to the acidic properties of OTA (Galtier, 1978; Kumagai and Aibara, 1982). 
However, Kabak et al. (2009) reported much lower bioaccessibilities; only 22% was found 
for buckwheat (24.9 μg OTA/kg) and 29-32% for infant food (2-13.1 μg OTA/kg), in 
spiked food samples. In our study, OTA levels decreased during intestinal digestion, with 
bioaccessibilities ranging from 21 to 26%, while less than 3.3% was detected in the 
intestinal dialysate (Table 2). Glahn et al. (1996) and Jovaní et al. (2001) also observed 
this behaviour, where the compounds that form complexes with proteins, or with mixed 
bile salt micelles, such as OTA, are likely to be less bioaccessible. 
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Results of in vivo experiments indicated that OTA could have highly variable bioavailability 
values. For example, the highest bioavailability was reported in mouse (92%), followed by 
pigs (65.7%), rats (61%), monkeys (57%), rabbits (55.6%), chickens (40%) and fish 
(1.6%) (Galtier and Alvinerie, 1981; Hagelberg et al., 1989). Unlike that of the in vitro 
systems, it has to be noted that the in vivo absorption in the proximal jejunum depends on 
gastric emptying, mechanical movements, can take place against a concentration gradient 
and depends on the pH at the mucosal surface of the jejunum (Kumagai and Aibara, 
1982; Kumagai, 1988). 
 
In our case, the bioaccessibility did not depend on initial mycotoxin levels (p > 0.05), 
either at the gastric or the intestinal phase. However, as with other mycotoxins, 
differences in bioaccessibility could also be related to the way the matrix (food or feed) is 
contaminated (spiked or naturally), and the bioaccessibility model employed for studying 
the release of mycotoxins from the matrix. Two in vitro models to study mycotoxin 
bioaccessibility have been primarily used by different authors: 1) the RIVM model 
(Versantvoort et al., 2004) and 2) the Gil-Izquierdo model (Gil-Izquierdo et al., 2002). A 
third model, the TIM-1 model, has been mainly employed in bioaccessibility assays of 
mycotoxins from cereals or food (Avantaggiato et al., 2003, 2004, 2007; Zeijdner et al., 
2003) in porcine gastrointestinal tract conditions. An in-depth review of the conditions and 
digestion models is presented in our previous study on mycotoxin bioaccessibility 
(González-Arias et al., 2013). 
 
Regarding formation of the OTα metabolite, in general, low amounts were detected in our 
in vitro digestion system. In the gastric chyme, OTα was detected in a range representing 
5.1-19.1% of the initial OTA. In the small intestine juice, 5.1% of the metabolite was 
detected, but only in the digestion of the wine spiked at 4 μg OTA/mL. In the dialysis 
fraction, OTα was detected but not quantified because the signal was below the LOQ. Our 
results are in agreement with Madhyasta et al. (1992); the authors used an in vitro system 
based on the incubation of OTA with rat digesta, and found that most OTA hydrolysis to 
OTα occurs in the presence of digesta from the large intestine or caecum, but little 
hydrolysis was observed in the stomach contents and digesta from the small intestine, 
despite the fact that the pancreatic enzymes, including carboxypeptidase A, are released 
into the small intestine. Additionally, the biotransformation of OTA into OTα is most likely 
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higher for in vivo or in vitro systems involving intestinal cellular systems in comparison to 
our in vitro system, where scarcely any biotransformation was observed. In our results, as 
in the case of other studies, several additional factors were not taken into account, e.g., 
the interaction of the toxin with the intestinal microbiota in the large intestine (mainly 
anaerobic bacteria) (Madhyastha et al., 1992), the effect of the toxin’s metabolism during 
the transport through the intestinal barrier and liver degradation of the oral bioavailable 
OTA in vivo (Berger et al., 2003; Schrickx et al., 2006). 
 
1.4 Conclusions 
The present study demonstrates that OTA is primarily released from the wine matrix 
during gastric digestion (providing high bioaccessibility at this point). However, in the 
small intestine the in vivo bioavailability of OTA may decrease due to a low bioaccessibility 
and, presumably, a low bioavailability. In vitro models are only approximations of what 
may occur in vivo, and the few studies carried out to determine the bioaccessibility of OTA 
in different food matrices that were naturally or artificially contaminated have yielded 
inconsistent results. Most in vitro bioaccessibility assays for mycotoxins have not been 
carried out for more than two hours of gastric digestion, and few matrices have been used 
under fasting or fed conditions. Further studies should be conducted to determine the 
effect that the OTA contamination level, type of contamination (natural vs. spiked), and 
food matrices exert on bioaccessibility. Additional data are required to consider these 
results representative of what happens under in vivo conditions. 
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Abstract 
Exposure to mycotoxins through dietary food intake involves a highly complex scenario 
where co-occurrence of different mycotoxins has been frequently demonstrated. On the 
other hand, the effect of the interaction of mycotoxins with other generally considered 
beneficial food components, as the antioxidants, has been scarcely studied. The main goal 
of the present work was to assess the cytotoxic effects on Caco-2 cells of the mycotoxins 
deoxynivalenol (DON) and ochratoxin A (OTA), alone or combined, and to explore 
potential protective effects of resveratol (RES), an antioxidant frequently found in wine. In 
parallel, reactive oxygen species (ROS) production has also been studied as a first 
approach to understand the underlying mechanism of cytotoxicity. Results indicate a 
higher toxic effect of the mycotoxins when they are co-exposed. This increase in 
cytotoxicity was not accompanied by an increase in ROS production. The co-exposure of 
OTA or DON with RES did not result in a decrease in cytotoxicity; on the contrary, it 
resulted in increased cytotoxicity not associated with an increase in ROS production. 
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2.1 Introduction 
Ochratoxin A (OTA) (Fig. 1a) is a fungal secondary metabolite produced by some species 
of the genera Aspergillus and Penicillium. Sources of human exposure to OTA are mainly 
foodstuffs of vegetal origin, such as cereals and derivatives, grapes, musts and wines, 
coffee, beer, nuts and dried fruits, spices and, to a minor extent, animal by-products. OTA 
is a potent kidney toxin and has been classified by the IARC as a 2B cancer compound 
(possibly carcinogenic to humans) (IARC, 1993). It is among the strongest carcinogenic 
compounds in rats and mice, and its toxicological profile includes teratogenesis, 
nephrotoxicity and immunotoxicity (Fernández-Cruz et al., 2010). Reported in vitro toxic 
effects of OTA include inhibition of cellular proliferation, apoptosis and impairment of 
barrier function and, increasing membrane permeability (McLaughlin et al., 2004). OTA 
has been found to induce oxidative damage in vitro (Schaaf et al., 2002; Kamp et al., 
2005; Mally et al., 2005) and in vivo (Petrik et al., 2003; Hsuuw et al., 2013) and to be 
genotoxic (Lebrun and Föllmann, 2002; González-Arias et al., 2014). 
 
 
 
Figure 1: Molecular structure of (a) ochratoxin A, (b) deoxynivalenol and (c) resveratrol 
 
 
Deoxynivalenol (DON) (Fig. 1b), is one of the most common fungal contaminants of 
cereals worldwide. This mycotoxin is produced by different species of Fusarium, thus a 
wide range of cereal-based foods have been reported to be contaminated by this toxin 
(JECFA, 2001). Acute effects of food poisoning by DON in humans are abdominal pains, 
dizziness, headache, throat irritation, nausea, vomiting, diarrhoea, and blood in the stool. 
It has also been shown that DON can act severely against the intestinal cells causing 
inflammation and increasing the permeability of the monolayers, resulting in a reduction of 
viability and immune function (Pinton et al., 2009; Van de Walle et al., 2010). DON also 
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increases cytokine levels, a fact that is closely related with immune function reduction and 
increases caspase-3 levels, a well-known apoptosis mediator (Pestka et al., 2004; Pestka, 
2008). Additionally, DON induced oxidative stress has been proposed as the mechanism of 
DNA damage in hepatic cells HepG2 (Pestka et al., 2004). 
 
Red wine is one of the most important beverages in the Mediterranean diet, and it is 
considered to have a more protective effect than white wine due to its greater content in 
antioxidant substances released from the grape’s skin and seeds, mainly polyphenols. Red 
wine contains a total of 1.8 g/L of polyphenols, whereas a white wine contains only 0.2-
0.3 g/L of polyphenols (Bertelli and Das, 2009). Resveratrol (RES; Fig. 1c), a polyphenolic 
product synthesized by a wide variety of plant fruit, including grapes, is naturally present 
in red wine. RES has gained considerable attention because of its potential as a 
chemopreventive and its anticancer properties, as well as for the evidence of decreasing 
heart disease and neural degeneration in animal studies (Vang et al., 2011). Among its 
various biological actions, RES was demonstrated to inhibit cellular survival signaling, and 
to interfere with apoptosis pathways, both by directly triggering apoptosis-promoting 
signaling cascades and by blocking antiapoptotic mechanisms (Fulda and Debatin, 2006). 
 
Human dietary intake of food and its relationships with the digestive tract make up a very 
complex system in the framework of exposure to food contaminants. Most toxicity studies 
commonly evaluate the effect of individual mycotoxins on the target cell biological 
functions. However human exposure to mycotoxins is well-known to be far off this 
simplified paradigm, involving sophisticated interactions with a lot of different matrices 
and different chemical species, including other mycotoxins, but also major nutrients, fibres 
and natural bioactive compounds. Co-contamination of different mycotoxins in food and 
feed has been frequently demonstrated, being a more common event than single 
contamination (Streit et al., 2013). Most of the published studies are reporting the 
toxicological properties of mycotoxins alone, and little is known concerning the effect of a 
specific mycotoxin mixed with other mycotoxins and/or with bioactive compounds, which 
may lead to unexpected subsequent effects. DON and OTA have shown to be among the 
most ubiquitous mycotoxins in foods of Mediterranean countries, and thus, continuously 
consumed in moderate levels through dietary intake. Moreover, the mycotoxin mixtures 
can interact with complex food matrices containing bioactive food compounds, as RES. 
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Polyphenols such as RES are also widely present in the diet with the main dietary sources 
being fruits, wine, tea, coffee or chocolate (Burns et al., 2002; Fernández-Mar et al., 
2012). These compounds are known for their beneficial effects on human health due to 
their antioxidants properties. Thus, the main goal of the present work was to assess the 
effect of DON and OTA on the viability of Caco-2 cells when these mycotoxins are 
combined with RES. Additionally, to try to understand the underlying mechanism of 
cytotoxicity, production of reactive oxygen species (ROS), as a first indicator of oxidative 
stress status, has been measured. 
 
2.2 Materials and methods 
2.2.1 Chemicals 
DON (3α, 7α, 15-trihydroxy-12,13-epoxytrichotech-9-en-8-one, purity ≥ 98 %), OTA 
((2S)-2-{[(3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-
yl]formamido}-3-phenylpropanoic acid, purity ≥ 98%), RES (3,40,5-trihydroxystilbene, 
purity ≥ 99%), trypsine, dimethylsulfoxide (DMSO), L-glutamine (200 mM), penicillin-
streptomycin (10.000 UI/mL-10.000 µg/mL), Minimum Essential Medium (MEM, ref 
56416C, dry powder), MEM non-essential amino acids 100x (NEAA), Hepes (Bio-
performance grade), chloramine-T and 2’,7’-dichlorofluorescein diacetate (DCFH-DA) were 
purchased from Sigma-Aldrich (Sigma, Madrid, Spain). Dulbecco’s Modified Eagle Medium 
(DMEM, ref. SH30022) was supplied by Thermo Scientific HyClone (Barcelona, Spain) and 
fetal bovine serum (FBS) by Biosera (Santa Coloma de Gramenet, Spain). CellTiter 96® 
Aqueous Non-Radioactive Cell Proliferation Assay (MTS) kit was purchased from Promega 
(Charbonnières, France). Solid phase extraction cartridge BondElut C18 was purchased 
from Varian (California, USA). 
 
2.2.2 Cell culture and treatment 
The Caco-2 cell line (ATCC HTB-37) derived from a human colorectal adenocarcinoma was 
purchased from LGC Standards, S.a.r.l. (Molsheim Cedex, France). Caco-2 cells were 
cultured at 37 ºC and 5 % CO2 in DMEM medium supplemented with penicillin (100 
UI/mL), streptomycin (100 μg/mL), 15 % fetal bovine serum, 2 mM L-glutamine, and 1% 
NEAA. DON, OTA and RES were dissolved in DMSO and stored at -20 °C before dilution in 
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cell culture media. Solvent control cells received the maximal DMSO concentrations used in 
the treated cells (0.1%, v/v). Caco-2 cells were seeded at a concentration of 105 cells/well 
in 100 μL of culture medium in flat-bottomed 96-well plates. After culturing for 48 h, 
different concentrations of OTA, DON and RES or their combinations (OTA-RES, DON-RES, 
OTA-DON) were added to the cells. Cell lines were exposed for 6, 24 and/or 48 h, 
depending on the assay. 
 
2.2.3 Stability of resveratrol in the culture medium 
Yang et al. (2010) reported the oxidation of resveratrol in culture medium due to 
bicarbonate ions. We checked the stability of resveratrol (160 µM) in two culture media, 
MEM (medium without bicarbonate) and DMEM (a medium that contains 3.7 g/L of 
bicarbonate). Hepes (25 mM) was added to MEM to maintain the pH in a range of 7.2-7.5. 
Stability assays were carried out with 3 mL of culture medium (spiked at 160 µM RES). 
Samples were incubated at 37 °C for 12, 24 and 48 h in the same conditions described for 
cell culture. Three culture medium samples were incubated for each time. Samples were 
collected at the end of the incubation period, and RES was extracted immediately. 
 
2.2.4 Solid-phase extraction of resveratrol and high performance liquid 
chromatography analysis (HPLC) 
RES from culture medium samples was extracted by solid-phase extraction using a Bond 
Elut C18 cartridge and ethanol as eluting solvent. Samples were dried under a nitrogen 
stream and stored at 4 ºC until analysis. RES was quantified by HPLC, using a Waters 
2695 Separations Module coupled to a Waters 2475 Multi λ fluorescence detector (Waters, 
Milford, MA, USA). HPLC conditions were a modification of those described by Serra et al. 
(2009). Mobile phase was: A) acetic acid 0.2% and B) acetonitrile, according to the 
following gradient: 0-10 min 95% A, 10-20 min 75% A, 20-25 min 95% A, with a flow-rate 
of 1 mL/min. A Waters Spherisorb ODS2 C18 column (3 μm, 4.6 x 250 mm) was used and 
column temperature was maintained at 30 ºC during analysis. Detection was performed at 
280 nm, and retention time was 14.66 min. Quantification was achieved with a software 
integrator (Empower 2, Milford, MA, USA). RES detection (LOD) and quantification (LOQ) 
limits were experimentally determined from the calibration curve of a set of seven 
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standards (from 1 to 320 µM RES), which was linear in the range of 10-320 µM RES (r
2 = 
0.989). The LOD and LOQ determined was 10 and 25 µM, respectively. 
 
2.2.5 MTS assay 
The effects on the mitochondrial activity of Caco-2 cells exposed to OTA and RES at 
concentrations ranging from 0.5 to 160 µM and DON (0.25-30 µM), and the combinations 
of OTA (20, 40 and 80 µM) or DON (0.5, 1 and 5 µM) with RES (1-100 µM), and OTA (20, 
40 and 80 µM) with DON (0.5, 1 and 5 µM), after a 24 and 48 h exposure period, were 
studied using the MTS assay kit. The kit is composed of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
(MTS) and phenazinemethosulfate (PMS), an electron coupling reagent. MTS is reduced by 
dehydrogenase enzymes in metabolically active cells into a formazan product that is 
soluble in tissue culture medium. After the 24 h or 48 h exposure period, the cells were 
washed with PBS, and 20 μL of a freshly prepared MTS/PMS solution in fresh medium was 
added to the wells. The cells were further incubated for 2-4 h. The amount of soluble 
formazan produced by cellular reduction of the MTS was measured by the absorbance at 
490 nm on an ELISA plate reader (Genios, TECAN, Männedorf, Switzerland). Results were 
expressed as percentage of the control. 
 
2.2.6 Reactive oxygen species (ROS) assay 
To study the ROS production, cells were exposed for 6, 24 and 48 h to OTA and RES at 
concentrations ranging from 0.5 to 160 µM, and DON at 0.25-30 µM. For the combination 
effects study, concentrations of OTA (5 and 80 µM) or DON (1 and 30 µM) with RES (10, 
40 and 160 µM), and OTA (5 and 80 µM) with DON (1, 10 and 30 µM) were tested. 
Intracellular ROS production was determined by using the dichlorofluorescein (DCF) assay 
(Wang and Joseph, 1999). DCFH-DA (100 mM) in phenol red and serum-free MEM 
medium was added after the incubation period and maintained during 30 min at 37 ºC in 
the dark. Chloramine-T, an effective inducer of oxidative stress, was used as a positive 
control, with cells being exposed to concentrations in the range of 0.3-10 mM. 
Fluorescence was measured at 485 nm excitation and 535 nm emission at 37 ºC, using a 
microplate reader. Fluorescence readings were taken every 15 min for 60 min, with the 
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plates being incubated at 37 ºC with 5 % CO2 between measurements. Oxidative stress 
was calculated as the percentage of increase in fluorescence per well over a 60-min period 
by the formula [(Ft60-Ft0)/Ft0 x 100]. This result was expressed as percentage of the 
solvent control. 
 
2.2.7 Statistical analysis 
The sodium bicarbonate effect on stability of RES in culture medium was determined by 
the analysis of variance ANOVA and the Bonferroni post-test. Cytotoxicity data are 
represented as mean ± standard deviation (SD) of three to five independent experiments 
(in each experiment, each concentration was applied by triplicate in the culture plates). 
Statistical analysis was performed using Sigma Plot version 12.0 (Jandel Scientific, San 
Rafael, CA, USA). Significant differences among treatments were determined by one-way 
repeated measures analysis of variance (RMANOVA, p < 0.05). Previously, normality 
(Shapiro-Wilk test, p < 0.05) and equal variance (p < 0.05) of the distribution was tested. 
Means of treatments were contrasted with respect to the control group using Dunnett’s 
test. 
 
2.3 Results 
2.3.1 Stability of resveratrol in culture media. 
Table 1 reports the decrease of RES (160 µM) over time (12-48 h) on a culture medium 
with or without bicarbonate. Results showed that RES concentration decreased with time 
in both culture media used, regardless of the presence of sodium bicarbonate in its 
composition. The decrease in RES level was moderate (10.5% loss) in samples incubated 
for 12 h in culture media with sodium bicarbonate (p < 0.05), and were increasing with 
time (19 to 41% after 24 and 48 h, respectively). Our results also show a statistical 
difference in RES levels due to the presence or absence of bicarbonate in the media .RES 
showed a moderate decrease after 24 h incubation in DMEM (19%), lower than in MEM 
(32.3%). However, at 48 h a minor decrease was observed in MEM (30.6%) than in DMEM 
(41.4%). 
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Table 1. Decrease of RES (160 µM) in cell culture medium with or without sodium 
bicarbonate. 
Incubation 
time 
(h) 
Resveratrol stability 
Medium with bicarbonate  
(DMEM) 
Medium without bicarbonate 
(MEM) 
RES (µM) (% RES loss) RES (µM) (% RES loss) 
12 143.18 ± 7.05* 10.51 n.d. n.d. 
24 129.70 ± 5.29**, 
A 
18.94 108.33 ± 9.22**, B 32.29 
48 93.84 ± 7.53**, A 41.35 111.09 ± 3.15 **, B 30.57 
Data are represented as mean ± SD of three analyses. n.d.: not determined. Stars 
indicate statistical differences regarding to RES control in DMEM medium (0 h) (*p < 0.05, 
**p < 0.0005). Different capital letters next to DMEM/MEM treatments, at the same time, 
mean significant differences (p < 0.005) due to bicarbonate. 
 
 
2.3.2 MTS assay 
The effect of OTA, DON and RES treatment on cell viability was tested by the MTS assay 
over 24 h and 48 h. Similar responses were observed between both times of exposure and 
only results after 48 h exposure are presented in Figure 2. A dose-response curve was 
obtained after OTA and DON treatment. A significant reduction in cell viability was 
observed with OTA at 40 µM (p < 0.01) (Fig. 2a) and DON 1 µM (p < 0.001) (Fig. 2b). 
The non observed effect concentration (NOEC) for OTA and DON were 20 and 0.5 µM, 
respectively. However, Caco-2 cells did not show any response after treatment with RES in 
the range 0-160 µM (Fig. 2c). 
 
The 48 h co-exposure of DON at non-toxic concentrations (0.5 µM) with increasing 
concentrations (1-100 µM) of RES induced an increase in cytotoxicity at a concentration of 
RES of 100 µM (p < 0.001) (Fig. 3a). However the cytotoxic effect at concentrations of 
DON of 1 and 5 µM was not significantly affected by the presence of RES. On the other 
hand, the cytotoxicity of OTA at 80 µM increased significantly (p < 0.05) when co-exposed 
with 100 µM of RES (Fig. 3b). An increase in toxicity could also be observed when cells 
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were co-exposed to a non toxic concentration of OTA (20 µM) and non toxic or low 
concentrations (0.5 µM and 1 µM) of DON (Fig. 3c). 
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Figure 2: Effect of OTA (a), DON (b) and RES (c) on Caco-2 cell viability after 48 h 
exposure measured with the MTS assay. Results are expressed as percentage of viability 
compared with the solvent control (0.1% DMSO). Data are represented as mean ± SD of 
3-5 independent experiments. Statistical differences with respect to the controls are 
indicated (**p < 0.01, ***p < 0.001). 
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Figure 3. Combined effect of DON, OTA and RES on Caco-2 cell viability after 48 h of 
treatment. Results are expressed as percentage of viability compared with the solvent 
control (0.1% DMSO). Data are represented as mean ± SD of 3-5 independent 
experiments. Statistical differences with respect to the control of RES for each 
concentration level of DON (3a) or OTA (3b) and with respect to the control of DON for 
each concentration level of OTA (3c) are indicated (*p < 0.05, **p < 0.01, ***p < 0.001). 
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2.3.3 Reactive oxygen species (ROS) production 
ROS produced by OTA, DON and RES was measured by comparison of fluorescence 
emitted by treated cells with the control using a dichlorofluorescein (DCF) assay (Fig. 4). 
Significant dose-dependent production of ROS was obtained when the cells were treated 
with OTA and RES for 24 h (data not shown) and 48 h (Fig. 4a and 4b), but not when 
treated for only 6 h (data not shown). The best response was obtained after 48 h. OTA 
and RES induced production of ROS at 80 and 20 µM (p < 0.01), respectively. However, 
there was not an increase in ROS production when Caco-2 cells were treated with DON 
during 6 and 24 h (data not shown) or 48 h (Fig. 4c). 
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Figure 4: Individual effect of DON, OTA and RES on ROS production by Caco-2 cells after 
48 h of treatment. Results are expressed as percentage of ROS production compared with 
the solvent control (0.1% DMSO). Data are represented as mean ± SD of 3-5 independent 
experiments. Statistical differences with respect to the controls are indicated (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
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Figure 5: Combined effect of DON, OTA and RES on ROS production by Caco-2 cells after 
48 h of treatment. Results are expressed as percentage of ROS production compared with 
the solvent control (0.1% DMSO). Data are represented as mean ± SD of 3-5 independent 
experiments. Statistical differences with respect to the control of RES for each 
concentration level of DON (5a) or OTA (5b) and with respect to the control of DON for 
each concentration level of OTA (5c) are indicated (**p < 0.01). 
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Binary mixtures of DON and OTA with different concentrations of RES (10, 40 and 160 µM) 
were tested (Fig. 5). To study the effects of DON on the ROS production, a low and a high 
cytotoxic concentration of DON (1 µM and 30 µM) were selected for these co-exposure 
studies. RES produced a notable increase of ROS levels when it was treated individually, 
however this ROS production decreased completely when co-exposed with DON at both 
concentration levels (Fig. 5a). To study the effects of the co-exposure of OTA with RES a 
non ROS-producing and non-cytotoxic concentration (5 µM), and a high cytotoxic and high 
ROS-producing concentration (80 µM) of OTA were selected. Combination of OTA at both 
doses with RES blocked the production of ROS by RES (Fig. 5b). Mixtures of OTA-DON 
didn’t increase the ROS production observed for the highest concentration of OTA (80 µM) 
(Fig. 5c). 
 
2.4 Discussion 
In this study we have used the human cell line Caco-2 to study the possible toxic effects 
of the presence in foods of two different mycotoxins when they are present alone or 
together as well as when the antioxidant RES is also present in food. Caco-2 cell model is 
an accepted intestinal model widely implemented to assess the effect of chemical 
compounds on the intestinal function. Hence, undifferentiated and proliferating Caco-2 
cells share some characteristics with crypt enterocytes. Studies focusing to assess the 
trans-cellular transport, barrier function and permeability properties are performed with 
differentiated cells, which exhibit structural and molecular characteristics similar to villous 
enterocytes. Cytotoxicity, viability and proliferation assays may be carried out also with 
un-differentiated (proliferating) Caco-2 phenotypes, which share some characteristics with 
crypt enterocytes (Manda et al. 2015; Sambruy et al 2001). Bony et al (2006) reported 
that proliferating cells were found to be more sensitive to DON than differentiated cells, 
therefore this model can be considered as the most conservative approach for hazard 
characterization. 
 
In the present work we have shown that the degradation of RES in DMEM, a medium with 
sodium bicarbonate, is lower than 20% after 24 h of incubation and around 40% after 48 
h. These results do not agree with those found by Yang et al. (2010) that reported a 96% 
of RES degradation after 24 h of incubation at 37 ºC when it was added at 200 µM to the 
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Base Modified Eagle (BME) medium, a medium with bicarbonate (2.2 g/L) in its 
composition. Our results also show that, independently of the presence or absence of 
bicarbonate, the decrease in RES levels after 24 h (18.94% and 32.29%) and 48 h 
(41.35% and 30.57%) of incubation is relatively similar. 
 
Regarding ROS production, Yang et al. (2010) reported a production of high levels (90 
µM) of H2O2 after incubating RES for 24 h in a medium with bicarbonate. Nakamura et al. 
(2003) demonstrated a significant toxicity in HeLa cells after a 15 min exposure to H2O2 at 
concentrations as low as 0.06 mM (2 µg/mL). However, our results show that after 24 h 
and 48 h of exposure, RES is capable to increase ROS levels but not after 6 h, and no 
induction of cytotoxicity was observed with RES. This suggests that the enhanced 
production of ROS by RES in our study is mainly due to RES itself. 
 
Both assayed mycotoxins are cytotoxic for the Caco-2 cell line. The NOEC and the lowest 
observed effect concentration (LOEC) were 0.5 and 1 µM for DON and 20 and 40 µM for 
OTA, respectively, indicating a highly toxic effect, especially for DON. Contrary to our 
results, Calvert et al. (2005) didn’t find cytotoxicity according to the MTT assay for the 
Caco-2 cell line after 48 h exposure to 0.34-1.7 µM of DON, but HeLa and Hep-2 cells 
were very sensitive to DON ≥ 0.34 µM. Also in the mammalian kidney epithelial (Vero) 
cells the cytotoxicity of DON, evaluated by the NR and MTT assays over 24, 48 and 72 h, 
showed IC50 values ranging from 3.30 to 10 µM (Ruiz et al., 2011). Berger et al. (2003) 
reported the toxic effect of OTA on Caco-2 cells with the MTT assay. They determined a 
lower IC50 (0.4 µM) after a 48 h exposure period. However, different results are reported 
in the HepG2 cell line. The IC50 of OTA, as measured by the NR assay and the MTT assay, 
was 35 µM after 24 and 48 h exposure (Hundhausen et al., 2005; Zheng et al., 2013). As 
expected, RES didn’t show cytotoxic effects up to concentrations of 160 µM. However, 
Sergent et al. (2005) found a slight cytotoxic effect of RES on Caco-2 cells after 48 h of 
treatment at 100 µM. 
 
To investigate the capacity of these compounds and their combinations to induce oxidative 
stress, production of ROS was also measured. Studies carried out with individual 
compounds showed that only OTA and RES increased ROS levels with NOECs and LOECs 
of 40 and 80 µM for OTA and 10 and 20 µM for RES, respectively. The implication of 
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oxidative stress in the cytotoxicity induced by OTA has been previously suggested (Schaaf 
et al., 2002; Petrik et al., 2003; Kamp et al., 2005; Mally et al., 2005; Hsuuw et al., 2013). 
In our study, the production of ROS is associated with a parallel reduction in viability, 
suggesting the same conclusion of other authors. Interestingly, although RES is known for 
its anti-oxidative properties, it was able to produce high levels of ROS at concentrations as 
low as 20 µM in the Caco-2 cell line. Juan et al. (2008) have also reported the generation 
of mitochondrial ROS in the human colon cancer cell line (HT-29) exposed to RES (150 
µM) for 4 h. Despite this ROS production, the basal redox status of the cells was not 
disturbed and no cytotoxicity was recorded with this compound in the cell line studied. 
From our results, the cytotoxicity induced by DON might not be explained by an oxidative 
stress mechanism. Previous results points to an apoptotic mechanism (Petska et al., 2004; 
Pestka, 2008). Recently, Ma et al. (2012) demonstrated the capacity of DON to induce 
apoptosis in the HT-29 cell line at very low concentrations ranging from 0.8 to 3.4 µM. 
They showed that the mechanism of apoptosis was caused by mitochondrial dysfunction 
and subsequent release of cytochrome c into the cytoplasm and successive activation of 
caspase-9 and caspase-3. 
 
There have been few works published to date attempting to contribute on the knowledge 
of mycotoxins interactions with bioactive compounds such as dietary polyphenols. The 
most common approach followed involves pre-treatments with the bioactive compound 
and a subsequent treatment with the mycotoxin (Hundhausen et al., 2005; Bosch-
Saadatmandi et al., 2006; Costa et al., 2007). In real exposure scenarios, interactions 
between the bioactive compounds and mycotoxins will occur simultaneously, which 
suggest that pre-treatment may not be the best approach. 
 
In this study using a co-exposure approach, we didn’t found a protective effect when OTA 
was co-exposed with RES. In fact, co-exposure of OTA at concentrations of 40 µM 
(moderately toxic dose) with the highest concentration of RES (100 µM) resulted in an 
increase in cytotoxicity. Sergent et al. (2005) showed that the Caco-2 absorption of OTA, 
at concentrations that should be easily encountered in the gut, is increased in the 
presence of RES. This would imply a greater bioavailability of the mycotoxin which could 
increase the toxicity of this compound. It could be that this also happens in the Caco-2 cell 
line, although this possibility has not been checked in this study. Co-exposure of DON with 
 77 
RES did neither result in a protective effect of the polyphenols to the toxic effects of this 
mycotoxin. Moreover, in the case of DON, the presence of RES at high doses (100 µM) 
increases the toxicity of a non-cytotoxic dose of DON (0.5 µM). In contrast, Kolesarova et 
al. (2012) showed in porcine ovarian granulosa cells that RES protected cells from the 
reproductive toxicity induced by DON. Co-exposure of OTA and DON with RES resulted in 
the complete abrogation of ROS levels induced by RES. This finding is difficult to explain 
especially in the case of the co-exposure of RES with the non-toxic and non-ROS 
producing dose of OTA (5 µM). The decrease in ROS production of RES observed when 
this compound is co-exposed with toxic doses of DON (1 µM and 30 µM) or OTA (80 µM) 
could be the result of loss in cell viability. The mechanism triggering the cytotoxic effect of 
DON and OTA enhanced by RES at a non- toxic and a sub-toxic concentration respectively 
cannot be completely elucidated with the present data. Several studies have reported that 
RES modulates multiple vias that elicite to apoptosis and cell damage. Fouad et al. (2013) 
and Pasciu et al. (2010) have related a response mediated by the caspase-3 and the cells 
damage observed. Zhai et al. (2015) reported that RES inhibits proliferation and induces 
apoptosis of fibroblasts through the mechanism involving transforming growth factor and 
Smad proteins (TGF-b1/Smads) signaling pathway. On the one hand, TGF-b1 is a 
multifunctional cytokine that controls a diverse set of cellular processes (cell proliferation, 
differentiation, and apoptosis). On the other hand, Smad proteins are downstream 
messengers of TGF-b signaling pathways, conveying the TGF-b-mediated extracellular 
signals to the nucleus (Zhai et al., 2015). 
 
When both mycotoxins were co-exposed at non-toxic concentrations of DON and OTA (0.5 
and 20 µM, respectively) a significant increase in cytotoxicity was observed. Also the toxic 
response induced by DON (1 µM) increased significantly with increasing doses of OTA (40 
and 80 µM), indicating that cocktails of these mycotoxins can suppose a risk for 
consumers. This increase in cytotoxicity could not be explained by an increase in ROS 
production. To our knowledge this is the first study where the in vitro toxicity of the co-
exposure of DON and OTA has been studied. Other authors have reported different 
interactions between binary and tertiary combinations of DON or OTA with other 
mycotoxins (T-2 toxin, zearalenone, beauvericin, fumonisin B1, nivalenol, fusarenon-X) 
resulting in antagonism, synergism or additive effects depending on the combinations, the 
78 
cell lines, the concentrations and the assays used (Ruiz et al., 2011; Alassane-Kpembi et 
al., 2013). 
 
Our results elucidated the complex behavior of mixtures of chemicals and bioactive 
compounds and the need of further research to better understand the biological responses 
and potential effects on the human health. Although the extrapolation of in vitro models to 
humans is very complex and requires an accurate approach, the concentration doses used 
in the present study are expected in the range of those levels expected from a common 
European diet. For example, the mean and highest (percentile 95) exposure levels of DON 
in Spain were estimated to be 0.37 and 1.9 mg/kg bw/day (Cano-Sancho et al., 2011). 
Thus, a mean intestinal dose of 0.5 µM can be expected in a relevant group of population. 
RES can be detected in Spanish wine at mean concentrations of 4.6 mg/L (Martelo-Vidal 
and Vázquez, 2014), leading to estimate an intestinal dose of 20 µM. While the risk 
assessment frameworks are developed on the basis of animal or human dose-response 
studies with isolated mycotoxins, potential interactions with other mycotoxins and 
bioactive compounds are missed. We focused the study to assess the simultaneous 
exposure of DON and OTA, the most concerning mycotoxins in Spain (Cano-Sancho et al., 
2011: Coronel et al. 2012) with RES, a polyphenol widely consumed on the Spanish 
households. Despite the risk characterization did not reveal a concern for the human 
health, in the present study we elucidated toxicological issues commonly misplaced on risk 
assessment, such as the potential interaction of bioactive compounds at sub-toxic doses of 
mycotoxins. Future studies should confirm these results on animal models and assess the 
interactions with other bioactive compounds, as well as to translate the effect of these 
interactions on the risk characterization frameworks. 
 
2.5 Conclusion 
The results from our study showed that the co-exposure of both mycotoxins increased 
significantly the cytotoxicity of these compounds in Caco-2 cells without increasing the 
ROS production. The co-exposure of OTA or DON with RES did not result in a decrease in 
cytotoxicity; on the contrary, it resulted in increased cytotoxicity not associated with an 
increase in ROS production. Further studies should be conducted to elucidate the 
mechanisms underlying the toxic effects observed in the co-exposures and confirm these 
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findings in animals. Further studies should be conducted to elucidate the mechanisms 
underlying the toxic effects observed in the co-exposures and confirm these findings in 
animals. These results also elucidated a need to better understand the interactions with 
other bioactive compounds present in the diet, and evaluate the impact on risk 
assessment. 
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Abstract 
Cytotoxicity of ochratoxin A (OTA) was evaluated using the MTS assay, and membrane 
integrity was measured using transepithelial electrical resistance (TEER). A transwell 
system was used to investigate the effect of OTA on the expression of the CYP450 (1A1, 
2A6, 2B6, 3A4 and 3A5), NAT2, COX-2, LOX-5, and MRP2 genes in Caco-2 and HepG2 
cells. TEER decreased by a mean of 63.2% after 24 h of treatment in Caco-2 differentiated 
cells without inducing cell detachment; revealing damage to the intestinal epithelial cell 
tight junction proteins and an increase in cell permeability. Gene expression analysis 
showed that modulation of gene expression by OTA was higher in Caco-2 cells than in 
HepG2 cells, and generally, the duration of exposure to OTA had a more significant effect 
than the OTA dose. A general OTA down-regulation effect was observed in Caco-2 cells, in 
contrast with the down- and up-regulation observed in HepG2 cells. In Caco-2 cells, 
CYP1A1 was the gene with the highest regulation, followed by CYP3A4 and CYP3A5. 
Conversely, in HepG2 cells, CYP2B6 was highly regulated at 3 and 12 h compared to the 
other cytochromes; CYP1A1 was slightly modulated during the first 12 hours, but an 
overexpression was observed at 24 hours. 
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Our data support the involvement of the CYP450, COX-2 and 5-LOX genes in liver 
metabolism of OTA. On the basis of the gene expression analysis, the results suggest a 
possible impairment in OTA secretion at the intestinal and hepatic level due to MRP2 
repression. In addition, we provide evidence of the effect of OTA on NAT2 gene 
expression, which had not been reported before. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: Food Chemical Toxicology (2015), 86: 245-252. 
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3.1 Introduction 
Ochratoxin A (OTA) is a mycotoxin produced by some species of two ubiquitous genera of 
fungi, Aspergillus and Penicillium. This mycotoxin is frequently found in a wide variety of 
raw materials (such as cereals and fruits) and foodstuffs (coffee, beer, wine, cocoa 
products, and grape juice) (EFSA, 2006). It can also be found in foods of an animal origin 
due to its bioaccumulation in tissues, even in the case of animals sub-chronically exposed 
to OTA (Perši et al., 2014). The presence of OTA in feed has been linked to the 
development of nephrotoxicity, which, in rats, has been associated with renal adenomas 
and kidney tumours (Boorman, 1989; IARC, 1993). Several mechanisms of OTA toxicity 
have been described, including competition with phenylalanine for protein synthesis, 
inhibition of mitochondrial ATP production, production of free radicals, promotion of lipid 
peroxidation, and direct and indirect damage to DNA (El Khoury and Atoui, 2010; 
González-Arias et al., 2014; Ringot et al., 2006). 
 
OTA is absorbed in the intestine, where the multi-drug resistance protein 2 (MRP2 gene) 
plays an important role acting as a xenobiotic outward transporter to reduce the oral 
bioavailability and the toxin load to organs and, thereby, OTA toxicity (Berger et al., 2003; 
Dietrich et al., 2003). Once OTA reaches the bloodstream, it can reach other organs such 
as the liver, and the MRP2 transporter is again a key primary active transporter involved in 
anionic conjugate and drug/xenobiotic extrusion into the extracellular space, which 
contributes to bile formation and the subsequent elimination of the toxin (Dietrich et al., 
2003; Jedlitschky et al., 2006). 
 
The CYP450 enzymes expressed in the liver have a major role in the in vitro and in vivo 
biotransformation of OTA and, therefore, in its toxicity. For example, Zepnil et al. (2001) 
showed that OTA oxidation was mediated by the CYP450 enzymes in in vitro reactions 
with microsomes of liver and kidney from Wistar rats. On the other hand, Pfohl-Leszkowicz 
et al. (2012) have demonstrated the formation of OTA-derived DNA adducts and 
mutations and the involvement of the CYP450 enzymes in the bioactivation of OTA. The 
presence of DNA double-strand breaks and the micronucleus formation observed in in vivo 
or in vitro assays with cells capable of expressing cytochrome P450 (CYP450) enzymes 
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support the OTA genotoxicity (González-Arias et al., 2014; Groene et al., 1996; Hibi et al., 
2013). 
 
Human N-acetyltransferase 2 (encoded by the NAT2 gene) is involved in the metabolism 
of drugs and xenobiotics during phase II metabolism. Lack of NAT2 function is also 
associated with higher incidences of cancer and drug toxicity. NAT2 shows a restricted 
tissue distribution, and high levels are found in the human liver and intestine (Husain et 
al., 2007). To our knowledge, the study of Lebrun et al. (2002) is the only one that has 
analysed the involvement of NAT2 in OTA genotoxicity. The authors observed a positive 
correlation between DNA damage and NAT2 polymorphisms in human urothelial cells 
exposed to OTA. 
 
Some in vitro and in vivo assays indicate that the level of expression of cyclooxygenase-2 
(COX-2) and lipoxygenase-5 (5-LOX) are associated with the presence of OTA (Ferrante et 
al., 2006; Kumar et al., 2013; Ramyaa et al., 2014). COX-2 and 5-LOX gene expression is 
related to cancer initiation or chronic inflammation processes in a variety of cancers in 
humans; for this reason, both genes have been described as inflammatory mediators 
(González-Périz and Clàira, 2007; Terzic et al., 2010). 
 
The present study aimed to investigate the effect of OTA on expression of five genes from 
the CYP450 family (CYP1A1, CYP2A6, CYP2B6, CYP3A4 and CYP3A5), as well as 
expression of the NAT2, COX-2, 5-LOX and MRP2 genes. Although the involvement of the 
CYP450 enzymes is well known in OTA biotransformation, much less is known about the 
role of COX-2, 5-LOX and NAT2 and the effect of OTA in the modulation of expression of 
these genes. Considering that OTA is a mycotoxin that mainly enters the human body via 
ingestion, we have used an in vitro cell co-culture system to mimic initial passage through 
the intestine and secondary hepatic metabolism, using Caco-2 and HepG2 cells. Caco-2 
cell line is a well established in vitro model especially indicated to study intestinal 
absorption, metabolism, and bioavailability of drugs and xenobiotics (Artursson et al., 
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2001; Natoli et al., 2011). On the other hand, the use of human liver cells, as the HepG2 
cell line, in the co-culture system tries to simulate the place where the main xenobiotic 
metabolism occurs in humans. 
 
3.2 Methodology 
3.2.1 Reagents and instrumentations 
The following products were obtained from Sigma-Aldrich (Steinheim, Germany): OTA 
standard (98% purity) (ref. O1877), non-essential amino acids (ref. M7145), L-glutamine 
(ref. G7513), antibiotic mixture (penicillin and streptomycin) (ref. P4333), dimethyl 
sulfoxide (DMSO) (ref. D8418), and oligonucleotide primers (Table 1). Foetal bovine serum 
(ref. FB1090500) was supplied by BioSera (Nauille, France). TRIzoI® (ref. 15596) 
reagent, ethidium bromide (EtBr) (ref. 15585011), TURBOTM DNase (Ambion) (ref. 
AM2238), SuperScriptTM III reverse transcriptase (ref. 18080) and Oligo(dT)12-18 primer 
(ref. 18418-012) were obtained from Gibco BRL Life Technologies (Grand Island, NY, 
USA). Dulbecco’s modified Eagle medium (DMEM) (ref. SH30022) and a solution of 
trypsin-EDTA (0.25%, 0.2 g/L) (ref. SH30042) were obtained from Thermo Fisher (Madrid, 
Spain). iTaqTM Universal SYBR® Green Supermix (ref. 172-5124) and the Hard-Shell® 96-
Well Thin-Wall PCR (ref.6340589) Plates were obtained from Bio-Rad (Hercules, CA, USA). 
75 cm2 flasks (ref. 156499) and 96-well plates (ref. 267313) were supplied by Nunc 
(Roskilde, Denmark). 6-transwell systems (4.67 cm2 and 0.4 µm polycarbonate pore size 
insert) and 6-well plates were obtained from Corning (ref. 3526) (New York, USA). The 
CellTiter 96® Aqueous One Solution Cell Proliferation Assay (ref. G3582) was obtained 
from Promega (Madison WI, USA). 
 
3.2.2 Cell culture 
The human colon cell line Caco-2 (HTB-37) and the hepatic line HepG2 (HB-8065) were 
obtained from the American Type Culture Collection (ATCC). Cells were grown as 
monolayer cultures in 75 cm2 flasks and maintained with DMEM in an atmosphere at 95% 
RH and 5% CO2 at 37 °C. DMEM was supplemented with foetal bovine serum (15% v/v 
for Caco-2 or 10% v/v for HepG2 cells), 1% (v/v) of non-essential amino acids, 1% (v/v) 
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of L-glutamine and 1% (v/v) of an antibiotic mixture (penicillin and streptomycin). Cellular 
monolayers (80% confluence) were detached with a solution of trypsin-EDTA, and the 
cells were reseeded to carry out the cytotoxicity assay or the co-culture system. Caco-2 
and HepG2 cells were used at passages from 33 to 42 and from 15 to 25, respectively. 
 
3.2.3 Viability assays 
3.2.3.1 MTS assay  
HepG2 cells were reseeded in 96-well plates at a density of 1.5 x 105 cells/cm2, and Caco-2 
cells were reseeded at a density of 105 cells/cm2, allowing 24 h for cell adherence. Cell 
viability was determined using a stable solution of MTS from the CellTiter 96® Aqueous 
One Solution Cell Proliferation Assay. OTA doses tested were 1, 5, 15, 45, 60, 75, 90 and 
180 μM (in DMSO) for 3, 12 and 24 h. The treatments were conducted in cell culture 
medium, and the percentage of DMSO in the treatments was 0.5% of the final volume. At 
the end of the treatment, cells were washed once with PBS. Immediately, 100 μL of 
culture medium with 317 μg/mL MTS-one solution was added per well. Cells were 
incubated for 2.5 h (Caco-2) or 2 h (HepG2). Optical density was determined using a 96-
plate reader (DAS-A3, Roma, Italy) with a 490 nm filter (FGF2, TSP1). Relative cell viability 
was expressed as a percentage with respect to the cells in the solvent control treatment. 
 
3.2.3.2 Trans epithelial electrical resistance (TEER) measurement 
The TEER value of all of the Caco-2 cell monolayers was recorded at day 21 (before 
treatments) to determine the effect of OTA on membrane integrity as a cytotoxicity 
parameter. The maintenance of cell monolayers was performed as described in the co-
culture section. TEER recordings were made using a Millicell-ERS electrical resistance 
system (Millipore Ibérica, Spain) with a STX01 electrode (Millipore Ibérica, Spain), 
according to the manufacturer´s instructions. Values are expressed as Ω•cm2, according 
to the equation 1: 
 
TEERmonolayer = (Resistancemonolayer – Resistanceblank)·(filter growth area in cm2)  Equation 1 
 
Resistanceblank is considered as the value of the resistance of a filter without cells. 
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3.2.4 Caco-2/HepG2 co-culture system 
3.2.4.1 Caco-2 differentiation 
Caco-2 cells were reseeded at 105 cells/cm2 on polycarbonate membrane inserts in 6-
transwell plates and maintained for 21 days with complete medium. The TEER increment 
was monitored at 9, 15 and 20 days (3 wells for each experiment) as a signal of 
progression of cell differentiation. The TEER increase (mean ± DS) was in the range of 
240 ± 20 to 500 ± 35 Ω•cm2. 
3.2.4.2 Co-culture system and OTA treatments 
HepG2 cells were seeded in 6-well plates at a density of 1.5 x 105 cells/cm2 (at day 20 of 
the Caco-2 cells differentiated monolayers). Twenty-four hours after the seeding of HepG2 
cells, the co-cultures were performed (day 21). Non-cytotoxic doses (5, 15 and 45 μM) of 
OTA were selected for 3, 12 and 24 h treatments in transwell plates. The treatments were 
carried out in culture medium, and the percentage of solvent (DMSO) in the treatments 
was 0.5% of the final volume in the transwell system for all of the treatments. 
 
3.2.5 Gene expression 
3.2.5.1 RNA extraction and cDNA synthesis 
Total RNA was prepared from freshly isolated cells using the Trizol® reagent, according to 
the manufacturer´s protocol. RNA integrity was checked on an agarose gel stained with 
ethidium bromide (EtBr). The concentration and purity of total RNA were determined by 
measuring the ratio of absorbance at 260/280 nm and 260/230 nm in a NanoDrop ND-
1000 (Thermo Scientific, USA), respectively. 5 µg of total RNA was treated with TURBOTM 
DNase to remove contaminating genomic DNA. The SuperScriptTM III reverse transcriptase 
kit and a Oligo(dT) primer were used to synthesize first-strand cDNA. 
 
3.2.5.2 Reverse transcription-quantitative polymerase chain reaction (RT-
qPCR) 
92 
Primers used in this study are listed in Table 1. The primer set used for amplifying the 
CYP2A6 gene was designed with OLIGO Primer Analysis Software V.7. Real-time RT-qPCR 
reactions were performed in a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad 
Laboratories, Hercules, CA, USA) monitoring cDNA amplification with iTaqTM Universal 
SYBR® green Supermix (Bio-Rad Laboratories, Hercules, CA, USA). The program included 
one cycle at 95 ºC for 2 minutes followed by 40 cycles of 15 s at 95 ºC and 30 s at 58 ºC 
and, finally, a dissociation and amplification curve step to check the PCR reaction quality. 
 
To validate the RT-qPCR, a standard curve was generated with 6 set points of two-fold 
serial cDNA dilutions. A pool of cDNA from Caco-2 or HepG2 cells was used to run the 
standard curve. The standard curve was generated by plotting the quantification cycle 
(Cq) versus the logarithmic value of the cDNA concentration. The real-time PCR efficiency 
(E) of one cycle in the exponential phase was calculated for each primer pair (equation 2), 
where the slope belongs to the standard curve (Rasmussen, 2001). 
 
E = 10[-1/slope]                Equation 2 
 
Expression level was normalized using glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) mRNA. The relative expression ratio (r) of the genes was calculated according to 
the 2-ΔΔCp mathematical model, based on E and the Cq deviation (equation 3) (Pfaffl, 
2001). 
 
r = (Etarget)∆CPtarget  / (Ereference)∆CPreference       Equation 3 
 
ΔCqtarget is the subtraction of Cqcontrol  from the Cqsample for the target gene, and ΔCqreference 
is the subtraction of Cqcontrol  from the Cqsample for the reference gene. 
 
3.2.6 Statistics 
Three experiments were run in triplicate, and two technical replicates were run for each of 
the treatments that constitute the experiment. Each value represents the mean ± SE. 
Statistical analyses were conducted using Statgraphics plus. Cell viability, membrane 
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integrity and gene expression were analysed using ANOVA and the Bonferroni post-test. p-
values < 0.05 were considered to be statistically significant. 
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Table 1. Primers used for the analysis of gene expression by RT-qPCR 
Target 
gen 
Forward 
(F) 
Reverse 
(R) 
Primer sequence (5´-3´) Length 
(bp) 
Primer 
reference 
CYP1A1 F TTCCGACACTCTTCCTTCGT  20 
Ayed-
Boussema et 
al. (2012) 
  R ATGGTTAGCCCATAGATGGG  20  
CYP2A6 F ACCCCAGTTTCTTCTCCAACCC  22  This study (*) 
  R CCGAAACAGTTCCGCTTTCCGAT  23   
CYP2B6 F GGCCATCGGGAGCCCTTG  18 
Ayed-
Boussema et 
al. (2012) 
  R AGGGCCCCCTTGGATTTCCG  20   
CYP3A4 F GCCTGGTGCTCCTCTATCTA  20 
Ayed-
Boussema et 
al. (2012) 
  R GGCTGTTGACCATCATAAAAG  21   
CYP3A5 F TGACCCAAAGTACTGGACAG  20 
Ayed-
Boussema et 
al. (2012) 
  R TGAAGAAGTCCTTGCGTGTC  20   
COX-2 F CAAATCCTTGCTGTTCCCACCCAT  24 Rasheed and Haqqi, (2012) 
  R GTGCACTGTGTTTGGAGTGGGTTT  24   
5-LOX F ACCACGGAGATGGTAGAGTGCAG  23 Zhou et al. (2007) 
  R GCAGCTCAAAGTCCACGATGAA  22   
NAT2 F ACGTCTCCAACATCTTCATTTATAACC  27 Kocabas et al. (2004) 
  R TCAACCTCTTCCTCAGTGAGAGTTTTA  27   
MRP2 F ACAGAGGCTGGTGGCAACC  19 Pascolo et al. (2003) 
  R ACCATTACCTTGTCACTGTCCATGA  25   
GAPDH F TGCACCACCAACTGCTTAGG  20 Vreeburg et al. (2011) 
  R GGCATGGACTGTGGTCATGAG  21   
*sequence designed with with OLIGO Primer Analysis Software V.7. (accession number 
NM_000762.5). 
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3.3. Results 
3.3.1 MTS assay 
Relative viability measured by the metabolic reduction of MTS is shown in Table 2. In 
general terms, the viability was slightly lower in Caco-2 cells (53.81-80.57 %) than in 
HepG2 cells (66.28-87.75 %) at 24 h. The mean values show that treatment with 1 µM 
OTA for 24 h resulted in viabilities of approximately 81% (Caco-2 cells) and 88% (HepG2 
cells), similar to the results observed after treatment with 180 µM OTA for 12 h in both 
type of cells (85 and 84%, respectively). Additionally, the higher OTA concentrations did 
not substantially affect Caco-2 cell viability at 3 and 12 h. 
Based on the results of the viability assay, three non-cytotoxic OTA concentrations (5, 15 
and 45 µM) were chosen for the membrane integrity and gene expression assays (> 70 % 
viability for both cell types). 
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Table 2. Relative viability (%) determined by the MTS test in cells treated with OTA (1-180 
µM) for 3, 12 and 24 hours. 
Cells 
 Relative viability (%) 
  
OTA 
(µM) 3 hours 12 hours 24 hours 
Caco-2 1 106.78 ± 1.75a 100.43 ± 5.14a 80.57 ± 5.00a 
 5 112.20 ± 3.32a 97.96 ± 3.01a 78.37 ± 3.34ab 
 15 102.60 ± 2.98a 96.80 ± 2.46a 72.17 ± 4.32ab 
 45 107.08 ± 2.37a 86.18 ± 1.21a 76.14 ± 8.23ab 
 60 99.18 ± 3.01a 90.99 ± 2.70a 74.00 ± 6.34ab 
 75 104.36 ± 2.61a 95.50 ± 6.78a 66.26 ± 3.57ab 
 90 104.81 ± 3.54a 91.15 ± 2.47a 66.34 ± 4.59ab 
 180 95.85 ± 5.14a 84.98 ± 4.72a 53.81 ± 6.03b 
     
HepG2 1 98.53 ± 0.48ab 97.48 ± 2.65a 87.75 ± 1.66a 
 5 97.34 ± 2.83ab 101.38 ± 2.71b 91.06 ± 1.50ab 
 15 91.81 ± 2.02ab 105.67 ± 3.37ab 85.58 ± 1.30c 
 45 100.85 ± 3.33ab 106.32 ± 2.68ab 91.53 ± 2.04ab 
 60 95.97 ± 2.54ab 105.20 ± 2.93ab 90.66 ± 2.04c 
 75 95.55 ± 2.81ab 103.97 ± 3.84ab 88.43 ± 2.06c 
 90 88.98 ± 2.06bc 98.34 ± 2.75bc 88.64 ± 1.51c 
 180 81.58 ± 2.37c 83.74 ± 2.20c 66.28 ± 2.21d 
Relative viability was calculated respect to solvent control (0.5% DMSO). Mean ± SE 
values followed by the same letter within an exposure time are not significantly different 
(p > 0.05). Statistical analysis was performed for each kind of cells separately. 
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3.3.2 Membrane integrity 
TEER measurement is useful to detect changes in physiological barrier function caused by 
the assayed compounds. In particular, TEER reflects the transepithelial permeability of 
water-soluble ions. The integrity of the Caco-2 cell monolayer was markedly and 
significantly affected after OTA treatments (5, 15 and 45 OTA µM) with the longest 
exposition time. Table 3 shows the TEER values at 3, 12 and 24 h. The observed 
decreases in TEER, expressed as a percentage of the value at 24 h of treatment, were 
63.6%, 61.5% and 64.6% (at 5, 15 and 45 µM OTA treatments, respectively), which 
means an increase in permeability without cell detachment. The 3 or 12 h treatments 
showed a slight but significant decrease in TEER values. Additionally, the solvent (DMSO) 
had no significant effect on the TEER-values (p > 0.05) compared to the monolayer 
exposed to culture medium alone (data not shown). 
 
 
Table 3. Effect of OTA on the transepithelial electrical resistance (TEER) in differentiated 
monolayers of Caco-2 cells. 
 TEER Ω•cm2 (Mean ± SE) 
OTA (µM) 3 hours  12 hours 24 hours p-value 
5 503.50 ± 5.68ª 475.16 ± 4.88b 137.74 ± 3.00bc    0.0008 
15 480.82 ± 2.19ª 496.67 ± 1.68b 179.06 ± 2.27c    0.0001 
45 595.56 ± 3.17ª 557.75 ± 3.65ª 170.89 ± 4.25c < 0.0001 
SD ± SE: mean ± standard error of TEER-values of the Caco-2 monolayer exposed to 
OTA. Different letters (a, b, c) mean significant differences within the same exposure time. 
 
 
3.3.3 Gene expression 
To elucidate OTA metabolism, gene expression of the CYP450 family (CYP1A1, CYP2A6, 
CYP2B6, CYP3A4 and CYP3A5), the inflammatory markers COX-2 and 5-LOX, the 
xenobiotic metabolizer NAT2, and the MRP2 transporter was analysed in a co-culture 
system of Caco-2 and HepG2 cells. It should be firstly noted that gene expression was not 
affected by the added solvent (DMSO) as there were no statistically significant differences 
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between the blank (medium alone) and DMSO treatments, with a p-value of 0.6882 for 
the Caco-2 cells and 0.3128 for the HepG2 cells. Hence, all relative gene expression ratios 
were calculated by referring to the Cp-values from the control treatments that were 
exposed to the same DMSO concentration as the OTA treatments. CYP2A6 expression was 
not detected in mRNA samples from HepG2 cells. Details of the statistical analysis of 
treatment (OTA concentration and time exposure) effects on gene expression in both 
Caco-2 and HepG2 cells are shown in Figures 1 and 2. 
 
The gene expression analysis shows that when Caco-2 cells were treated with increasing 
amounts of OTA, expression of most of the analysed genes was down-regulated (Figure 
1). Among the CYP450 family, CYP1A1 was the gene with the highest down-regulation, 
with statistical significance for the three treatments and different exposure times (p < 
0.0001). CYP1A1 expression was greatly reduced by OTA within the first 3 h; however, the 
highest effect of OTA was observed after 12 h, with a 52-fold decrease in CYP1A1 gene 
expression. Interestingly, cells exposed for 24 h showed a much lower repression of 
CYP1A1, compared with the mean-value of cells treated for 12 h. 
 
According to our results, OTA had an effect on the expression level within the first 3 
hours, but we did not detect large changes in the expression level of the CYP2A6 and 
CYP2B6 genes. It is known that CYP3A4 is a very active gene in the presence of 
endogenous substrates and xenobiotics. Under our conditions, we obtained an unexpected 
result for the level of CYP3A4 expression, showing a very stable level during the 3 first 
hours and poor modulation by OTA compared to the results with CYP1A1 and NAT2. 
Increasing OTA concentrations did not cause a significant difference in the expression of 
CYP3A4 in cells treated for 3 and 12 h. At 24 h, only the treatment with 45 µM caused a 
significant difference (p = 0.0396) with regard to 5 and 15 µM OTA. A similar expression 
pattern was observed in CYP3A5, but the down-regulation was slightly higher. 
 
Interestingly, NAT2, of which there is limited information regarding its interaction with 
OTA, was the gene with the second largest down-regulation during 12 and 24 h of 
exposure (p < 0.0001). Expression levels of the inflammation markers, COX-2 and 5-LOX, 
were also decreased. The presence of OTA caused a larger regulation of COX-2 than 5-
LOX. Additionally, the higher effect on COX-2 (45 µM for 24 h) shows a greater statistical 
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significance (p = 0.0003). Finally, in general, the down-regulation was more pronounced 
in Caco-2 cells at 24 h and 45 µM OTA. 
 
Regarding the results of the hepatic cells, OTA induced both up- and down-regulation 
(Figure 2). Unlike the results obtained in Caco-2 cells, the CYP3A4 expression increased 
significantly after 12 h of exposure to OTA (p < 0.05), regarding the results at 3 h of 
exposure. In this case, CYP3A5 was down-regulated by OTA at 45 µM, but after 12 h only 
showed a slight response to OTA exposure at 5 and 15 µM. The CYP1A1 expression level 
results obtained with HepG2 cells showed a significant change with respect to other CYPs 
analysed, which is very different to the strong down-regulation observed in Caco-2 cells. 
CYP1A1 was slightly down-regulated by OTA at 12 h, but a significant increase was 
detected in the cells exposed for 24 h (p = 0.00258 compared to 12 h). The CYP2B6 gene 
was down-regulated within the first 3 h, whereas an up-regulation effect was observed 
after 12 h exposure with a statistically significant difference (p = 0.002). However, after 
24 h, CYP2B6 expression once again decreased in cells exposed to 15 and 45 µM OTA. 
 
The NAT2 gene showed a different response at 24 h compared to 3 and 12 h. This gene 
increased its expression after a longer OTA exposure, in contrast to what happens in 
Caco-2 cells. With respect to the inflammation markers, these genes were slightly 
modulated by OTA at 3 h of treatment; both COX-2 and 5-LOX genes appeared to be up-
regulated within the first 12 h. However, at 24 h, COX-2 maintained its expression level, 
but 5-LOX was down-regulated. Unlike Caco-2 cells, in HepG2 cells, the MRP2 transporter 
showed a slight but significant down-regulated response (p < 0.05) after treatments at 15 
and 45 µM OTA for 12 and 24 h. 
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Figure 1. Relative gene expression ratio (in logarithmic scale) in differentiated Caco-2 cells 
exposed to 5, 15 and 45 OTA µM. The corresponding ratios of relative expression respect 
to GAPDH gene were calculated through a mathematical model (equation 2). Different 
letters (a, b, c) mean differences within time of treatment (vertical), whereas different 
symbols (asterisks or rhombus) mean a statistical significance (p < 0.05) for the same 
gene and between different OTA treatments during the same period of exposure. 
*Statistically significant respect to 5 µM or ♦respect to 15 µM.
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Figure 2. Relative expression ratio (in logarithmic scale) in HepG2 cells exposed to 5, 15 
and 45 OTA µM. The corresponding ratios of target genes of relative expression respect to 
GAPDH gene were calculated through a mathematical model (equation 2). Different letters 
(a, b, c) mean differences within time of treatment (vertical), whereas the symbols 
(asterisks or rhombus) indicate a statistical significance (p < 0.05) for the same gene and 
between different OTA treatments during the same period of exposure. *Statistically 
significant respect to 5 µM or ♦respect to 15 µM. 
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3.4 Discussion 
The first OTA evaluation conducted by the IARC (IARC, 1983) concluded that the evidence 
for nephrotoxicity, teratogenicity and carcinogenicity was insufficient to classify OTA as a 
carcinogenic compound to humans. Later, the toxic potential of OTA was greatly 
supported. However, the toxicological mechanism of this mycotoxin is still unclear, and a 
controversy exists about its genotoxic or epigenetic mode of action (IARC, 1993; Marin-
Kuan et al., 2006). Kinetics studies in animal species showed that OTA is slowly distributed 
to peripheral compartments (Galtier et al. 1979, Sreemannarayana et al., 1988; Li et al., 
1997), and that the molecule could be reabsorbed and redistributed (Hagelberg et al., 
1989; Fuchs and Hult, 1992; Sreemannarayana et al., 1988). Several studies have 
reported a prolonged half-life of the toxin and a secondary reintroduction to the intestine 
through the enterohepatic circulation, since the biliary excretion of OTA is very efficient, 
making the presence of OTA in the intestine prolonged in time (Li et al., 1997; Ringot et 
al., 2006). OTA toxicity has been attributed to its isocoumarin moiety, and it is well known 
that OTA is inactivated/bioactivated by cytochrome P450 enzymes (Faucet-Marquis et al., 
2006; Malaveille et al., 1991; Ringot et al., 2006; Tozlovanu et al., 2012). 
In order to observe the change induced in vitro by OTA over time, and taking into account 
the high half-life and the enterohepatic circulation of OTA observed in in vivo studies, in 
the present study the toxicity and the effect on gene expression of OTA were assayed at 
three times of exposure (3, 12 and 24 h). To carry out our study we have used a co-
culture system with Caco-2 and HepG2 cells that mimics the absorption in the intestine 
(through of the porous membrane) and the hepatic metabolism. 
In this system, the effect of OTA on the expression of cytochrome genes, the NAT2 gene 
(involved in phase II of metabolism), two inflammation markers (COX-2 and 5-LOX) and 
the MRP2 gene (encoding for a transporter of xenobiotics outward during absorption and 
in liver metabolism) was evaluated. 
 
The cell viability results from the MTS assay showed that only 24 h of OTA exposure 
caused a decrease in viability. Our data agree with other studies which also described high 
viability percentages (low cytotoxicity values) in treatments with <100 µM OTA for 24 h or 
less (Berger et al., 2003; Maresca et al., 2001; McLaughlin et al., 2004; Sergent et al., 
2005; Ramyaa et al., 2013). Similarly, other authors obtained viabilities of 75% (HT-29-
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D4) and 80% (in Caco-2 cells) at 48 h (Maresca et al., 2001; McLaughlin et al., 2004), 
using low OTA concentrations (20 µM and 30 µM) in the case of Caco-2 cells. Different 
results were reported by Zheng et al. (2013), who found that 37.27 µM OTA for 24 h 
caused 50% cytotoxicity in HepG2 cells. 
In addition, OTA cytotoxicity was also determined by evaluating membrane integrity in 
Caco-2 cells. Our results showed that OTA caused damage in physiological barrier 
functions through a paracellular transport that decreases TEER. This mechanism involves 
substances up to 10 but not 20 kDa, as OTA, and the elimination of tight junction proteins 
(Claudin 3 and 4). Conversely, good membrane homeostasis is related to high TEER and 
the presence of tight junctions (Kiatsurayanon et al., 2014; Yuki et al., 2007). 
In Caco-2 cells, membrane integrity (measured by TEER) and cell viability (from the MTS 
assay) were closely related. In this study, we found a decrease of 60% in TEER 
(disruption of the paracellular barrier) and a significant loss of viability when Caco-2 cells 
were treated with 45 µM OTA for 24 h. Maresca et al. (2001) recorded a decrease of 50% 
in TEER after a treatment of 100 µM OTA for 48 h that was related to a decrease in the 
whole cellular protein content, the inhibition of growth cell and morphological changes. In 
our assay (5-45 µM for 24 h) as well as Maresca et al. (2001) (0.001-1 µM for 48 h), we 
did not record a decrease of TEER in a time-dependent manner, possibly due to the low 
range of OTA doses assayed. Conversely, McLaughlin et al. (2004), with higher OTA doses 
(20-160 µM for 5 to 25 h), recorded a time-dependent reduction in TEER. Studies 
evaluating TEER during short-term exposures and at low OTA concentrations, did not 
detect a significant decrease of TEER in Caco-2 cells, as found by Berger et al. (2003), 
using 10 µM OTA for 3 h, or in our study during the 3 h treatment. 
To further investigate the effect of OTA on the xenobiotic transporter gene (MRP2), the 
metabolic enzymes (cytochrome P450: CYP1A1, CYP2A6, CYP2B6, CYP3A4 and CYP3A5; 
and NAT2), and the inflammatory response genes (COX-2 and 5-LOX), a gene expression 
analysis was performed using Caco-2 and HepG2 cells. Our data showed a down-
regulation of MRP2 expression, indicating an impairment of the secretion of OTA. The 
MRP2 transporter is a key primary active transporter involved in anionic conjugate and 
drug extrusion from the human liver but which is also present in the apical membranes of 
enterocytes, kidney-proximal tubules and other cells (Jedlitschky et al., 2006). In rat, it 
has been observed that OTA was excreted 15% less in the proximal tubules of the kidney, 
while the proximal tubular transport of amino acids was not impaired by OTA (Gekle and 
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Silbernagl, 1994). Therefore, the down-regulation of MRP2 and the TEER decrease found 
in this study could be the mechanism through which OTA reaches high percentages of 
bioavailability in vivo. In this way, the OTA exposure in hepatic cells would be magnified, 
contributing to the hepatotoxicity. Considering the nephrotoxic potential of OTA, the 
down-regulation of the MRP2 gene may also have a major impact on the proximal tubule, 
leading to a decreased capacity to eliminate OTA. However, further studies are needed on 
the OTA transporter mechanism to corroborate this hypothesis. 
Concerning the expression of the CYP450 genes, these genes were down-regulated and 
up-regulated by OTA in Caco-2 and HepG2 cells, respectively. The induction of CYP450 
genes in the xenobiotic response has been previously studied, and the mechanism is now 
largely understood. Nevertheless, the mechanism involved in CYP450 suppression still 
remains to be clarified. The CYP450 genes show a similar response because they often 
involve activation of common cytosolic or nuclear receptors, including the aromatic 
hydrocarbon receptor, the constitutive androstane receptor, the pregnane X receptor, and 
the peroxisome proliferator-activated receptor-alpha (Honkakoski and Negishi, 2000). The 
effect of polycyclic and halogenated aromatic hydrocarbons is used as model for 
understanding the mechanisms of CYP450 suppression, and the results of OTA-modulation 
gene expression in the present study show both effects, up- and down regulation mainly 
on HepG2 cells. The literature suggests that the down-regulation is a response to 
physiological and pathological signals: a) stress signals caused by toxicants and 
inflammation, b) an adaptive response, allowing controlled generation of reactive oxygen 
species (ROS), nitric oxide, or arachidonic acid metabolism, or c) a collateral response 
after controlling a physiological pathway (Morgan, 2001). 
In agreement with our results with OTA-treated hepatocytes, in which there was an 
increase in gene expression (mainly 1A1, 2B6 and 3A4 in HepG2 cells), Zepnik et al. 
(2001) reported an increase of OTA hydrolysis by microsomal enzymes from rat liver, 
specifically for P450 3A1/2, 3A4 and P450 1A1/2. In terms of gene expression, Ayed-
Boussema et al. (2012) described an up-regulation of expression levels in all cytochromes 
assayed (CYP3A4, 2B6, 3A5, and 2C9) in a primary human hepatocyte culture. CYP3A4 
mRNA did significantly increase after OTA treatment at 0.1 μM (from 3.1- to 16.7-fold 
induction, respective of each donor). In contrast, Marin-Kuan et al. (2006) showed a slight 
but predominant effect of down-regulation (> 56% of the genes) in the liver and kidney 
from male Fisher-344 rats. In Dark Agouti rats of both sexes, only CYP3A4 expression was 
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detected in male livers after OTA treatment, and CYP1A expression was higher than 
CYP2A (Pfohl-Leszkowicz et al., 1998), as in our in vitro assay. 
With regard to CYP2B6, our results at 5-45 µM OTA for 3 h showed a down-regulation up 
to 8-fold in both cell types, but an increase was detected at 12 h in HepG2 cells. In 
contrast with the up-regulation of CYP2B6 in primary human hepatocytes, the level of 
CYP2B6 mRNA was higher (22.5-6.8-fold induction) than the mRNA level of other 
cytochromes after treatment at 10 μM (Ayed-Boussema et al., 2012). 
NAT2 gene, encoding for an inducible and xenobiotic metabolizing enzyme of phase II, 
had lower expression in Caco-2 cells than in HepG2 cells, in line with results described in 
the literature (Husain et al., 2007). In our study, the highest effect on NAT-2 expression 
was detected after 24 h of OTA exposure, where the NAT2 gene was strongly modulated 
by OTA. It is noteworthy that expression of the NAT2 gene regarding OTA exposure has 
not been studied previously, although Lebrun et al. (2002) reported a high correlation 
between NAT2 polymorphism and DNA damage in an in vitro culture of OTA-exposed 
human urothelial cells. OTA intake has been linked to a chronic tubulointerstitial renal 
disease (chronic nephropathy) frequently accompanied by urothelial cell carcinomas of the 
urinary tract, although this relationship has not been proven completely (Batuman, 2006; 
Grollman and Jelacovic, 2007; Reddy and Bhoola, 2010). Besides, a very strong 
epidemiological association has been established between the NAT2 genotypes and a 
variable risk of urinary bladder cancer caused by arylamines, possibly due to an impaired 
detoxification of carcinogenic metabolites in the liver (Hein et al., 2000; Husain et al., 
2007). 
To investigate modulation of the inflammatory response induced by OTA, the expression 
of COX-2 and 5-LOX genes was determined. We have detected a rapid change from 3 to 
12 h in cellular 5-LOX expression in Caco-2 cells, while in HepG2 cells, the changes were 
over time. The COX-2 gene was down- and up-regulated in Caco-2 and HepG2 cells, 
respectively. Changes in the regulation pattern could be due to an adaptive response 
(Chung et al., 2008; Morgan, 2001). 
Changes in the regulation pattern could be due to an adaptive response for controlling the 
generation of ROS, as observed by Chung et al. (2008) in A549 human lung carcinoma 
cells treated with acenaphthenequinone. In this sense, the oxidative stress caused by OTA 
has been widely described in the literature as ROS generation (Ramyaa et al. 2013), DNA 
damage (González-Arias et al., 2014; Ramyaa et al., 2013) and histopathological changes 
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in the liver and kidney (Aydin et al., 2003). Recently, Kumar et al. (2013) and Ramyaa et 
al. (2013) investigated the relationship between OTA exposure and COX-2 expression and 
obtained similar results as our study. Thus, in mouse (with a single dermal application of 
OTA), an early inflammatory response, demonstrated by COX-2 expression, increased after 
6 h of OTA exposure and a maximum was observed at 18 h (Kumar et al., 2013). Ramyaa 
et al. (2013) observed that COX-2 expression increased after 15 h exposure to OTA in 
HepG2 cells, but, curiously, it was inhibited after 24 h. In the present study, we have not 
studied NF-κB expression, but several studies indicate that the expression of COX-2 and 5-
LOX is related to NF-κB, the main transcription factor that regulates the proinflammatory 
response (González-Périz and Clàira, 2007; Chung et al., 2008). Nowadays, few studies 
have investigated the effect of OTA on the COX-2 and 5-LOX genes, or on their proteins 
(Ramyaa et al., 2014; Kumar et al., 2013; Ferrante et al., 2006 and 2008), and a possible 
mechanism of down-regulation has not been established. Some authors have observed an 
inhibition of nuclear factor-kappa B (NF-κB) expression and an increase in heat shock 
protein 72 expression, both in in vivo and in vitro studies, after OTA exposure, leading the 
down-regulation of proinflammatory mediators (Ferrante et al., 2006, Ramyaa et al., 
2014). Our results support previous studies which described a pro-inflammatory role of 
OTA but further studies are necessary. 
 
5. Conclusion  
The use of cell lines is an alternative to overcome the disadvantages of the primary cell 
lines, as their scarce availability, limited growth potential, short lifespan, differences 
between batches, and their susceptibility to undergo early and variable phenotypic 
alterations. Additionally, basal gene expression in freshly isolated primary human cells is 
also different between culture passages (Hart et al., 2010). The proper use of data 
published in literature can support the results and the focus of our study. However, 
depending on the human cell line or primary cell line used, and its ability to express or 
induce the genes, comparison of results can be difficult. In addition, an increase in the 
mRNA level in cells or liver tissues does not necessarily mean that similar results occur at 
protein level (Hart et al., 2010; Sun et al., 2002). It is known that different processes are 
implicated in OTA metabolism and toxicity. Direct or indirect DNA damage, as well as 
epigenetic mechanisms, are responsible for the tumour promotion phase during 
carcinogenesis, and all of these mechanisms have been related to OTA toxicity at non-
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cytotoxic doses during long-term exposure (Gonzalez-Arias et al., 2014; Horvath et al., 
2002; Qi et al., 2014). Conversely, histological changes in the liver, kidney and skin have 
been detected after high doses of OTA exposure (Kamp et al., 2005; Kumar et al., 2013; 
Palabiyik et al., 2013; Qi et al., 2014). The co-culture system that mimics the passage 
through the intestine as a first barrier allowed us to obtain results that could be more 
similar than those recorded in in vivo studies. The data generated from the gene 
expression analysis in enterocytes and hepatocytes exposed to OTA suggest a different 
mechanism of action in intestinal epithelium during absorption than in OTA metabolism in 
the liver. 
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Study IV. 
Low doses of ochratoxin A induce micronucleus formation and delay DNA repair 
in human lymphocytes. 
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Abstract 
Contamination of food and feed commodities by fungal mycotoxins has attracted great 
interest because many of these mycotoxins are responsible for different diseases, 
including cancer and other chronic illnesses. Ochratoxin A (OTA) is a mycotoxin naturally 
present in food, and long-term exposure to food contaminated with low levels of OTA has 
been associated with renal cancer. In the present study, the cytotoxicity, cytostaticity, and 
genotoxicity of OTA (0.075, 0.15, 1.5, 5.0, and 15 μM) in human lymphocytes were 
evaluated. The comet assay and the modified comet assay (DNA repair assay), which use 
N-hydroxyurea (NHU) to detect non-repaired lesions produced by OTA, and the 
cytokinesis-blocked micronucleus (CBMN) assay were used. Treatments with OTA were not 
cytotoxic but caused a cytostatic effect in human lymphocytes at 15 μM. OTA (0.075-5 
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μM) produced a slight increase in the percentage of DNA in the comets and a delay in the 
DNA repair capacity of the lymphocytes. Micronucleus (MN) induction was observed at 
OTA concentrations of 1.5 and 5 μM. In conclusion, our results indicate that OTA induces 
DNA stable damage at low doses that are neither cytotoxic nor cytostatic, and OTA delays 
DNA repair kinetics. These two findings indicate that OTA affects two pivotal events in the 
carcinogenesis pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: Food Chemical Toxicology (2014), 74: 249-254. 
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4.1 Introduction 
Ochratoxin A (OTA) is a fungal toxin produced by species of the Aspergillus and Penicillium 
genera. It was first described by Van der Merwe et al. (1965). Foodstuffs for human and 
animal consumption are frequently contaminated with OTA worldwide, and the main 
contaminated foods are cereals, dried fruits, coffee, grapes, wine, and beer. The 
consumption of OTA-contaminated food is known to have a close relationship with the 
development of diseases, such as Balkan Endemic Nephropathy (BEN), a chronic tubule 
interstitial renal disease observed in settlements along the Danube River in the Balkan 
Peninsula (Stoev, 1998; Vrabcheva et al., 2004). 
 
OTA consists of a dihydroisocoumarin with a para-chlorophthalic group that is linked to an 
L-β-phenylalanine by an amino bond (Moss, 1996). OTA is mainly nephrotoxic, but other 
toxic effects have been described, including teratogenicity, neurotoxicity, immunotoxicity, 
and genotoxicity. The nephrotoxic mechanisms of OTA have been studied in vitro and in 
vivo, but the mechanisms through which OTA exerts carcinogenic effects are not entirely 
understood (IARC, 1993; Benford et al., 2001; Abouzied et al., 2002). Two hypotheses are 
still discussed when dealing with the carcinogenicity of OTA. The first hypothesis suggests 
that the carcinogenicity of OTA is linked to its epigenetic nature because OTA produces 
effects in target cells that either indirectly lead to neoplasic transformation or facilitate the 
development of neoplasms from cytogenetically transformed cells (O’Brien and Dietrich 
2005; Schilter et al., 2005; Turesky, 2005). The second hypothesis suggests that its 
carcinogenicity is due to genotoxic mechanisms (Manderville, 2005; Mantle et al., 2010a; 
Pfohl-Leszkowicz and Castegnaro, 2005). In any case, OTA has been classified as a 
possible group 2B human carcinogen by the International Agency for Research on Cancer 
(IARC, 1993). It has also been classified in the germ cell mutagen group 3B (MAK Value 
Documentation, 2006) and recommended to be regulated as a non-threshold carcinogen 
(Kuiper-Goodman et al., 2010). 
 
Several in vitro studies using microbial and mammalian models have suggested that OTA 
does not act as a direct genotoxic compound. Some studies have reported that OTA shows 
no mutagenic capacity in the Ames assay, either with or without metabolic activation 
(Bendele et al., 1985). However, other studies have shown that OTA has mutagenic 
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capacity using the same Ames assay when OTA metabolites were formed by hepatocytes 
in culture (Hennig et al., 1991) or were generated by a kidney microsomal fraction 
(Obrecht-Pflumio et al., 1999). 
 
Additionally, controversial results have been obtained with the Sister Chromatid Exchange 
(SCE) assay. Although an OTA treatment did not increase the SCE frequency in human 
peripheral blood lymphocytes (Cooray, 1984; Mosesso et al., 2008) or in the bone marrow 
of Chinese hamsters (Bendele et al., 1985), (Föllmann et al., 1995; Lioi et al., 2004) and 
Anninou et al. (2014) detected an increase in the SCE frequency with and without 
metabolic activation in response to treatment with OTA. 
 
DNA adduct formation has been reported in many in vitro and in vivo studies and results 
from the direct covalent binding of OTA to DNA, which is related to the metabolic 
activation of OTA (El Adlouni et al., 2000; Mantle et al., 2010; Pfohl-Leszkowicz and 
Castegnaro, 2005; Hadjeba-Medjdoub et al., 2012). However, three different studies failed 
to identify DNA adducts following OTA exposure (Gautier et al. 2001; Gross-Steinmeyer et 
al., 2002; Mally et al., 2005). 
 
Chromosomal instability caused by OTA has also been measured using the micronucleus 
(MN) assay. This assay is a tool to evaluate the clastogenic capacity of compounds that 
can induce chromosomal aberrations and aneugenicity through mitotic spindle dysfunction 
(Fenech, 2007). Some MN assays performed with OTA did not show a dose-response 
relationship. However, in most studies, the concentrations tested were higher than 12 µM 
(4.8 µg/mL) (Degen et al., 1997; Ehrlich, et al., 2002; Knasmüller et al., 2004; Fuchs et 
al., 2008). 
 
The aim of this study was to evaluate the genotoxic potential of OTA in human 
lymphocytes through the comet and repair assays and through the cytokinesis-blocked 
micronucleus (CBMN) technique. This study also assessed the effects of low 
concentrations of OTA, which have not been frequently assayed in past research. 
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4.2 Materials and methods 
4.2.1 Chemicals 
The following products were obtained from Sigma-Aldrich (Steinheim, Germany): low-
melting-point agarose, regular agarose type IIA, cytochalasin-B (Cyt-B) from Drechslera 
dematioidea (ref. C6762), ethylenediamine tetraacetic acid (EDTA) (ref. E9884), 
fluorescein diacetate (25 mg/mL) (ref. F7378), hydrogen peroxide (H2O2) at 30%, 
mitomycin C (ref. M4287), phytohemagglutinin (PHA) from Phaseolus vulgaris (red kidney 
bean) (ref. L4144), RPMI-1640 medium (ref. R4130), trypan blue solution (ref. T8154) and 
trypsin solution (1X) (ref. T3924). 
 
Standard OTA (98% purity) was obtained from Chem Service® (ref. O1877) (West 
Chester, PA, USA), and ethanol 96° was obtained from Jalmek® (ref. A3380) (Nuevo 
León, México). The L-glutamine solution (100X) (ref. 25030) and 100X nonessential amino 
acid solution (ref. 11140-050) were obtained from Gibco BRL Life Technologies (Grand 
Island, NY, USA). 
 
Microscopy Hemacolor (ref. 111661) was obtained from Merck KGaA (Darmstadt, 
Germany). Ethidium bromide (ref. 161-0433), Tris (ref. 161-0716) and triton X-100 (ref. 
1610407) were obtained from BioRad (Hercules, California. USA). Dimethyl sulfoxide 
(DMSO) for molecular biology (ref. D8418), glacial acetic acid, methanol, sodium 
hydroxide (NaOH), and sodium chloride (NaCl) were supplied by JT-Baker (Center Valley, 
PA, USA), and Petri dishes (1.9 cm2) were obtained from Corning (ref. 3526) (New York, 
USA). 
 
4.2.2 Cell culture and OTA treatments 
Heparinized venous blood samples from healthy non-smoking male donors of 21-23 years 
of age were used for the experiments. 
 
For the comet assay, a volume of 20 µL of whole blood in 1 mL of RPMI-1640 medium 
(without supplement) was treated with OTA for 3 h at 37 °C. 
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For the CBMN assay, a volume of 0.5 mL of whole blood was cultured in 7 mL of RPMI-
1640 medium supplemented with 1% L-glutamine and non-essential amino acids (100x). 
The lymphocytes were stimulated with PHA (7.1 μg/mL) and cultured for 72 h at 37 °C. 
Cytochalasin B (6 μg/ml) was added in the last 24 h of culture to accumulate cells that had 
divided only once. OTA was added 24 h after the beginning of the PHA stimulation, and 
the OTA incubation lasted for the remaining 48 h of the assay. The OTA doses assayed 
were 0.075, 0.15, 1.5, 5.0 and 15 μM (ethanol: DMSO, 3:2) for both techniques. The 
percentage of solvent was less than 0.05% of the final volume. 
 
4.2.3 Cell viability tests 
4.2.3.1 Double staining w ith fluorescein diacetate and ethidium bromide  
The cytotoxicity was evaluated using the fluorescent dyes fluorescein diacetate (FDA) and 
ethidium bromide (EtBr). The OTA-treated cells were resuspended, and 100-µL aliquots of 
each treatment group were transferred to new tubes and centrifuged at 3000 rpm for 2 
min. The supernatant was removed, and the cell pellet was maintained on ice until use. 
For the cell viability analysis, a fresh staining solution was prepared with 30 μL of FDA in 
acetone (5 mg/mL), 200 μL of EtBr in phosphate buffer saline (200 μg/mL), and 4.8 mL of 
PBS. The cell pellet was resuspended in 20 µL of the FDA/EtBr solution, placed on a slide, 
and covered with a coverslip. Cell counting was performed with an Axio Scope A1 
fluorescence microscope (Carl Zeiss, Gottingen, Germany) using the 20X objective. The 
living cells could be visualized in green, whereas the dead cells could be visualized in red; 
a total of 200 cells were counted for each treatment. 
 
4.2.4 Comet assay 
The alkaline comet assay was performed as described by Tice et al. (2000). After OTA 
treatment, button cells were mixed with 150 µL of low-melting-point agarose (0.5%) at 37 
°C, placed on slides that had been precoated with a layer of regular agarose (0.5%) and 
allowed to polymerize at 4 °C. Another layer of low-melting-point agarose was added and 
allowed to solidify. The slides were placed for 24 h in Coplin jars with 50 mL of lysis 
solution (2.5 M NaCl, 100 mM EDTA-Na2 and 10 mM Tris, pH>10) at 4 °C, 5 mL of DMSO 
and 0.5 mL of Triton X-100. Prior to electrophoresis, the slides were incubated for 20 min 
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in an alkaline buffer (10 M NaOH, 200 mM EDTA-Na2, pH>13), which is capable of 
detecting DNA damage, including single-strand breaks (SSB), alkali-labile sites (ALS), and 
DNA-DNA/DNA-protein cross-linking. After alkali unwinding, the slides were run by 
electrophoresis at 25 V and 300 mA for 20 min, neutralized, and fixed. The slides were 
stained with EtBr for analysis and prepared in duplicate per treatment. Slides were 
randomized and coded to blind the scorer. A total of 100 individual cells were screened 
per treatment (50 cells from each slide). The scoring was performed in a fluorescence 
microscope Carl Zeiss Axio Scope A1 with 20X objective. The percentage of DNA was 
determined using the Image Comet software version 2.2. 
 
The results are presented as the means from three independent experiments. To 
determine the kinetics of DNA repair in the lymphocytes exposed to OTA, a modified 
comet assay was conducted. Four Eppendorf tubes (T0 (DNA damage produced by a 
second known exposition); T30 and T60 (two repair times in minutes) and TNHU (10 µL of 
N-hydroxyurea was used as positive control for DNA repair) were used for each of the 
following conditions: whole blood lymphocytes treated with OTA (1.5 and 5 µM), a positive 
control (10 µL, 30% H2O2) and a negative control (ethanol:DMSO <0.05%). All of the 
tubes were incubated for 3 h at 37 °C. After incubation, the samples were treated with 10 
µL of H2O2 (30%) for 10 min at room temperature, centrifuged, washed with 1 mL of 
culture medium and centrifuged again. Slides were prepared for the T0 sample as 
described above. The T30 and T60 samples were incubated for their respective repair 
times, and the tubes were then centrifuged prior to slide preparation. TNHU was also 
incubated for 60 min. 
 
4.2.5 Cytokinesis-block micronucleus assay (CBMN) 
4.2.5.1 Nuclear index (NI) 
To evaluate the effect of OTA on the mitogenic response of lymphocytes, the NI was 
evaluated according to a method described by Eastmond and Tucker (1989). The viable 
cells (n=200) were scored to determine the frequency of cells with one, two, three, or 
four nuclei, and the NI was calculated according to NI = (M1+2(M2)+3(M3)+4(M4))/N, 
where M1 to M4 represent the number of viable cells with one to four or more nuclei and 
N represents the total number of viable cells scored. 
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4.2.5.2 CBMN technique 
The evaluation of MN was performed using the CBMN technique with criteria established 
through the work conducted by Fenech et al. (2003). Mitomycin C was used as a positive 
control for MN induction. The slides were codified, and the examination of the slides was 
performed blindly. One thousand binucleated cells per slide were evaluated, and the 
resulting MN frequency was expressed as the number of MN in 1000 binucleated cells. 
 
The mitogenic response of lymphocytes and the frequency of MN were evaluated using a 
light microscope (Carl Zeiss Axiostar Plus, Gottingen, Germany) at 1000X magnification. 
 
4.2.6 Statistical analysis 
Statistical analysis were conducted using the GraphPad Prism 5.01 and Stata 8.0 programs 
(Stata statistical software, Stata Corporation, College Station, TX, USA). The effects of 
OTA on cell viability, percentage of binucleated cells and NI were analysed using the 
analysis of variance (ANOVA) and the Bonferroni post-test. The results of the MN and 
comet assays were analysed with Mann Whitney and Dunn’s tests. P values of p<0.05 
were considered to be statistically significant. 
 
4.3 Results 
4.3.1 Cytotox icity and cytostaticity 
At the doses assayed (0.075-15 µM OTA), the viability of the lymphocytes was 
approximately 80% or slightly higher, and no significant differences were noted between 
the treated and the solvent control cells. In addition, OTA did not statistically decrease NI 
or the percentage of binucleated cells at concentrations lower or equal to 5 µM compared 
with the solvent control. However, a cytostatic effect was observed at a concentration of 
15 µM (Table 1). 
 121 
 
Table 1. Citotoxicity and citostaticity in human lymphocytes treated with ochratoxin A 
                               Treatment Viability  
(%) 
P-value Nuclear index P- value Binucleated 
cells (%) 
P-value 
OTA (µM) 0.075 88.3 ± 9.3 0.647 1.9 ± 0.2 0.89 55.2 ± 11.8 0.92 
 0.15 89.0 ± 9.1 0.525 1.8 ± 0.2 0.85 50.7 ± 19.1 0.53 
 1.5 89.0 ± 6.8 0.419 1.8 ± 0.1 0.47 54.1 ± 13.2 0.80 
 5 90.6 ± 9.3 0.290 1.7 ± 0.1 0.10 54.7 ± 7.5 0.85 
 15 88.0 ± 7.6 0.645 ND  ND  
Mitomycin C (1 µM) (+) 90.0 ± 4.7 0.016 1.4 ± 0.24 <0.0001 15.8 ± 10.4 <0.0001 
Control (-) 87.3 ± 6.8 0.831 1.8 ± 0.1 0.56 60.3 ± 20.3 0.21 
Solvent (DMSO %) 0.05 86.6 ± 4.8  1.9 ± 0.2  61.1 ± 10.2  
Data represent the means ± SD of three independent experiments run in triplicate. P-values are significantly different than the 
dissolvent control (p<0.05). ND: No data, the amount of cells was not sufficient to complete one thousand binucleated cells per 
slide.  
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4.3.2 Comet Assay 
The results obtained from the comet assay showed that although no differences were 
found in the tail length in the concentration range assayed (data not shown), a slight 
increase was observed in the percentage of DNA at the 0.075, 1.5 and 5 µM treatments 
(Fig. 1) without a dose-response pattern. In addition, according to the repair assay 
results, although the lymphocytes repaired their DNA within 30 min following oxidative 
treatment (H2O2), co-exposure to H2O2 and OTA delayed their repair capacity for a period 
of 60 min, until then, the DNA percentage was similar to control (p>0.05), suggesting that 
OTA can alter the capacity of lymphocytes to repair their DNA (Fig. 2). 
 
 
 
Figure 1. DNA damage (measured as DNA percentage, %DNA) in human lymphocytes 
after 3 h exposure to OTA. Positive control: 10 µL H2O2 (30%), solvent control: 0.05% 
ethanol:DMSO (3:2). Each value represents the mean ± SD of three independent 
experiments run in duplicate. *Significantly different than the solvent control (p<0.05). 
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Figure 2. Kinetics of DNA repair in human lymphocytes treated with OTA (1.5 and 5 µM) 
measured as DNA percentage at 0, 30, and 60 min. The response of lymphocytes to 10 
mM NHU (N-hydroxyurea) was determined at 60 min. Each value represents the mean ± 
SD of three independent experiments run in duplicate. *Significantly different from the 
solvent control at time 0, and ** Repair effect at time 60 (min) is significantly different 
from the OTA + H2O2 treatment at time 30 (min) (p<0.05). ***OTA treatments with NHU 
are different from the OTA + H2O2 treatments at time 60 (min) without NHU (p<0.05). 
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4.3.3 CBMN assay  
Fig. 3 shows the formation of MN in binucleated human lymphocytes after OTA exposure. 
OTA induced a slight but significant increase in the MN frequency in cells treated with OTA 
concentrations of 1.5 µM and 5 µM compared with the solvent control. MN induction was 
not scored accurately in the cells treated with OTA at a concentration of 15 µM due to the 
cytostatic effect observed. 
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Figure 3. Effect of OTA on the formation of MN in binucleate human lymphocyte cells. 
Values are means ± SD of three independent experiments run in triplicate (1000 
binucleated cells were analysed per treatment). Positive control: 1 µM mitomycin C; 
solvent control: 0.05% ethanol:DMSO (3:2). *Significantly different than the solvent 
control (p<0.05). **Significantly different than the 1.5 µM treatment (p<0.05). 
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4.4 Discussion 
Several studies have shown that the levels of OTA found in food are often in the range of 
µg/kg (ppb). In foods intended for direct human consumption, such as grape juice, wine, 
or beer, the mean contamination levels in the EU were 0.56 µg/kg, 0.36 µg/kg and 0.03 
µg/kg, respectively (Jørgensen, 2005), making these items important sources of OTA in 
the diet. OTA is associated with chronic toxicity following long periods of exposure to 
relatively low levels of this mycotoxin, and therefore toxicity tests must necessarily be 
carried out at low OTA levels. For this reason, lower levels of OTA than those commonly 
referenced in the literature were included in this study. 
 
OTA has been reported as either a carcinogen or non-carcinogen compound (IARC, 1993; 
JECFA, 2006; 2010), and diverse tests and cell types have been used to investigate its 
genotoxic potential. Among them, the CBMN assay is a well-known comprehensive system 
that provides data from the DNA damage measures of cytostaticity and cytotoxicity 
(Fenech, 2007). In contrast, the comet assay measures DNA damage by assessing strand 
breaks in single cells. In this study, we performed the alkali version to detect single- and 
double-strand breaks and the comet assay to assess DNA repair. These studies provide 
data on the mechanism of damage and on the capacity of cells to block the base excision 
repair system, which can allow the accumulation of breaks for longer periods of time. 
 
The results of the cytotoxicity assay performed in this study are consistent with other 
reports, in which the viability was above 70-80% when the OTA concentration was lower 
than 20 µM (Golli-Bennour et al., 2010; Ali et al., 2011), indicating that the viability values 
were higher than the recommended level (cytotoxic limit) for performing the in vitro CBMN 
assay (OECD, 2010) and for the in vitro comet assay (Tice et al., 2000). Regarding the 
cytostatic effect of OTA, our data showed that this mycotoxin, at a concentration of 15 
µM, decreased the NI in human lymphocytes. Dönmez-Altuntaş et al. (2003) reported that 
OTA did not decrease the percentage of binucleated cells at concentrations ranging from 
100 pM to 10 µM; however, the authors also reported the opposite results at higher 
concentrations (25 µM), and these latter results were consistent with our findings. 
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In our study, the OTA treatments did not appear to increase the tail length (data not 
shown) but did increase the percentage of DNA at concentrations of 0.075, 1.5 and 5 µM, 
although not in a dose-dependent manner. In addition, when an oxidative stress (co-
incubation with H2O2) was applied in conjunction with the OTA treatments to evaluate the 
repair capacity of the lymphocytes, the DNA repair of the lymphocytes was found to be 
delayed to a time point of 60 min. Our results thus agree with those previously reported 
by Lebrun and Föllmann (2002), who found that OTA induced single-strand breaks in 
Madin-Darby canine kidney (MDCK) cells at high concentrations (up to 100 µM) in a dose-
dependent manner. The authors also observed an increase in the genotoxic effect of OTA 
when an external metabolizing enzyme system (S9-mix from rat liver) was added, 
although the damage was completely repaired within 2 h. Additionally, in two studies 
performed by Ali et al. (2011; 2014), a non-significant increase in the DNA damage (% tail 
intensity, 4 h of treatment, without S9 treatment) was found with 5 µM OTA in three 
different cell lines (TK6, CHO and L5178Y tK+/-). However, L5178Y tK+/- cells were more 
sensitive than the other two cell lines at 10 µM OTA. A dose-response pattern was 
observed in the range of 20 to 50 µM OTA in the TK6 and CHO cells and in the range of 
10 to 100 µM OTA in the L5178Y tK+/- cells. 
 
Russo et al. (2005) found that human fibroblasts treated with OTA for 72 h (6-50 µM) 
exhibit an exposure time-dependent increase in the percentage of damaged DNA. This 
study also suggested the involvement of oxidative stress (due to an increase in ROS) in 
the OTA genotoxicity, which is also consistent with the work of Schilter et al. (2005) and 
Zheng et al. (2013). This finding is further supported by a study conducted by Kamp et al. 
(2005) in the V79 and CV-1 cell lines and in primary rat kidney cells, which revealed a 
slight increase in the basic DNA damage (percent of DNA) without treatment with DNA 
repair enzymes (formamidopyrimidine-DNA glycolyase and endonuclease III) in both cell 
lines. However, this study was performed using only a short exposure time (1 h) and a 
high OTA concentration (≥500 µM). 
Based on their work with human leukocytes, Klarić et al. (2010) reported that OTA does 
not cause genotoxicity at concentrations of 1 and 5 µM (1 h of exposure), as measured by 
the tail length extension. However, the tail intensity and tail moment parameters were 
significantly higher, which is consistent with our results. 
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Although the mechanism that leads to OTA genotoxicity, as measured through the comet 
assay, is not fully understood, evidence from in vitro (with different cell types) and in vivo 
studies suggests the role of oxidative stress (Lebrun and Föllmann, 2002; Arbillaga et al., 
2007; Hadjeba-Medjdoub et al., 2012; Aydin et al., 2013; Hibi et al., 2013a; Hibi et al., 
2013b; Ali et al., 2014; Yang et al., 2014). It has also been reported that OTA 
biotransformation produces metabolites that are more genotoxic than the original toxin. 
However, it is important to note that this type of DNA damage can be effectively repaired 
(Lebrun and Föllmann, 2002; Simarro et al., 2006). 
 
The results obtained in the present study show that OTA produces a slight but significant 
MN induction at concentrations as low as 1.5 µM (1.8 times more MN than in the solvent 
control) and 5 µM (3 times more MN than in the solvent control). Similar results were 
observed in seminal vesicle cell cultures treated with 12 µM OTA for 6 h (Degen et al., 
1997). 
 
Several studies have reported that the OTA-based MN induction is dependent on the 
concentration of OTA at doses higher than 5 µM (Degen et al., 1997; Dopp et al., 1999; 
Knasmüller et al., 2004; Fuchs et al., 2008; Klarić et al., 2008). In contrast, studies 
conducted at low OTA concentrations have reported MN induction but have not shown a 
dose-response pattern (Ehrlich et al., 2002; Dönmez-Altuntaş et al., 2003; Ali et al., 
2011). Unlike the studies previously mentioned, our results with the CBMN assay showed 
that OTA is genotoxic at concentrations as low as 1.5 µM. The mechanism underlying 
OTA-induced genotoxicity has been the subject of controversy. Some studies have 
suggested that genotoxicity results from the direct covalent binding of OTA to DNA (El 
Adlouni et al., 2000; Pfohl-Leszkowicz and Mandeville, 2012). In contrast, Dopp et al. 
(1999) determined that 3 h of exposure to 10 µM OTA causes an induction of MN 
production in Syrian hamster embryo (SHE) fibroblasts. Ehrlich et al. (2002) reported that 
only 1 h of OTA treatment (61.9 µM) is sufficient to increase the MN frequency in HepG2 
cells, with an effect that was approximately 30% lower than when the cells were exposed 
for 24 h at the same concentration. 
 
In the case of human lymphocytes, Mosesso et al. (2008) reported that OTA did not cause 
an increase in the MN frequencies at concentrations ranging from 5.3 to 53.2 µM in both 
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the absence and presence of S9 metabolism. However, it is important to consider the high 
cytotoxicity (32-67%) and the low values of the cytokinesis block proliferation index 
(CBPI) (1.17-1.08) reported in this study. Additionally, Dönmez-Altuntaş et al. (2003) 
treated a lymphocyte culture (48 h) with OTA at concentrations of 100 pM, 1 nM, 10 nM, 
100 nM, 1 µM, 10 µM and 25 µM. At the highest concentration, the authors reported that 
OTA induced MN but also led to a clear decrease in the percentage of binucleated cells 
observed. 
 
The available evidence suggests that OTA increases MN production by inducing clastogenic 
events (60-70%) more commonly than aneugenic events due to chromosomal breakage 
(Degen et al., 1997; Dopp et al., 1999; Knasmüller et al., 2004). To this end, Dopp et al. 
(1999) reported that OTA is an effective inducer of DNA damage and serves to disrupt 
intracellular calcium homeostasis and actin stress fibres. The study concluded that OTA 
has a predominantly clastogenic mode of action. 
 
In contrast, the mechanisms through which OTA can cause a clastogenic effect in both 
comet and MN assays have not been well established. Some studies have reported that 
OTA can induce cell cycle arrest in the G1 phase by down-regulating the expression of 
CDK4 and the cyclin D1 protein and by limiting apoptosis in human peripheral blood 
mononuclear cells (hPBMC) in vitro (Liu et al., 2012). Kuroda et al. (2014) demonstrated 
that OTA also produces an increase in γ-H2AX expression and was capable of inducing 
double-strand breaks (DSBs) in DNA in a rat model. OTA also increases the mRNA and 
protein expression levels of homologous recombination (HR) repair-related genes (Rad51, 
Rad18 and Brip1) and genes involved in G2/M arrest (Chek1 and Wee1) and the S/G2 
phase (Ccna2 and Cdk1) in a dose-dependent manner. 
 
It is important to note that inconsistencies in the OTA genotoxicity results could be due to 
differences in the concentrations of OTA, the characteristics of the particular cell lines, the 
exposure time, the specific genotoxicity endpoint analysed, and the criteria used to assess 
a valid study and/or a positive response (Ali et al., 2011). Furthermore, it is important to 
remember that OTA is known for its rather high affinity to serum proteins. It is therefore 
possible that the serum content of the cell cultures under different culture conditions could 
affect the bioavailability and toxicity of OTA in in vitro systems (Degen et al., 1997). 
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Human lymphocytes are frequently exposed to low amounts of OTA under in vivo 
conditions. The amount of OTA in the plasma/serum of healthy volunteers from 23 
European countries and several additional countries from around the world ranged from 
0.15 to 9.15 ng/mL, with a mean of 0.45 ng/mL (74% of positive samples) (Coronel et al., 
2010). Although these levels appear low, OTA has been associated with the induction of 
adverse effects in humans, especially in some specific cell types, such as urothelial cells. 
However, questions regarding the OTA genotoxicity at low concentrations remain unsolved 
(JECFA, 2006; 2010). 
 
In conclusion, our results indicate that OTA induces DNA stable damage at low doses, 
which are neither cytotoxic nor cytostatic, and delays the DNA repair kinetics, thus 
inducing pivotal events in the carcinogenesis pathway of xenobiotics. 
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The research conducted in this PhD thesis was carried out to fulfil one of the objectives of 
the Spanish national research project ”Integrated approach to simultaneous human 
exposure to ochratoxin A and deoxynivalenol” (project AGL2011-24862) for which the 
Applied Mycology Unit of the University of Lleida received a grant. The overall aims of the 
project were the ”in vitro evaluation of the bioaccessibility of deoxynivalenol (DON) and 
ochratoxin A (OTA) in several food matrices, the effect of absorption and the cytotoxicity 
induced” and were thus clearly linked to the proposed objectives of this thesis. To 
accomplish these objectives, the studies carried out for this thesis were divided into two 
research lines – i) OTA bioaccessibility and ii) OTA toxicity – as presented in the 
”Objectives and work plan” section. 
 
Due to the ubiquity of mycotoxins, the food matrix to be used in the bioaccessibility study 
was selected based on previous research by our research group on OTA exposure (Belli et 
al., 2004; Coronel et al., 2009, 2012; Valero et al., 2008) showing that red wine is one of 
the most frequently OTA-contaminated foods. 
 
The OTA toxicity studies were planned taking into account previous results reported in the 
literature (Ali et al., 2011; Degen et al., 1997; Ehrlich et al., 2002; Fuchs et al., 2008; 
Knasmüller et al., 2004) and following the recommendations of the European Food Safety 
Authority (EFSA) on conducting toxicity and genotoxicity studies (EFSA, 2011), as well as 
the guidelines for in vitro assays published by the Organisation for Economic Co-operation 
and Development (OECD, 2010). 
 
The results of our work are discussed in detail in the “Results and discussion” sections of 
each of the studies (Studies I to IV) comprising the Results chapter of this thesis. This 
“General discussion” section offers an overview of the results obtained, highlighting the 
most important findings and comparing them with those reported to date in the literature. 
It likewise addresses certain aspects of the experimental designs and methodological 
points that are not fully considered in the discussion sections of the corresponding studies. 
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4.1 Bioaccessibility of OTA 
As mentioned in the Introduction section, bioaccessibility has only been evaluated in in 
vitro systems. Methodologically, in vitro bioaccessibility is a rapid and relatively 
inexpensive alternative for predicting relative bioavailability (Brandon et al., 2006). One of 
the aims of this PhD thesis was to assess OTA bioaccessibility in red wine at different 
levels of contamination. To this end, it was conducted a highly detailed review of the 
digestion models that have been used to study mycotoxin bioaccessibility (see Gonzalez-
Arias et al., 2013; section 3.2 In vitro models used in bioaccessibility or absorption of 
studies on mycotoxins, page 192). In this regard, we concluded that in vitro digestion 
models (based on human or animal physiology and developed for compounds other than 
mycotoxins) are useful tools that can be used in our area of interest. These models usually 
simulate oral, gastric and small intestine digestion and, occasionally, include simulation of 
the large intestine. Moreover, most digestion models are developed to be easily operated 
and thus require minimal features for implementation, unlike the highly sophisticated 
models as TIM-1 and TIM-2 dynamic models. TIM systems mimic the gastric emptying and 
intestinal transit times, and a computer-controlled system introduces the simulated 
salivary, gastric, biliary and pancreatic juices at the appropriate moment. After comparing 
the numerous methods described in the literature, we selected two digestion models 
(based on a wide use in mycotoxins bioaccessibity studies and on the best composition of 
the digestions juices): 1) the RIVM model (Versantvoort et al., 2005) and 2) the Gil-
Izquierdo model (Gil-Izquierdo et al., 2002), both in vitro digestion models developed and 
validated to evaluate digestion in simulated human conditions (Gil-Izquierdo et al., 2002; 
RIVM, 2004). 
 
To assess the bioaccessibility of OTA in red wine, we decided to use the composition of 
digestive juices described in the RIVM model (Annex 2) and in the in vitro dynamic 
digestion model described by Gil-Izquierdo (Study I, Figure 1). As for the analytical 
method used to quantify the bioaccessibility of OTA in red wine (Study I), we chose the 
HPLC method described by Muñoz et al. (2010); the use of immunoaffinity columns was 
rejected because OTα is not recovered, since the antibodies are specific for OTA. The 
liquid-liquid extraction methods described by Muñoz et al. (2010) (for the OTA extraction 
from the gastric chyme) and Zimmerli and Dick (1995) (for the OTA extraction from the 
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intestinal chyme) were selected, and the in-house validation of the method yielded good 
recoveries for both toxins (62.4 to 89.55% for OTα and 75.57 to 89.19% for OTA). The 
EU has no established performance criteria for OTα analysis in foodstuffs, but all OTA 
recovery rates met the performance criteria established in EU Regulation 401/2006 (EC, 
2006) for official control in foodstuffs, which may be used as a reference. 
 
During the liquid-liquid extraction, we found that the gastrointestinal digestion samples 
were so large that handling them could be troublesome. The sample volumes ranged from 
22 to 45 mL, depending on the chyme studied (gastric or intestinal), plus the extraction 
solvent added for OTA purification. Despite the technical difficulties, the results from Study 
I had little variability (a small standard deviation). Variability of results has been described 
by the US Environmental Protection Agency (EPA) and the Bioaccessibility Research Group 
of Europe (BARGE) in bioaccessibility studies of other contaminants. For example, in one 
study using a single soil sample, the bioaccessibility of arsenic varied from 10% to 59% 
and lead bioaccessibility ranged from 3% to 90% (EPA, 2005). Nevertheless, in vitro 
assessment of bioaccessibility is considered a good indicator of the maximal oral 
bioavailability, which can be used for risk assessment of a realistic worst-case scenario for 
a given compound in a food product (Brandon et al., 2006; EPA, 2005). 
 
Our study of OTA bioaccessibility in red wine (Study I) found that the bioaccessibility 
depended on the section of the simulated gastrointestinal tract considered. Thus, the 
bioaccessibility of OTA in the simulated stomach was 102.8%, 128.3%, and 122.3% for 
the contamination levels assayed in the wine (5, 10 and 20 ng OTA, respectively). The 
percentage of bioaccessible OTA drastically decreased in the simulated intestinal section 
(ranging from 21% to 26%), in the presence of lipase and bile salts. With regard to the 
inherent properties of OTA, compounds that form complexes with proteins or mixtures of 
bile salt micelles (such as OTA) have been found to be less likely to be bioaccessible 
(Jovaní et al., 2001), unlike what happens in gastric conditions, where the lower number 
of proteins and low pH favour OTA stability, due to its acidic properties (Galtier, 1977; 
Kumagai and Aibara, 1982). 
 
We also investigated the hydrolysis of OTA to OTα by gastrointestinal peptidases based on 
the initial OTA level in the wine (Study I). While this process was evidenced in our in vitro 
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digestion system, the formation of OTα was relatively low in both gastric (5.11-19.12% 
detected, from wine spiked at 20 ng OTA) and intestinal (only 5.1% detected) chyme. In 
the dialysed fraction, OTα was detected but it was not quantified because the signal was 
below the LOQ. Hydrolysis of OTA to OTα is probably higher in in vivo or in vitro systems 
involving intestinal cellular systems (enterocytes) than in our in vitro dynamic 
gastrointestinal system, where OTα formation was scarce. As in other studies of in vitro 
bioaccessibility, it is important to note that several biological factors were not taken into 
account for the formation of OTα, e.g. the interaction of the toxin with the intestinal 
microbiota in the large intestine (mainly anaerobic bacteria) (Madhyastha et al., 1992) or 
the metabolism of the toxins during their transport through the intestinal barrier (Berger 
et al., 2003; Schrickx et al., 2006). 
 
Regarding the bioaccessibility results from other works, the bioaccessibility of OTA in the 
gastric chyme reported in this PhD thesis (102.8%, 128.3%, and 122.3%, as mentioned 
above) was as high as in other studies using the RIVM method (reported bioaccessibility 
percentages of 25 to 115%), in contrast with the OTA bioaccessibility in the intestinal 
chyme (21-26%). Interestingly, our results on bioaccessibility in the intestinal chyme were 
similar to those from studies including a dialysis membrane, as in the Gil-Izquierdo method 
(25-71%) (See the Table 3 from Annex I, Gonzalez-Arias et al., 2013). To this end, it 
should be noted that the in vitro digestion model used to assess bioaccessibility (static or 
dynamic) can influence the results obtained. Additionally, the use of different compositions 
of digestive juices can affect the bioaccessibility data obtained, as contradictory results 
have been reported when different rates of enzymes and food have been used (BARGE, 
2015; Gonzalez-Arias et al., 2013). 
 
Hence, the determination of oral bioaccessibility will have a strong significance as long as 
the results are similar to those from in vivo assays. In this regard, the EPA (2005; 2007) 
has recommended both the inter-laboratory validation of methods and the validation of 
results with in vivo data. We have not carried out an in vivo study but the bioaccessibility 
found in our bioaccessibility study does agree with results from in vivo studies (Galtier et 
al., 1981; Hagelberg et al., 1989). We obtained high values of in vitro bioaccessibility for 
OTA (102.8-128.3% in gastric chyme), in keeping with the in vivo bioavailability data in 
humans and in the most important animal species. For example, in humans, up to 84% of 
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OTA has been detected in plasma (Studer-Rohr et al., 1995); in animal species, the 
highest bioavailability has been reported in mice (92%), followed by pigs (65.7%), rats 
(61%), monkeys (57%), rabbits (55.6%), chickens (40%) and fish (1.6%). 
 
Regardless of the contamination level assayed, OTA in red wine proved to be highly 
bioaccessible in gastric chyme, but not in intestinal chyme. Unlike the in vitro 
bioaccessibility, the in vivo bioavailability could increase, as OTA absorption depends on 
gastric emptying, mechanical movements, and the pH at the mucosal surface of the 
intestine (Gonzalez-Arias et al., 2013). 
Other way to assess the bioaccessibility are the in vitro cultures using Caco-2 cells, a cell 
line from human epithelial colorectal adenocarcinoma. The Caco-2 cells differentiated 
monolayers achieve morphological/physiological function, like intestinal epithelium, during 
its growth in cell cultures. Therefore, mycotoxins passing through cell membrane can be 
measured in cell culture media. Normally, data are presented as relative percentage of 
toxin or as concentration in the basolateral compartment (in a Transwell® plates). In 
humans, an intervention study was conducted in human volunteers, using a chlorophyllin 
adsorbent (Egner et al. 2001). In in vivo studies, results are reported as bioavailability or 
presence of compounds in urine. Additionally to toxicokinetics of toxins, toxicity data can 
be obtained from animal/cellular models with/without adsorbents (toxin-DNA levels and 
albumin adducts, and biotransformation) and the results may be extrapolated and applied 
to human conditions for risk assessment (Breinholt et al., 1999; Kensler; et al., 1998). To 
our knowledge, only a study in humans has been published regarding ochratoxin 
bioavailabilty (Studer-Rohr et al., 1995). The results showed that OTA has a bioavailabity 
of 84% in plasma, similar to the observed in animal species, as mentioned above.  
 
4.2 In vitro assessment of OTA tox icity 
Three studies (Studies II, III and IV) were planned in the context of this PhD thesis for 
the in vitro assessment of OTA toxicity. The primary human lymphocytes and two human 
cell lines (Caco-2 and HepG2 cells) were used to perform the assays. To assess OTA 
toxicity, we selected several cytotoxicity assays widely used in the in vitro assessment of 
the toxicity of compounds, as well as an array of three genotoxic tests from amongst the 
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most common and well-accepted by the EFSA. These tests/assays helped to: a) predict 
potential genotoxic carcinogens, and b) contribute to understanding the mechanism of 
action recommended by the EFSA Scientific Committee (EFSA, 2011). There is likewise a 
need to avoid unnecessary animal tests (EFSA, 2011). A third endpoint not investigated in 
this thesis was the heritable damage in humans caused by OTA; this has been addressed 
in other studies with either positive or negative (Mosesso et al., 2008; NIH, 1989; Zepnik 
et al., 2001) results. 
 
To establish the range of OTA doses for the treatments in this research, a review of the 
cytotoxic data on OTA was carried out. The most important references to this end were 
the studies by Akman et al. (2012), Ali et al. (2011), Degen et al. (1997), Ehrlich et al. 
(2002), IARC (1993), JECFA (2001), Kamp et al. (2005), Kuiper-Goodman et al. (2010), 
Lioi et al. (2004), and Simarro Doorten et al. (2006). We performed the cytotoxicity, 
genotoxicity and gene expression assays using doses lower than 45 µM for the treatments, 
since the chronic toxicity caused by OTA has been found to be associated with long 
periods of exposure to low levels of toxin (IARC, 1993; JECFA, 2001; Kuiper-Goodman et 
al., 2010). 
 
4.2.1 Cytotox icity of OTA in cultured human cells 
The first stage of the cytotoxic assay was carried out in independent assays with primary 
human lymphocytes, and the Caco-2 cell and HepG2 cell line (Studies II, III and IV). The 
viability values (expressed as the percentage of viability compared to the solvent control) 
obtained in the different assays were over 60%, as recommended for the performance of 
both in vitro cytokinesis-block micronucleus (CBMN) assays (OECD, 2010) and in vitro 
comet assays (Tice et al., 2000). 
 
Figure 1 summarises the viability values obtained in the three studies. These results were 
obtained using the MTT assay (Studies II and III), the trypan blue exclusion test and 
fluorescein diacetate assay (Study IV). In general, no large differences were found in cell 
viability in the three studies based on the different cell types used. We were thus able to 
use a similar range of OTA doses in all three studies conducted as part of this PhD thesis. 
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A higher loss of viability was observed in Caco-2 cells treated with doses higher than 75 
µM OTA for 24 h (Studies III) and 48 h exposure (Studies II). 
 
The viability values from the three studies (Studies II, III and IV) were similar to those 
reported by Ali et al. (2011) (using CHO cells and TK6 cells) and Ramyaa et al. (2014) 
(with HepG2 cells). Viability was approximately 70% when the OTA concentration was 
lower than 45 µM. The results from Study II show that OTA (80 µM) caused viability to fall 
to 60% in Caco-2 cells after a period of 48 h. Hundhausen et al. (2005) and Zheng et al. 
(2013) independently found that HepG2 cells were more sensitive than Caco-2 cells. A 
50% loss in viability was detected in HepG2 cells treated with 35 µM OTA after an 
exposure of between 24 and 48 h (Hundhausen et al., 2005; Zheng et al., 2013). As with 
OTA nephrotoxicity, the highest decrease in viability was observed in OK cells, a cell line 
from the kidney of an adult female opossum. The exposure of OK cells to OTA at 
concentrations as low as 10 µM caused cell viability to fall to 60% or less after 24 and 48 
h (Faucet-Marquis et al., 2006; Hadjeba-Medjdoub et al., 2012). 
 
In order to compare the cytotoxic effect of OTA with that of other mycotoxins, a viability 
assay was performed using Caco-2 cells exposed to DON and Caco-2 cells co-exposed to 
OTA and DON (Study II). DON was chosen because it is a mycotoxin commonly found in 
co-occurrence with OTA in foods (Streit et al., 2013). Since the toxicity of DON was higher 
than the toxicity of OTA, co-exposure to OTA (20, 40 and 80 µM) and DON (0.5, 1 and 5 
µM) increased the toxicity for the cells. Co-exposure to the mycotoxin mixture resulted in a 
loss of cell viability (64.1%) at lower concentrations of OTA (20 µM) and DON (0.5 µM) as 
compared to that observed in the single treatments, in which OTA and DON at the 
referred doses led to 95.18% and 96.27% cell viability, respectively. 
 
There are many ways to assess viability/cytotoxicity and each one provides information 
about different cellular processes (Stoddart, 2011). As noted in the work plan section, this 
PhD thesis used different methods to assess OTA cytotoxicity. The most interesting 
findings are described below. For example, in the study of MN induction (Study IV), the 
cytostaticity caused by OTA was also determined. In this case, the cytostatic effect was 
determined at 15 µM OTA using human lymphocyte cells.  
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Figure 1. Mean of cell viability (percentage relative to controls) in Caco-2, HepG2 and 
lymphocites exposed to OTA. The viability assays used to determine the effect of OTA on 
cell viability were: an MTT assay (Study II and III) and the trypan blue exclusion test (─) 
and fluorescein diacetate assay (◊) (Study IV). 
 
 
Interestingly, this OTA concentration did not cause a high loss of viability (88% cellular 
viability) compared to the solvent control. The cytostatic effect refers to the suppression of 
cell growth (cellular biomass) and proliferation (cell cycle arrest) (Fenech, 2007; MacLaine 
et al., 2008). Neither biomass nor cell cycle arrest were determined during the different 
assays conducted in this thesis, but a decrease in cellular density could be observed under 
Caco-2 cells (0.5-160 µM, Study II) 
Caco-2 cells (5-180 µM, Study III) 
HepG2 cells (5-180 µM, Study III) 
Lymphocytes (0.075-15 µM, Study IV) 
 
 147 
a microscope compared to the cell cultures treated in control conditions (DMSO as vehicle 
control), or with the lower concentrations of OTA (Studies II, III and IV). 
 
The study of membrane integrity and ROS production are other methods for assessing 
cytotoxicity. Both assays were conducted on Caco-2 cells (differentiated and 
undifferentiated, respectively). To evaluate membrane integrity, the change in 
transepithelial electrical resistance (TEER) before and after treatment with OTA was 
recorded using a TEER system (Figure 2a and 2b). The results of the TEER measurements 
showed that the Caco-2 monolayers (cells grown in a transwell plate, Figure 2c) were 
depolarised (decrease in TEER) after 24 h of exposure to OTA, regardless of the OTA 
concentration. 
Interestingly, in our study (Study III), TEER decrease and loss of cell viability were 
detected in cell cultures exposed to OTA for 24 h. The mean TEER values of the 
monolayers exposed for 24 h were 63.6%, 61.5% and 64.6% for 5, 15 and 45 µM OTA, 
respectively, in sharp contrast to the results of the TEER measures at 3 h and 12 h, in 
which OTA did not cause any significant decrease. Our findings revealed cellular damage 
to the intestinal epithelial cell tight junction proteins and increased cell permeability. 
Maresca et al. (2001) recorded a 50% decrease in TEER after treatment with 100 µM OTA 
(48 h of exposure), which was related to a decrease in whole cell protein content, the 
inhibition of cell growth and morphological changes. Like Maresca et al. (2001), we did not 
observe a time-dependent decrease in TEER over a 24 h period. Possibly, such a time-
dependent response was not observed due to the low range of OTA doses assayed 
(0.001-1 µM OTA for 48 h) (Maresca et al., 2001). 
With regard to ROS production due to OTA exposure, both in vitro (Kamp et al., 2005; 
Mally et al., 2005; Schaaf et al., 2002) and in vivo (Hsuuw et al., 2013; Petrik et al., 2003) 
studies have been described in the literature. Our findings suggest that low doses of OTA 
do not cause significant ROS production in undifferentiated Caco-2 cells (Study II). Only 
cells treated with > 80 µM OTA for 48 h showed an increase in ROS production with a 
parallel reduction in cell viability. This finding showed that the ROS produced after a long 
period of exposure to OTA (48 h) can be neutralised by the antioxidant mechanisms  in 
the cell (Study II), but also that the pathway of oxidative damage to DNA acts early (as 
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observed in human lymphocytes) (Study IV) (this latter finding will be discussed in greater 
detail in the section on OTA genotoxicity). It is therefore possible that OTA concentrations 
higher than 20 µM play an important role in cytotoxicity due to a free radical-mediated 
mechanism in short periods of exposure. 
 
 
 
 
Figure 2. Transepithelial electrical resistance (TEER) measurement: a) Millicell-ERS-2 
model by Millipore® (Bedford, MA); b) STX01 electrode; and c) transwell plate with 
microporous membrane inserts. 
 
 
This study also looked at the capacity of OTA to induce oxidative stress in combination 
with DON, as well as the protective effects of resveratrol (RES) (an antioxidant present in 
grapes and wine) in Caco-2 cells (Study II). The oxidative stress induced by these three 
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compounds was measured in terms of the fluorescence intensity of the DCFH-DA (2′,7′-
dichlorodihydrofluorescein diacetate) hydrolysed by metabolically active cells. The OTA-
DON mixtures did not increase the ROS production observed at the highest concentration 
of OTA (80 µM), but a reduction in the cellular antioxidant defence of Caco-2 cells was 
observed after treatment with a mixture of OTA (80 µM) and RES (40 µM and 160 µM 
RES). Other authors have also described the non-protective effect of antioxidant 
compounds, including increased ROS production. For example, Juan et al. (2008) reported 
increased mitochondrial ROS in a human colon cancer cell line (HT-29) exposed to RES 
(150 µM) for 4 h, and Badding et al. (2014) reported a positive association between loss 
of viability and the non-protective effect of the antioxidant N-acetyl-L-cysteine in RAW 
264.7 mouse macrophages. In case of resveratrol, a polyphenolic compound described as 
a strong antioxidant, its antioxidant activity is associated with its ability to scavenge free 
radicals, donate hydrogen, break radical chain reactions, chelate metals, and quench 
singlet oxygen in vitro and in vivo (Duthie et al., 2000; Perron et al., 2009). 
As mentioned in study II, the mechanism triggering the cytotoxic effect of DON and OTA 
enhanced by RES or the mechanism triggering the enhanced production of ROS by RES 
itself, respectively, cannot be completely elucidated with the present data. The research 
conducted in the Study II of this thesis is the first study in which the in vitro toxicity of the 
co-exposure of DON and OTA has been studied in the presence of RES. 
Despite of an increase in ROS levels from in vitro assays (Study II), epidemiological 
studies have revealed a positive association between the consumption of phenolic-rich 
foods and the prevention of oxidative stress-related diseases by dietary antioxidants (Vang 
et al., 2011; Willcox et al. 2008), being RES one of the most abundant antioxidant 
compound in the diets (Burns et al., 2002; Fernández-Mar et al., 2012). Results in 
literature support our findings, and it was described that RES can modulate multiple vias 
that elicite to apoptosis and cell damage. For example: 1) cells damage related with a 
response mediated by the caspase-3 (Fouad et al., 2013; and Pasciu et al., 2010); 2) the 
proliferation inhibition and apoptosis induction through the mechanism involving 
transforming growth factor and Smad proteins (TGF-b1/Smads) (Zhai et al., 2015). 
Further investigations will be required to elucidate an action mechanism with the Study II 
conditions. 
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4.3 Gene expression 
In order to assess the effect of OTA on the expression of certain genes, the mRNA levels 
were quantified using real-time-qPCR. To carry out this study (Study III), we used an in 
vitro cell co-culture system (Figure 3) to mimic initial passage through the intestine and 
hepatic metabolism, using Caco-2 and HepG2 cells. To assess the effect of OTA over time, 
we assayed periods of 3, 12 and 24 h of exposure. The CYP1A1, CYP2A6, CYP2B6, 
CYP3A4 and CYP3A5 genes from the CYP450 family; the NAT2 xenobiotic metaboliser 
involved in Phase II; the COX-2 and 5-LOX inflammatory markers; and the MRP2 
transporter were studied. 
 
 
 
 
Figure 3. Co-culture of differentiated Caco-2 cells and HepG2 cells in a transwell plate with 
microporous membrane inserts. 
 
 
The results (Study III) in differentiated Caco-2 cells showed that expression was down-
regulated in most genes. Amongst the genes from the CYP450 family, the CYP1A1 gene 
was the most down-regulated by OTA in all treatments. Monolayer exposure to OTA for 12 
h was found to have the greatest effect on CYP1A1 expression (52-fold decrease), 
whereas CYP1A1 was less modulated by OTA in cells exposed for 24 h. 
 
The CYP2A6 and CYP2B6 genes from the CYP2 family were slightly down-regulated by 
OTA within the first 3 hours. No additional significant changes were detected in cells 
exposed for 12 and 24 h. Interestingly, OTA did not modulate the expression of the 
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CYP3A4 gene in cells exposed for 3 h. Nonetheless, treatment with 45 µM (24 h) caused a 
significant difference in the expression level of CYP3A4. To date, few studies have been 
conducted on the toxicodynamics of OTA in relation to the genes that encoded for 
metabolising enzymes in the intestinal epithelium, as research has tended to focus on 
absorption mechanisms. In this sense, with regard to CYP1A1, our results for gene 
expression differ from those of the study performed at the protein level by Ribonnet et al. 
(2011). They measured the activity of the CYP1A1 and CYP3A4 enzymes from Caco-2 cells 
and found that OTA increased CYP1A1 activity and inhibited CYP3A4 activity. 
 
With regard to the results obtained in hepatic cells, OTA caused both up- and down-
regulation. Unlike the results obtained in Caco-2 cells, the expression level of CYP1A1 
showed a significant up-regulation, mainly in cells exposed for 24 h. In the case of 
hepatocytes, CYP3A4 expression increased significantly after 12 h, and the expression 
level was stable for up to 24 h of exposure to OTA. In contrast, CYP3A5 did not show a 
significant response to exposure to OTA, as exposure to 45 µM OTA for 24 h had only a 
slight down-regulation effect. As for the CYP2 family in hepatic cells, CYP2A6 mRNA was 
not detected, and the CYP2B6 gene was down-regulated within the first 3 h, whereas an 
up-regulation effect was observed in cells exposed to OTA for 12 and 24 h. 
 
The above results for gene expression over time (3, 12 and 24 h) suggest that the 
changes in the expression level are the result of (Chung et al., 2008; Morgan, 2001; 
Ramyaa and Padma, 2013): 
a) stress signals caused by toxicity, 
b) an adaptive response that promotes the controlled generation of ROS, nitric oxide or 
arachidonic acid metabolism. 
 
This was observed in Study II, where OTA induced different level of ROS production 
depending on the OTA dose assayed, as well as in Study III, where changes were 
detected in the mRNA expression levels of genes involved in the metabolic response and 
inflammation (to be discussed in greater detail below). 
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In parallel, the expression of the NAT2 gene was assessed. The NAT2 gene has a very 
strong epidemiological association with a variable risk of urinary bladder cancer, possibly 
due to impaired detoxification of carcinogenic metabolites in the liver (Hein et al., 2000; 
Husain et al., 2007). To our knowledge, the expression of the NAT2 gene has not been 
studied previously in cell cultures after exposure to OTA. Only Lebrun and Follmann 
(2002) reported a high correlation between NAT2 polymorphisms and DNA damage in an 
in vitro culture of OTA-exposed human urothelial cells. It is important to highlight the 
results obtained with the NAT2 gene in this thesis (Study III): amongst the genes tested, 
the NAT2 gene was the second most OTA-modulated gene in Caco-2 cells (after a period 
of 12 and 24 h of OTA exposure); this stands in contrast to HepG2 cells, in which the 
NAT2 gene was both up- and down-regulated. 
 
The inflammatory response was evaluated by determining the mRNA levels of the COX-2 
and 5-LOX genes. In Caco-2 cells, OTA presence caused a higher decrease in COX-2 
mRNA expression than in 5-LOX mRNA expression in a time-dependent manner. This is in 
keeping with what has been observed for most genes, but in contrast to what has been 
observed in the HepG2 cells, in which OTA caused changes in the expression level over 
time. For example, the inflammatory markers were slightly modulated by OTA at 3 h of 
treatment, but after 12 h of exposure, both COX-2 and 5-LOX genes appeared up-
regulated. As in other studies, the 5-LOX gene did not maintain the same level of 
expression over the course of the 24 hours of exposure to OTA. In this regard, Kumar et 
al. (2013) and Ramyaa et al. (2014) described an increase in the mRNA level over a period 
of less than 24 h. 
 
Regarding the mechanism of OTA secretion in the cells, our results suggest a possible 
impairment in OTA secretion at the intestinal and hepatic levels due to MRP2 repression, 
especially in the enterocytes. The repression of the MRP2 gene suggests an increase in in 
vivo bioavailability due to a decreased first-pass effect in the small intestine, as the 
function of the MRP2 transporter is the active transport of anionic conjugates and drug 
extrusion from the intestine, although it is also expressed in the liver, kidney-proximal 
tubules and other cells (Jedlitschky et al., 2006). At the hepatic level, the MRP2 repression 
supports the finding that OTA is not highly excreted in bile, resulting in an increase in its 
plasmatic half-life. 
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The induction of genes in response to xenobiotics has been previously studied, and the 
mechanism is largely understood. For instance, it is known that CYP450 genes show 
similar responses because they often involve activation of common cytosolic or nuclear 
receptors, including the aromatic hydrocarbon receptor, the constitutive androstane 
receptor, the pregnane X receptor, and the peroxisome proliferator-activated receptor-
alpha (Honkakoski and Negishi, 2000). In the case of OTA, some genes have been linked 
to OTA metabolism/biotransformation (Marin-Kuan et al., 2006). Nevertheless, the 
mechanism of action through which the CYP450 and other genes can be suppressed 
remains unclear (Marin-Kuan et al., 2006; Ramyaa and Padma, 2013). 
 
In summary, our transwell cell system allowed us to obtain data from both types of cells 
during the same OTA exposure, mimicking intestinal absorption and hepatic metabolism. 
The analysis of gene expression showed that the modulation of gene expression by OTA 
was higher in the Caco-2 cells than in the HepG2 cells. The CYP1A1 gene was the most 
modulated by OTA in Caco-2 cells, followed by the CYP3A4 and CYP3A5 genes. In 
contrast, in HepG2 cells, CYP2B6 was highly regulated at 3 and 12 h as compared with the 
other cytochrome genes. Moreover, the CYP1A1 gene was slightly modulated during the 
first 12 hours, but over-expression was observed at 24 hours. Our data support the 
findings on the effects of OTA on the COX-2 and 5-LOX genes during liver metabolism. 
Thus, the COX-2 and 5-LOX genes may be proposed as early inflammatory markers of 
OTA exposure. All this suggests that OTA acts on the same genes in a different way 
depending on whether the toxin is in the enterocytes or the hepatocytes. Additionally, we 
were able to provide evidence of the effect of OTA on the NAT2 gene expression, which 
had not been previously reported. 
 
4.4 Genotox icity of OTA  
Genotoxicity is a broad term and refers to processes that alter genetic materials (DNA, 
histones and chromosomes). Genotoxic processes have been described in both germinal 
and somatic cells. We used the alkaline comet assay and the MN test to assess OTA 
genotoxicity in vitro. Both the comet assay and the MN test provide data on damage to 
DNA through different action mechanisms (both direct and indirect) (Collins, 2014; Fenech 
et al., 2003). A DNA repair assay with N-hydroxyurea (NHU) was carried out to obtain 
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data on the effect of OTA on cells’ DNA repair systems (Collins, 2004). This repair assay is 
a modified comet assay and was conducted in conjunction with a second comet assay in 
order to compare the repair capacities of cells exposed to OTA and NHU. In the latter 
case, only the OTA concentrations that caused significant damage in the DNA (as revealed 
in the first comet assay) were used in the DNA repair assay. 
 
The alkaline comet assay was conducted for 3 h, and the results after the exposure to 
OTA showed that the mycotoxin had caused DNA single- and double-strand breaks. An 
increase in the percentage of DNA in the tails of the comets was observed in cells treated 
with 0.075, 1.5 and 5 µM OTA, although no dose-response pattern was detected. The 
results of the comet assay provide direct evidence regarding DNA damage at low doses. 
Possibly, these OTA doses do not generate detectable free radicals, as was observed in 
Study II, in which low OTA doses did not result in increased ROS production. 
As mentioned above, the repair of specific DNA lesions by cellular repair processes was 
monitored by means of a DNA repair assay (Study IV). Thus, to enable comparison of the 
effects caused by OTA, we exposed cells to 1.5 or 5 µM OTA (concentrations that 
increased the percentage of DNA in the comet tails) jointly with NHU and hydrogen 
peroxide (H2O2). The repair assay was conducted in parallel with a second comet assay to 
compare the delay in the repair pathway within a period of 0-60 minutes. The use of short 
periods of time has been suggested in the literature (Collins, 2004), as strand breaks are 
quickly repaired during the activation of the excision repair pathway. This mechanism can 
be inhibited by co-exposure to DNA synthesis inhibitors, such as NHU. 
 
In this study, 1.5 and 5 µM OTA inhibited DNA repair in the presence of 10 mM NHU by 
blocking DNA synthesis, leading to an accumulation of breaks. The accumulation of breaks 
resulted in an increased percentage of DNA compared to non-NHU-exposed cells. 
Interesting results were observed using the repair assay in lymphocytes. For example, 
OTA treatment with NHU led to different results from OTA+H2O2 treatment at 60 min 
without NHU. Similarly, in the OTA+H2O2 treatment, the repair effect at 60 min was 
different from that observed at 30 min. Güerci et al. (2009) used NHU to investigate the 
repair activity of human lymphocytes. As in this study, those authors assayed ethyl and 
methyl methanesulfonate (compounds with alkylating activity) during a repair assay with 
10 µM NHU, as in the present thesis. Methanesulfonates did not cause delays in the repair 
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pathway in human lymphocytes co-exposed to 10 µM NHU. Like OTA (Group 2B), these 
methanesulfonate compounds are also classified as Group 2 by the IARC (Group 2A and 
Group 2B, respectively). It can thus be stated that OTA is able to inhibit a repair pathway 
that other compounds from the same group (Group 2) cannot, indicating that OTA causes 
damaged DNA to accumulate in cells. 
 
Additionally, an MN test was performed (Study IV) using the same range of micromolar 
OTA concentrations. The identification of MN showed a significant increase in lymphocytes 
treated with 1.5 and 5 µM OTA, for which the mean MN was 4.6 ± 1.8 and 7.7 ± 1.3 
MN/1000 binuclear cells, respectively. The MN induction was not quantified in cells treated 
with 15 µM OTA due to the cytostatic effect observed, and discussed in the section on 
cytotoxicity above. In this case, OTA cytostaticity was evidenced by high cell viability 
(88%) in the absence of binuclear cells in treatments done with 15 µM OTA. 
 
OTA-based MN induction has been reported in the literature at doses higher than 5 µM 
(Degen et al., 1997; Dopp et al., 1999; Fuchs et al., 2008; Klarić and Pepeljnjak, 2008; 
Knasmüller et al., 2004). Other studies conducted with a wide range of OTA 
concentrations have reported MN induction at doses higher than 25 µM, and have not 
shown a dose-response pattern (Ali et al., 2011; Dönmez-Altuntaş et al., 2003; Ehrlich et 
al., 2002). Unlike the aforementioned studies, our results with the MN assay showed that 
OTA is a micronuclei inducer at concentrations as low as 1.5 µM. With regard to the 
statistics of the results of the comet assay, Figure 1 and 2 of Study IV (page 122 and 123) 
showed a high standard deviation. The protocol of the comet assay was published by Tice 
et al. (2000), but with regard to the statistical treatment of data, the authors does not 
provide any useful guidance. At the International Workshop on Genotoxicity Test 
Procedures, the expert panel did not infom of the most appropriate statistical method(s) to 
be used, and there was no consensus in this regard (Tice el al., 2000). Nowadays, the 
prevailing idea is that the kind of sample used (animals per group or cultures per 
treatment, number of gels per animal/culture and number of measured cells per gel) has a 
big influence on the result, as with the comet assay the risk in neglecting the hierarchical 
nature of data must be taken into account (Tice et al., 2000). Our results of Study IV are 
shown as the mean ± SD of three independent experiments run in duplicate, and the size 
sample by slide was higher than 50 cells/slide. An experimental desing like this is well 
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accepted, and it was pointed out that experimental data from comet assays do not show a 
normal distribution (Tice et al., 2000). Until now, literature describes multiples ways, as 
suggestions, to carry out a statical analysis in the comet assays (Bright et al., 2011; 
Wiklund et al., 2003). 
 
In summary, Study IV allowed us to conclude that OTA is an MN inducer that also causes 
stable damage to DNA through an oxidative via without a dose-response pattern at doses 
that do not cause losses in viability or cytostaticity. Our results moreover showed an 
indirect mechanism of action of OTA – the inhibition of the DNA repair pathway – in 
addition to MN induction and the induction of DNA single-strand and double-strand breaks. 
 
Recent decades have seen considerable debate about the genotoxicity of OTA and its role 
in the carcinogenic process (Akman et al., 2012; González-Arias et al., 2014; Mosesso et 
al., 2008; Pfohl-Leszkowicz and Castegnaro, 2005; Turesky, 2005; Yang et al., 2014). This 
debate over the carcinogenicity of OTA has not yet been resolved, and data such as ours 
suggest that exposure to low doses of this toxin can cause serious damage. The many 
effects of OTA have attracted significant public health attention; consequently, OTA 
surveys in foods and feeds have been conducted worldwide. 
 
International and national food safety organisations (EFSA, JECFA, ILSI, Health Canada) 
have reviewed these data and defined a risk assessment of OTA in foods to provide insight 
into its health significance (JECFA, 2008; Kuiper-Goodman et al., 2010). The approaches 
used by these expert groups to establish the safe levels of OTA exposure have been based 
on uncertainty factors (key events compatible with a threshold effect). As a result, 
amongst the possible mechanisms of action, oxidative stress has been presented as one of 
the most probable (JECFA, 2007; Kuiper-Goodman et al., 2010). 
 
The results of the study conducted as part of this thesis (Study IV) indicate that OTA is a 
genotoxic mycotoxin. Moreover, other cellular processes (ROS induction at high doses and 
gene expression modulation) and the effect of OTA dose on cells have been implicated in 
the toxicity induced by this mycotoxin, as observed in Studies II and III. These findings 
indicate that OTA affects pivotal events in the carcinogenesis pathway, and all these 
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mechanisms of action have been related to OTA toxicity at non-cytotoxic doses during 
long-term exposure (González-Arias et al., 2014; Horvath et al., 2002; Qi et al., 2014). 
 
References 
Akman, S.A, Adams, M., Case, D., Park, G., Manderville, R.A., 2012. Mutagenicity of 
ochratoxin A and its hydroquinone metabolite in the SupF gene of the mutation reporter 
plasmid Ps189. Toxins. 4, 267-280. 
Ali, R., Mittelstaedt, R.A, Shaddock, J.G., Ding, W., Bhalli, J.A, Khan, Q.M., Heflich, R.H., 
2011. Comparative analysis of micronuclei and DNA damage induced by ochratoxin A in 
two mammalian cell lines. Mutat. Res. 723, 58-64. 
Badding, M.A., Fix, N.R., Antonini, J.M., Leonard, S.S., 2014. A comparison of cytotoxicity 
and oxidative stress from welding fumes generated with a new nickel-, copper-based 
consumable versus mild and stainless steel-based welding in RAW 264.7 mouse 
macrophages. PLoS One 9. 
Belli, N., Marin, S., Duaigues, A., Ramos, A.J., Sanchis, V., 2004. Ochratoxin A in wines, 
musts and grape juices from Spain. J. Sci. Food Agric. 84, 591-594. 
BARGE (Bioaccessibility research group of Europe). The BARGE unified bioaccessibility 
method. Available at: http://www.bgs.ac.uk/barge/home.html [Consulted: 31 march 
2014]. 
Berger, V., Gabriel, A.F., Sergent, T., Trouet, A., Larondelle, Y., Schneider, Y.J., 2003. 
Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a 
multidrug resistance-associated protein (MRP2). Toxicol. Lett. 140, 465-476. 
Brandon, E.F., Oomen, A.G., Rompelberg, C.J., Versantvoort, C.H., van Engelen, J.G., 
Sips, A.J., 2006. Consumer product in vitro digestion model: Bioaccessibility of 
contaminants and its application in risk assessment. 44, 161. 
Breinholt, V., Arbogast, D., Loveland, P., Pereira, C., Dashwood, R., Hendricks, J., Bailey, 
G., 1999. Chlorophyllin chemoprevention in trout initiated by aflatoxin B(1) bath 
158 
treatment: An evaluation of reduced bioavailability vs. target organ protective 
mechanisms. Toxicol. Appl. Pharmacol. 158, 141-51.  
Bright, J., Aylott, M., Bate, S., Geys, H., Jarvis, P., Saul, J., Vonk, R., 2011. 
Recommendations on the statistical analysis of the Comet assay. Pharm. Stat. 10, 485-
493.  
Chung, S.W., Toriba, A., Chung, H.Y., Yu, B.P., Kameda, T., Tang, N., Kizu, R., Hayakawa, 
K., 2008. Activation of 5-lipoxygenase and NF-kappa B in the action of 
acenaphthenequinone by modulation of oxidative stress. Toxicol. Sci. 101, 152-158. 
Collins, A.R., 2004. The comet assay for DNA damage and repair: principles, applications, 
and limitations. Mol. Biotechnol. 26, 249-261. 
Collins, A.R., 2014. Measuring oxidative damage to DNA and its repair with the comet 
assay. Biochim. Biophys. Acta 1840, 794-800. 
Coronel, M.B., Marín, S., Cano-Sancho, G., Ramos, A.J., Sanchis, V., 2012. Exposure 
assessment to ochratoxin A in Catalonia (Spain) based on the consumption of cereals, 
nuts, coffee, wine, and beer. Food Addit. Contam. Part A. Chem. Anal. Control. Expo. Risk 
Assess. 29, 979-993. 
Coronel, M.B., Sanchis, V., Ramos, A.J., Marin, S., 2009. Assessment of the exposure to 
ochratoxin A in the province of Lleida, Spain. Food Chem. Toxicol. 47, 2847-2852. 
Degen, G.H., Gerber, M.M., Obrecht-Pflumio, S., Dirheimer, G., 1997. Induction of 
micronuclei with ochratoxin A in ovine seminal vesicle cell cultures. Arch. Toxicol. 71, 365-
271. 
Dönmez-Altuntaş, H., Hamurcu, Z., Imamoglu, N., Liman, B.C., 2003. Effects of ochratoxin 
A on micronucleus frequency in human lymphocytes. Nahrung 47, 33-35. 
Dopp, E., Müller, J., Hahnel, C., Schiffmann, D., 1999. Induction of genotoxic effects and 
modulation of the intracellular calcium level in syrian hamster embryo (SHE) fibroblasts 
caused by ochratoxin A. Food Chem. Toxicol. 37, 713-721. 
 159 
Duthie, G.G., Duthie, S.J., Kyle, J.A., 2000. Plant polyphenols in cancer and heart disease: 
implications as nutritional antioxidants. Nutr. Res. Rev. 13, 79-106.  
EFSA (European Food Safety Authority), 2011. Scientific Opinion on genotoxicity testing 
strategies applicable to food and feed safety assessment. EFSA Journal 9:23-79. 
Ehrlich, V., Darroudi, F., Uhl, M., Steinkellner, H., Gann, M., Majer, B.J., Eisenbauer, M., 
Knasmüller, S., 2002. Genotoxic effects of ochratoxin A in human-derived hepatoma 
(HepG2) cells. Food Chem. Toxicol. 40, 1085-1090. 
EPA (U.S.Environmental Protection Agency), 2005. International workshop on the potential 
use of bioaccessibility testing in risk assessment of land contamination. Science Report 
SC040054. Oxford, UK. Ed. Environment Agency. P. 31. Available at: 
http://www.cieh.org/uploadedFiles/Core/Policy/Environmental_protection/Contaminated_la
nd/Standing_Conference_on_Contaminated_Land/Bioaccessibility_Testing.pdf [Consulted: 
31 march 2014]. 
EPA (U.S. Environmental Protection Agency), 2007. Estimation of relative bioavailability of 
lead in soil and soil-like materials using in vivo and in vitro methods. OSWER 9285.7-77. 
Available at: 
http://www.epa.gov/superfund/health/contaminants/bioavailability/guidance.htm 
[Consulted: 31 march 2014]. 
EPA (U.S.Environmental Protection Agency), 2014. Summary report: state-of-the-science 
workshop on chemically-induced mouse lung tumors: applications to human health 
assessments. Available at: 
http://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=291094 [Consulted: 31 march 
2014]. 
Faucet-Marquis, V., Pont, F., Størmer, F.C., Rizk, T., Castegnaro, M., Pfohl-Leszkowicz, A., 
2006. Evidence of a new dechlorinated ochratoxin A derivative formed in opossum kidney 
cell cultures after pretreatment by modulators of glutathione pathways: correlation with 
DNA-adduct formation. Mol. Nutr. Food Res. 50, 530-542. 
160 
Fenech, M., 2007. Cytokinesis-block micronucleus cytome assay. Nat. Protoc. 2, 1084-
1104. 
Fenech, M., Chang, W.P., Kirsch-Volders, M., Holland, N., Bonassi, S., Zeiger, E., 2003. 
HUMN project: detailed description of the scoring criteria for the cytokinesis-block 
micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534, 65-75. 
Föllmann, W., Hillebrand, I.E., Creppy, E.E., Bolt, H.M., 1995. Sister chromatid exchange 
frequency in cultured isolated porcine urinary bladder epithelial cells (PUBEC) treated with 
ochratoxin A and alpha. Arch. Toxicol. 69, 280-286. 
Fuchs, S., Sontag, G., Stidl, R., Ehrlich, V., Kundi, M., Knasmüller, S., 2008. Detoxification 
of patulin and ochratoxin A, two abundant mycotoxins, by lactic acid bacteria. Food Chem. 
Toxicol. 46, 1398-1407. 
Galtier, P., 1977. Contribution of pharmacokinetic studies to mycotoxicology - Ochratoxin 
A. Vet. Sci. Commun. 1, 349-358. 
Galtier, P., Alvinerie, M., Charpenteau, J.L., 1981. The pharmacokinetic profiles of 
ochratoxin A in pigs, rabbits and chickens. Food Cosmet. Toxicol. 19, 735-738. 
Gil-Izquierdo, A., Zafrilla, P., Tomas-Barberan, F.A., 2002. An in vitro method to simulate 
phenolic compound release from the food matrix in the gastrointestinal tract. Eur. Food 
Res. Technol. 214, 155-159. 
González-Arias, C.A., Benitez-Trinidad, A.B., Sordo, M., Robledo-Marenco, L., Medina-Díaz, 
I.M., Barrón-Vivanco, B.S., Marin, S., Sanchis, V., Ramos, A.J., Rojas-García, A.E., 2014. 
Low doses of ochratoxin A induce micronucleus formation and delay DNA repair in human 
lymphocytes. Food Chem. Toxicol. 74, 249-254. 
González-Arias, C.A., Marin, S., Sanchis, V., Ramos, A.J., 2013. Mycotoxin 
bioaccessibility/absorption assessment using in vitro digestion models: a review. World 
Mycotoxin J. 6, 167-184. 
 161 
Güerci, A., Liviac, D., Marcos, R., 2009. Detection of excision repaired DNA damage in the 
comet assay by using Ara-C and hydroxyurea in three different cell types. Cell Biol. 
Toxicol. 25, 73-80. 
Hadjeba-Medjdoub, K., Tozlovanu, M., Pfohl-Leszkowicz, A., Frenette, C., Paugh, R.J., 
Manderville, R.A., 2012. Structure-activity relationships imply different mechanisms of 
action for ochratoxin A-mediated cytotoxicity and genotoxicity. Chem. Res. Toxicol. 25, 
181-190. 
Hagelberg, S., Hult, K., Fuchs, R., 1989. Toxicokinetics of ochratoxin A in several species 
and its plasma-binding properties. J. Appl. Toxicol. 9, 91-96. 
Hein, D.W., Doll, M.A., Fretland, A.J., Polymorphisms, A., Leff, M.A., Webb, S.J., Xiao, 
G.H., Devanaboyina, U., Nangju, N.A., 2000. Molecular genetics and epidemiology of the 
NAT1 and NAT2 acetylation polymorphisms molecular genetics and epidemiology of the 
NAT1 and NAT2. Cancer Epidemiol. biomarkers Prev. 9, 29-42. 
Hennig, A., Fink-Gremmels, J., Leistner, L., 1991. Mutagenicity and effects of ochratoxin A 
on the frequency of sister chromatid exchange after metabolic activation. IARC Sci. Publ. 
255-260. 
Honkakoski, P., Negishi, M., 2000. Regulation of cytochrome P450 (CYP) genes by nuclear 
receptors. Biochem. J. 337, 321-337. 
Horvath, A., Upham, B.L., Ganev, V., Trosko, J.E., 2002. Determination of the epigenetic 
effects of ochratoxin in a human kidney and a rat liver epithelial cell line. Toxicon 40, 273-
282. 
Hsuuw, Y.D., Chan, W.H., Yu, J.S., 2013. Ochratoxin a inhibits mouse embryonic 
development by activating a mitochondrion-dependent apoptotic signaling pathway. Int. J. 
Mol. Sci. 14, 935-953. 
Hundhausen, C., Bösch-Saadatmandi, C., Augustin, K., Blank, R., Wolffram, S., Rimbach, 
G., 2005. Effect of vitamin E and polyphenols on ochratoxin A-induced cytotoxicity in liver 
(HepG2) cells. J. Plant Physiol. 162, 818-822. 
162 
Husain, A., Zhang, X., Doll, M.A., States, J.C., Barker, D.F., Hein, D.W., 2007. 
Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of 
NAT2-specific mRNA in human tissues. Drug Metab. Dispos. 35, 721-727. 
IARC (International Agency for Research on Cancer), 1993. Monographs on evaluation of 
carcinogenic risks to humans. Some naturally occurring substances: food items and 
constituents, heterocyclic aromatic amines and mycotoxins.JECFA (Joint FAO/WHO Expert 
Committee on Food Additives), 2007. Evaluation of certain food additives and 
contaminants. Technical report serie 947. 599 pp. 
Jedlitschky, G., Hoffmann, U., Kroemer, H.K., 2006. Structure and function of the MRP2 
(ABCC2) protein and its role in drug disposition. Expert Opin. Drug Metab. Toxicol. 2, 351-
366. 
Jørgensen, K., 2005. Occurrence of ochratoxin A in commodities and processed food - a 
review of EU occurrence data. Food Addit. Contam. 22 Suppl 1, 26-30. 
Jovaní, M., Barberá, R., Farré, R., Martín de Aguilera, E., 2001. Calcium, iron, and zinc 
uptake from digests of infant formulas by Caco-2 cells. J. Agric. Food Chem. 49, 3480-
3485. 
Juan, M.E., Wenzel, U., Daniel, H., Planas, J.M., 2008. Resveratrol induces apoptosis 
through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. 
J. Agric. Food Chem. 56, 4813-4818. 
Kamp, H.G., Eisenbrand, G., Schlatter, J., Würth, K., Janzowski, C., 2005. Ochratoxin A: 
induction of (oxidative) DNA damage, cytotoxicity and apoptosis in mammalian cell lines 
and primary cells. Toxicology 206, 413-425. 
Kensler, T.W., Groopman, J.D., Roebuck, B.D., 1998. Use of aflatoxin adducts as 
intermediate endpoints to assess the efficacy of chemopreventive interventions in animals 
and man. Mutat. Res. Mol. Mech. Mutagen. 402, 165-172.  
Klarić, M.S., Pepeljnjak, S., 2008. Genotoxicity of fumonisin B1, beauvericin and ochratoxin 
A in porcine kidney PK15 Cells: effects of individual and combined treatment 81, 14-17. 
 163 
Knasmüller, S., Cavin, C., Chakraborty, A., Darroudi, F., Majer, B.J., Huber, W.W., Ehrlich, 
V.A, 2004. Structurally related mycotoxins ochratoxin A, ochratoxin B, and citrinin differ in 
their genotoxic activities and in their mode of action in human-derived liver (HepG2) cells: 
implications for risk assessment. Nutr. Cancer 50, 190-197. 
Kuiper-Goodman, T., Hilts, C., Billiard, S.M., Kiparissis, Y., Richard, I.D.K., Hayward, S., 
2010. Health risk assessment of ochratoxin A for all age-sex strata in a market economy. 
Food Addit. Contam. Part A. Chem. Anal. Control. Expo. Risk Assess. 27, 212-240. 
Kumagai, S., Aibara, K., 1982. Intestinal absorption and secretion of ochratoxin A in the 
rat. Toxicol. Appl. Pharmacol. 64, 94-102. 
Kumar, R., Alam, S., Chaudhari, B.P., Dwivedi, P.D., Jain, S.K., Ansari, K.M., Das, M., 
2013. Ochratoxin A-induced cell proliferation and tumor promotion in mouse skin by 
activating the expression of cyclin-D1 and cyclooxygenase-2 through nuclear factor-kappa 
B and activator protein-1. Carcinogenesis 34, 647-657. 
Lebrun, S., Follmann, W., 2002. Detection of ochratoxin A-induced DNA damage in MDCK 
cells by alkaline single cell gel electrophoresis (comet assay). Arch. Toxicol. 75, 734-741. 
Lioi, M., Santoro, A., Barbieri, R., Salzano, S., Ursini, M., 2004. Ochratoxin A and 
zearalenone: a comparative study on genotoxic effects and cell death induced in bovine 
lymphocytes. Mutat. Res. Toxicol. Environ. Mutagen. 557, 19-27. 
MacLaine, N.J., Wood, M.D., Holder, J.C., Rees, R.W., Southgate, J., 2008. Sensitivity of 
normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal 
growth factor receptor signaling pathway. Mol. Cancer Res. 6, 53-63. 
Madhyastha, M.S., Marquardt, R.R., Frohlich, A.A., 1992. Hydrolysis of ochratoxin A by the 
microbial activity of digesta in the gastrointestinal tract of rats. Arch. Environ. Contam. 
Toxicol. 23, 468-472. 
Mally, A., Pepe, G., Ravoori, S., Fiore, M., Gupta, R.C., Dekant, W., Mosesso, P., 2005. 
Ochratoxin a causes DNA damage and cytogenetic effects but no DNA adducts in rats. 
Chem. Res. Toxicol. 18, 1253-1261. 
164 
Mantle, P.G., Faucet-Marquis, V., Manderville, R.A., Squillaci, B., Pfohl-Leszkowicz, A., 
2010. Structures of covalent adducts between DNA and ochratoxin a: a new factor in 
debate about genotoxicity and human risk assessment. Chem. Res. Toxicol. 23, 89-98. 
Maresca, M., Mahfoud, R., Pfohl-Leszkowicz, A., Fantini, J., 2001. The mycotoxin 
ochratoxin A alters intestinal barrier and absorption functions but has no effect on chloride 
secretion. Toxicol. Appl. Pharmacol. 176, 54-63. 
Marin-Kuan, M., Nestler, S., Verguet, C., Bezençon, C., Piguet, D., Mansourian, R., 
Holzwarth, J., Grigorov, M., Delatour, T., Mantle, P., Cavin, C., Schilter, B., 2006. A 
toxicogenomics approach to identify new plausible epigenetic mechanisms of ochratoxin a 
carcinogenicity in rat. Toxicol. Sci. 89, 120-134. 
NIH (National Toxicology Program), 1989. Toxicology and carcinogenesis studies of 
ochratoxin A. Technical report series 358. Available at: 
http://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr358.pdf [Consulted: 31 march 2014]. 
Morgan, E.T., 2001. Regulation of cytochrome p450 by inflammatory mediators: why and 
how?. Drug Metab. Dispos. 29, 207-212. 
Mosesso, P., Cinelli, S., Piñero, J., Bellacima, R., Pepe, G., 2008. In vitro cytogenetic 
results supporting a DNA nonreactive mechanism for ochratoxin A, potentially relevant for 
its carcinogenicity. Chem. Res. Toxicol. 21, 1235-1243. 
Muñoz, K., Blaszkewicz, M., Degen, G.H., 2010. Simultaneous analysis of ochratoxin A and 
its major metabolite ochratoxin alpha in plasma and urine for an advanced biomonitoring 
of the mycotoxin. J. Chromatogr. B-Analytical Technol. Biomed. Life Sci. 878, 2623-2629. 
Obrecht-Pflumio, S., Chassat, T., Dirheimer, G., Marzin, D., 1999. Genotoxicity of 
ochratoxin A by Salmonella mutagenicity test after bioactivation by mouse kidney 
microsomes. Mutat. Res. Toxicol. Environ. Mutagen. 446, 95-102. 
OECD (Organisation for Economic Co-operation and Development), 2010. OECD guideline 
for the testing of chemicals. In vitro mammalian cell micronucleus Test. No. 487. Available 
at: http://www.oecd-ilibrary.org/environment/test-no-487-in-vitro-mammalian-cell-
 165 
micronucleus-test_9789264224438-en;jsessionid=36rrsflwl1ug6.x-oecd-live-03 [Consulted: 
31 march 2014]. 
Petrik, J., Žanić-Grubišić, T., Barišić, K., Pepeljnjak, S., Radić, B., Ferenčić, Ž., Čepelak, I., 
2003. Apoptosis and oxidative stress induced by ochratoxin A in rat kidney. Arch. Toxicol. 
77, 685-693. 
Pfohl-Leszkowicz, A., Castegnaro, M., 2005. Further arguments in favour of direct covalent 
binding of ochratoxin A (OTA) after metabolic biotransformation. Food Addit. Contam. 22 
Suppl. 1, 75-87. 
Perron, N.R., Brumaghim, J.L., 2009. A review of the antioxidant mechanisms of 
polyphenol compounds related to iron binding. Cell Biochem. Biophys. 53, 75-100.  
Qi, X., Yang, X., Chen, S., He, X., Dweep, H., Guo, M., Cheng, W.-H., Xu, W., Luo, Y., 
Gretz, N., Dai, Q., Huang, K., 2014. Ochratoxin A induced early hepatotoxicity: new 
mechanistic insights from microRNA, mRNA and proteomic profiling studies. Sci. Rep. 4, 
5163. 
Ramyaa, P., Krishnaswamy, R., Padma, V.V., 2014. Quercetin modulates OTA-induced 
oxidative stress and redox signalling in HepG2 cells - up regulation of Nrf2 expression and 
down regulation of NF-κB and COX-2. Biochim. Biophys. Acta 1840, 681-692. 
Ramyaa, P., Padma, V.V., 2013. Ochratoxin-induced toxicity, oxidative stress and 
apoptosis ameliorated by quercetin - modulation by Nrf2. Food Chem. Toxicol. 62, 205-
216. 
Ribonnet, L., van der Heiden, E., Nobels, I., Chaumont, A., Remacle, A-S., De Saeger, S., 
Schneider, Y.-J., Scippo, M.-L., Blust, R., Pussemier, L., Larondelle, Y., 2011. Potential of 
an in vitro toolbox combined with exposure data as a first step for the risk assessment of 
dietary chemical contaminants. Food Addit. Contam. Part A. Chem. Anal. Control. Expo. 
Risk Assess. 28, 1136-1158. 
Schaaf, G., Nijmeijer, S., Maas, R.F., Roestenberg, P., de Groene, E., Fink-Gremmels, J., 
2002. The role of oxidative stress in the ochratoxin A-mediated toxicity in proximal tubular 
cells. Biochim. Biophys. Acta - Mol. Basis Dis. 1588, 149-158. 
166 
Schrickx, J., Lektarau, Y., Fink-Gremmels, J., 2006. Ochratoxin A secretion by ATP-
dependent membrane transporters in Caco-2 cells. Arch. Toxicol. 80, 243-249. 
Simarro Doorten, Y., Nijmeijer, S., de Nijs-Tjon, L., Fink-Gremmels, J., 2006. Metabolism-
mediated ochratoxin A genotoxicity in the single-cell gel electrophoresis (Comet) assay. 
Food Chem. Toxicol. 44, 261-270. 
Smith, J.E., Solomons, G., Lewis, C., Anderson, J.G., 1995. Role of mycotoxins in human 
and animal nutrition and health. Nat. Toxins 3, 187-192. 
Stoddart, M.J., 2011. Mammalian cell viability. methods and protocols. Methods in 
Molecular Biology, Humana Press. Springer Science. 240 pp. 
Studer-Rohr, I., Dietrich, D.R., Schlatter, J., Schlatter, C., 1995. The occurrence of 
ochratoxin A in coffee. Food Chem. Toxicol. 33, 341-355. 
Tice, R.R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., Miyamae, 
Y., Rojas, E., Ryu, J.C., Sasaki, Y.F., 2000. Single cell gel/comet assay: guidelines for in 
vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35, 206-221. 
Turesky, R.J., 2005. Perspective: ochratoxin A is not a genotoxic carcinogen. Chem. Res. 
Toxicol. 18, 1082-1090. 
Valero, A., Marin, S., Ramos, A.J., Sanchis, V., 2008. Survey: Ochratoxin A in European 
special wines. Food Chem. 108, 593-599. 
Versantvoort, C.H.M., Oomen, A.G., Van de Kamp, E., 2005. Applicability of an in vitro 
digestion model in assessing the bioaccessibility of mycotoxins from food. Food Chem. 
Toxicol. 43, 31-40. 
Wiklund, S.J., Agurell, E., 2003. Aspects of design and statistical analysis in the Comet 
assay. Mutagenesis 18, 167-175. 
Willcox, B.J., Curb, J.D., Rodriguez, B.L., 2008. Antioxidants in cardiovascular health and 
disease: key lessons from epidemiologic studies. Am. J. Cardiol. 101, 75-86.  
 167 
Yang, Q., Shi, L., Huang, K., Xu, W., 2014. Protective effect of N-acetylcysteine against 
DNA damage and S-phase arrest induced by ochratoxin A in human embryonic kidney cells 
(HEK-293). Food Chem. Toxicol. 70, 40-47. 
Zepnik, H., Pähler, a, Schauer, U., Dekant, W., 2001. Ochratoxin A-induced tumor 
formation: is there a role of reactive ochratoxin A metabolites? Toxicol. Sci. 59, 59-67. 
Zheng, J., Zhang, Y., Xu, W., Luo, Y., Hao, J., Shen, X.L., Yang, X., Li, X., Huang, K., 
2013. Zinc protects HepG2 cells against the oxidative damage and DNA damage induced 
by ochratoxin A. Toxicol. Appl. Pharmacol. 268, 123-131. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
168 
 
 
169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Conclusions 
 
 
 
 
 
 
170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 171 
• The in vitro dynamic digestion system used is a good tool to assess the bioaccessibility 
of OTA and may help researchers understand and monitor the complex processes of 
transformation that take place in in vivo gastrointestinal digestion. In red wine, and at 
the assayed concentrations (1.0-4.0 µg/L), ochratoxin A (OTA) bioaccessibility was not 
affected by the initial contamination level in an in vitro simulated gastrointestinal 
system. OTA showed a high bioaccessibility after gastric digestion (103-128%) at pH 2-
3, whereas at the intestinal level, at pH 7.2-8.0 and in the presence of bile salts, OTA 
bioaccessibility decreased to levels below 26%. This fact suggests that in vivo 
absorption of OTA could depend on pH and other environmental conditions. 
  
• Low doses of OTA did not cause less than 65% cell viability in the three human cell 
types assayed; however, they did cause cytostaticity by inhibiting cell proliferation in 
human lymphocyte cells and decreasing transepithelial electrical resistance in polarised 
monolayers of Caco-2 cells. 
 
• ROS production occurred in parallel to a significant decrease in the viability of cells 
treated with the highest OTA concentrations. A joint treatment with OTA and DON 
increased cytotoxicity in Caco-2 cells, whereas the antioxidant resveratrol did not 
protect against the deleterious effect of these mycotoxins. 
 
• In an in vitro co-culture system with Caco-2 and HepG2 cells, OTA caused a down-
regulation in the gene expression of most of the CYP450 genes in differentiated Caco-2 
cells; in contrast, both up- and down-regulation were detected at different exposure 
times in gene expression in HepG2 cells. The CYP1A1 gene was highly modulated by 
OTA in all treatments in both Caco-2 and HepG2 cells, while the CYP3A5 gene was the 
second most OTA-modulated gene in Caco-2 cells. The CYP2B6 and CYP3A4 genes 
were moderately modulated in HepG2 cells, while the CYP1A1 gene was weakly 
modulated by OTA in HepG2 cells. 
 
• NAT2 gene expression was strongly down-regulated by OTA in Caco-2 cells, but was 
usually moderately down-regulated in HepG2 cells, except when exposed to OTA for 24 
h. 
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• The expression of the MRP2 transporter gene decreased in the presence of OTA, 
suggesting an increase in in vivo bioavailability through a lowering of the first-pass 
effect in the small intestine and poor excretion of OTA in the bile. 
 
• In general, longer exposure times to OTA had stronger effects on gene expression 
modulation and membrane integrity than increasing the OTA dose used in the 
treatments. 
 
• OTA proved to be a genotoxic mycotoxin at low doses (0.075-5 µM) in human cell 
cultures. OTA induced micronuclei, and, in the comet assay, led to an increase in the 
DNA percentage and DNA accumulation in the comet tails, indicating DNA damage and 
a delay in the DNA repair system, respectively. 
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Since both the BARGE and the EPA recommend the validation of methods to assess the 
bioaccessibility of compounds, complementary in vivo assays should be conducted to 
validate the bioaccessibility data for OTA obtained using the in vitro digestion model 
described in this research. 
 
OTA bioaccessibility should be studied in other liquid or solid food matrices, as well as in 
the presence of other mycotoxins. In this regard, the efficacy of the in vitro system 
employed could be compromised, as the recoveries and chromatographic determination of 
toxins could be profoundly affected due to the matrix effect. Thus, validation of the 
system for more complex foods will be necessary in future. 
 
The expression levels of the CYP1A1, CYP2B6, CYP3A4 and CYP3A5 genes should also be 
investigated at the protein level in the presence of OTA, in order to understand the real 
OTA effect on gene expression modulation and to establish a positive/negative correlation. 
In addition, there is a need to investigate the involvement of the NAT2 gene during OTA 
metabolism more deeply. 
 
This research found that OTA is able to modulate the expression of the COX-2 and 5-LOX 
genes. Nevertheless, more studies are needed before these genes can be proposed as 
early inflammatory markers of OTA exposure. 
 
Particular attention should be given to the OTA doses that cause cytostaticity and DNA 
damage, which have not been related to the production of ROS at detectable levels in the 
cells, in order to determine an alternative mechanism of action linked to the doses 
assayed in the treatments. 
 
Using the transwell system employed in this thesis, an in vitro study of the 
biotransformation of OTA into other metabolites should be carried out to complete the 
toxicity studies conducted in this research. To this end, it should be noted that such a 
study is currently being conducted. 
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Abstract 
In the evaluation of the oral bioavailability of a mycotoxin, the first step is the 
determination of its bioaccessibility, i.e., the percentage of mycotoxin released from the 
food matrix during digestion in the gastrointestinal (GI) tract that could be absorbed 
through the intestinal epithelium. As a first approximation to the problem, different in vitro 
digestion models have been recently used for bioaccessibility calculation, thereby avoiding 
the use of more complex cell culture techniques or the use of animals in expensive in vivo 
experiments. 
In vitro methods offer an appealing alternative to human and animal studies. They usually 
are rapid, simple and reasonably low in cost, and can be used to perform simplified 
experiments under uniform and well-controlled conditions, providing insights not 
achievable in whole animal studies. The available in vitro methods for GI simulation differ 
in the design of the system, the composition of the physiological juices assayed, as well as 
in the use or not of intestinal microbiota. There are models that only simulate the upper 
part of the GI tract (mouth-stomach-small intestine), whereas other methods include the 
large intestine, so that the model chosen could have some influence on the bioaccessibility 
data obtained. 
Bioaccessibility depends on the food matrix, as well as on the contamination level and the 
way the food/feed is contaminated (spiked or naturally). 
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This review focuses on the currently available data regarding the in vitro digestion models 
for the study of the bioaccessibility or absorption of mycotoxins, detailing the 
characteristics of each digestion step and the importance of the physiological juices 
employed during digestion. The effect that different factors play on the mycotoxin release 
from food matrix in the GI tract is also considered, and existing data on bioaccessibility of 
the main mycotoxins are given. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publication: World Mycotoxin Journal (2013), 6: 167-184. 
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1. Introduction 
Mycotoxins are a wide group of fungal secondary metabolites that exert multiple toxic 
effects on humans and animals. Some mycotoxins can cause autoimmune illnesses, have 
allergenic properties, and some of them are teratogenic, carcinogenic, mutagenic, 
nephrotoxic or estrogenic (CAST, 2003). Although hundreds of mycotoxins exist, the most 
important for public health are aflatoxins (AFs, aflatoxins AFB1, AFB2, AFG1 and AFG2 being 
the main ones), ochratoxin A (OTA), patulin (PAT), fumonisins (FBs) zearalenone (ZEA), 
and the trichothecene group, among them deoxynivalenol (DON), nivalenol (NIV), T-2 and 
HT-2 toxins being the most important. Recently, other mycotoxins - the so-called 
emerging mycotoxins, such as fusaproliferin, beauvericin (BEA), enniatins (ENs), 
moniliformin and the Alternaria toxins - are attracting the attention of researchers. 
 
The major mycotoxin-producing fungal genera are Aspergillus, Penicillium, Fusarium and 
Alternaria (Moss, 1992; Sweeney and Dobson, 1998). The growth of mycotoxigenic strains 
of these fungi on crops, either in the field or during storage, could lead to the 
accumulation of mycotoxins in a great variety of foods. Besides, the metabolism of 
ingested mycotoxins could result in modified mycotoxins, as happens when aflatoxin B1 
(AFB1) is converted by hydroxylation to aflatoxin M1 (AFM1), mycotoxin mainly present in 
milk as a result of AFB1 metabolism in cow and other mammals (Prandini et al., 2009). 
Natural occurrence of mycotoxins in food has been broadly documented. Thus, mycotoxins 
have been widely detected in food of vegetal origin, mainly in cereals (barley, wheat, corn, 
oat, etc.) and their by-products (Marín et al., 2012; Rodrigues and Naehrer, 2012), as well 
as in nuts, dried fruits, spices, cocoa, coffee, beer, wine, and fruits, particularly apples 
(Bellí et al., 2002; Fernández-Cruz et al., 2010; Molyneux et al., 2007; Placinta et al., 
1999; Santos et al., 2010; Turcotte et al., 2011). Mycotoxins also enter the human food 
chain via meat or other animal products such as eggs, milk and cheese as a result of 
contaminated livestock feed (Chen et al., 2012; Meyer et al., 2003). 
This huge variety of food matrices in which mycotoxins occur can have a very significant 
effect on the bioavailability of mycotoxins, as complex and diverse reactions can occur 
between mycotoxin and the food matrix, which could interfere in the way these toxins are 
absorbed through the intestinal tract. 
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On the other hand, in the last years many structurally related compounds generated by 
plant metabolism or by food processing have been described in mycotoxin-contaminated 
commodities, which can co-exist together with the native toxins. These mycotoxin 
derivatives (named conjugated or “masked” mycotoxins) may have a very different 
chemical behaviour, thus they can easily escape routine analyses. Nevertheless, these 
forms could be hydrolysed to their precursors in the digestive tracts of animals or could 
exert toxic effects comparable to those imputable to free mycotoxins (De Saeger and van 
Egmond, 2012; Galaverna et al., 2009). This can make in some occasions very difficult to 
establish a clear relationship between the amount of ingested toxin and the toxic effects 
observed, and expected, for a given amount of mycotoxin. All these facts could help to 
explain the so-called “fumonisin paradox” (i.e. the fact that apparently low contaminated 
commodities induce severe toxic effects in animals), whereby the oral bioaccessibility of 
this mycotoxin could be affected by different factors, one of them the uptake of fumonisin 
B1 (FB1) strongly conjugated to the food matrix or FB1 derivatives with higher 
bioavailabilities (Shier, 2000). This could also happen with other mycotoxins. 
 
So, knowing the amount of mycotoxin ingested may not be enough for exposure 
assessment. Knowing the amount of toxin that becomes available for absorption through 
the intestinal epithelium (which will be the measure of its bioaccessibility) is also required. 
Different factors, as pH changes, enzymatic activities, etc., play an important role during 
the gastrointestinal transit of mycotoxins and thus affect bioaccessibility. 
To determine the bioaccessibility of mycotoxins (or in same cases, the absorption), and as 
a first approximation to the problem, different in vitro digestion models have been used, 
avoiding the use of more complex cell cultures or the ethically questionable use of animals 
in in vivo experiments. 
 
This review focuses on the currently available data regarding the in vitro digestion models 
for the study of the bioaccessibility of mycotoxins, detailing the characteristics of each 
digestion step and the importance of the physiological juices employed during digestion. 
The effect that different factors play on the mycotoxin release from food matrix in the GI 
tract is also considered, and existing data on bioaccessibility of the main mycotoxins are 
given.  
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2. Bioaccessibility and bioavailability 
The amount of mycotoxin consumed via food does not always reflect the amount of this 
compound that is available to exert its toxic action in a target organ of the body, as only a 
part of the ingested compound will be bioavailable. Thus the oral bioavailability (F) of a 
mycotoxin has been defined as the fraction of an orally ingested mycotoxin, in a certain 
food matrix, that finally reaches the systemic circulation and is distributed throughout the 
entire body to exert its toxic effect (Versantvoort, 2004). This definition assumes that 
toxicity is exerted by the parent compound and not by formed metabolites. 
 
In fact, the oral bioavailability comprises three different and sequential processes 
(Brandon et al., 2006): 
 
a) the release of the mycotoxin from the food matrix during digestion in the GI tract. In 
this step we are measuring the bioaccessible mycotoxin (FB). 
b) the absorption of the bioaccessible mycotoxin through the intestinal epithelial cells of 
the GI tract (FA), being transported to the blood (or lymph) stream. 
c) the metabolism of the mycotoxin previous to systemic circulation (i.e., the 
biotransformation and excretion by the intestinal epithelium or the liver), the so-called first 
pass effect (FM). 
So, the equation that defines the bioavailable fraction of an ingested mycotoxin, that is, 
the fraction that reaches the systemic circulation, is defined by: 
 
F = FB x FA x FM   (1) 
 
Bioaccessibility (B) has become important because it represents the amount of the 
mycotoxin that can reach the blood after intestinal absorption. It is worth to mention that 
bioaccessibility has been calculated only in in vitro systems. This concept is only applicable 
to oral exposure. Other routes of exposure do not depend on the process described above. 
Bioaccessibility is given in percentages and calculated with the following formula: 
 
B (%) = [mycotoxinchyme] after GI digestion / [mycotoxinfood matrix] before GI digestion   (2) 
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Physiologically speaking, bioaccessibility refers to the amount of toxin that is liberated 
from the food matrix in the stomach and is available for absorption in the small intestine 
(Peijnenburg and Jager, 2003; Ruby et al., 1996). Bioaccessibility (some times called 
digestibility) involves all the events that occur before intestinal and hepatic presystemic 
metabolism, and that take place during the digestion of food until the macronutrients and 
micronutrients can be assimilated into the cells of the intestinal epithelium (Fernandez-
García et al., 2009), and can be considered as an indicator for the maximal oral 
bioavailability of the toxin, which can be used for realistic worst case risk assessment of 
the toxin in a consumer product (Brandon et al., 2006). 
 
For a mycotoxin administered in solution, as it is with drinking water, the bioaccessibility 
of the toxin is assumed to be 100%. The toxin does not need to be mobilized from the 
matrix as it is already in solution and, thereby, available for absorption in the intestine. 
After ingestion of other matrices such as feed or food, the toxin may be partially or totally 
released from their matrix during digestion in the GI tract. Only the bioaccessible fraction 
is available for transport across the intestinal epithelium and can contribute to the internal 
exposure (Versantvoort et al., 2004). 
 
The food matrix mainly affects the bioaccessibility, whereas absorption and metabolism 
depend more on the toxin specific properties and on the animal physiology and, therefore, 
the food matrix is expected to have less influence on theses processes (Brandon et al., 
2006). Thus the bioaccessibility of a given mycotoxin can differ according to the 
considered food, as has recently been demonstrated in the case of the bioaccessibilities of 
DON in different types of Italian pasta (Raiola et al., 2012b), of BEA in wheat crispy 
breads with different fiber concentrations (Meca et al., 2012b) and of PAT in different 
apple products (Raiola et al., 2012a). 
 
3. In vitro digestion models 
As described before, the bioaccessibility depends on the mycotoxin and the food matrix 
considered. This implies that for health risk assessment of the more important mycotoxin-
contaminated foods, it would be convenient to obtain food-specific results of oral 
bioavailability in order to better adjust the legal limits of different food groups. Thus, in 
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vitro digestion models based on human or animal physiology have been developed, not 
only for mycotoxins, but also for other areas of application. Most researches have been 
devoted to investigation of bioaccessibility of food components and contaminants, but also 
of  toxics on soils (Avantaggiato et al., 2003; Boisen and Eggum, 1991; Brandon et al., 
2006; Döll et al., 2004; Dominy et al., 2004; Garret et al., 1999; Gil-Izquierdo et al., 2002; 
Larson et al., 1997; Miller et al., 1981; Minekus, 2005; Minekus et al., 1999, Oomen et al., 
2003; Ortega et al., 2009; Ruby et al., 1999; Savoie, 1994; Versantvoort et al., 2004, 
2005). Most of the in vitro digestion models simulate, in a simplified manner, the digestion 
processes in mouth, stomach, and small intestine, often obviating some physiological 
processes that occur during digestion, such as peristalsis or the existence of intestinal 
microbiota. 
 
Digestion is a well known process in which the breaking down of food into smaller 
components that can be absorbed by the bloodstream and distributed throughout the 
body takes place. Briefly, in humans, and in general in the monogastric animals, digestion 
is a sequential process that begins with a mechanical and chemical digestion in the mouth, 
where food is chewed and mixed with saliva (rich in amylases) and where many 
polysaccharides are breaking down. Then, the stomach continues smashing the food and 
breaking food constituents mechanically and chemically with the aid of pepsine and some 
gastric lipases; mainly protein and peptide degradation takes place, although some 
lipolysis also occurs (Forte, 1996). In the small intestine, where absorption of nutrients is 
mainly conducted, the presence of lipids in the duodenum stimulates the secretion of bile 
salts, phosphatidylcholine, and cholesterol from the gall bladder and pancreatic fluids 
(containing pancreatic lipase/colipase, etc.) from the pancreas. Water and minerals are 
reabsorbed back into the blood in the colon (large intestine), together with some vitamins, 
such as biotin and vitamin K produced by bacteria (Conigrave and Young, 1996). 
 
The in vitro digestion models try to mimic this layout, especially in the first three 
compartments of the GI tract (because mycotoxin absorption takes place mainly in the 
small intestine). Main parameters to control are temperature (although if simulates human 
GI tract all reactions are carried out at 37 ºC), time in each compartment, pH changes, 
ionic strength, gastric/intestinal juice composition and enzymatic activities.  
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The main features that are requested to an optimum in vitro dynamic digestion model are 
(Minekus, 2005; Versantvoort et al., 2004;):  
 
1) The model must be similar and representative of the physiological processes in the 
human body (or in the considered animal).  
2) Digestion must be a dynamic process which helps to food disintegration and absorption. 
Biochemical reactions, flow (hydrodynamics) and mechanical forces must be in 
accordance with the kinetics of digestion. The rate of release (emptying) should be 
controlled for a quick or prolonged release. 
3) The system should allow simulating fasted or fed conditions. 
4) The model should include anaerobic conditions and presence of typical GI microbiota. 
5) The methodology should be easy and applicable, robust and reproducible.  
 
Most of the designed models attempt to fulfill with the first four requirements, the latter 
being the more difficult to achieve due to methodological complications related to the 
anaerobic assay conditions. 
With regard to the type of models used, most models are static GI models which simulate 
the transit through the digestive tract by sequential (compartmentalized) exposure of the 
food to simulated mouth, gastric and small intestinal conditions. These models are a good 
first approximation to the problem, as they are of easy performance, and generally allow 
rapid processing of a large number of samples, but represent in a lesser extent the GI 
physiological reality. 
 
On the other hand, dynamic GI models mimic the gradual transit of ingested compounds 
through the simulated compartments of the GI tract, giving a more realistic simulation. In 
these models, successive physiological conditions in the stomach and segments of the 
intestines of humans and animals are closely simulated. Digestion products and other 
small molecules are absorbed from the different intestinal compartments by dialysis. 
These models usually take into account factors as gastric emptying patterns, GI transit 
times in combination with changing pH values, variable concentration of electrolytes, 
enzymes and bile salts, absorption of water and, in some cases, microbial activity during 
passage of the food through the entire GI tract (Zeijdner et al., 2004). 
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There are many biological conditions which differ from in vitro and in vivo systems. The 
best approximation to the composition of digestive juices ensures better mimicked 
digestion in the GI tract and the results may be approximate to those observed in vivo. 
However, in some cases the results do not agree with those observed in in vivo, as will be 
seen below for FB1 in vitro simulation. 
 
3.1 Main physiological components of the in vitro models 
3.1.1 Saliva 
Digestion is a physiological process that starts in the mouth with a mechanic action during 
which salivary fluids initiate the hydrolytic processes, the central nervous system is 
stimulated and the cephalic phase of digestion is initiated. Salivary fluid is an exocrine 
secretion consisting of approximately 99% water, containing a variety of electrolytes 
(sodium, potassium, calcium, chloride, magnesium, bicarbonate, phosphate) and proteins, 
including enzymes (mainly amylases and, in a minor extent, lipases), immunoglobulins and 
other antimicrobial factors (lysozyme, peroxidase systems, lactoferrin, histatins and 
agglutinins), hormones, mucosal glycoproteins, traces of albumin and some polypeptides 
and oligopeptides of importance to oral health. There are also glucose and nitrogenous 
products, such as urea and ammonia (Rantonen, 2003). 
Saliva production is stimulated by visual and olfactory stimuli, sour taste, chewing and the 
presence of food particles in the mouth. Composition of saliva depends on the flow rate: 
at higher flow rates, sodium, calcium, chloride, bicarbonate and amylases increase, whilst 
phosphate concentrations and mucin decrease, and the potassium concentration show 
little change (Versantvoort et al., 2004).  
 
The salivary α-amylase, which acts as an endoglycosidase, hydrolyzes starch and related 
R-1,4-linked polysaccharides starting the starch digestion and its transformation to 
oligosaccharides and monosaccharides. The lingual lipase is a triacylglycerol lipase that 
hydrolyzes dietary lipids on the carboxylic ester to produce diglycerols. This hydrolysis 
continues in the stomach by the gastric lipase, but the activity of lingual lipase has been 
described between pH 2 and 6.4, indicating that the lingual lipase is active from the mouth 
to the small intestine where the activity decreases at pH 6.9, while gastric lipase is still 
active in the intestine (Liao et al., 1984). 
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Mucin lubricates oral surfaces, provides a protective barrier between underlying hard and 
soft tissues and the external environment, and aid in mastication, speech and swallowing. 
Saliva behaves as a buffer system to protect the mouth. Urea acts as a buffer present in 
total salivary fluid; it is a product of aminoacid and protein catabolism that causes a rapid 
increase in biofilm pH by releasing ammonia and carbon dioxide when hydrolyzed by 
bacterial ureases. 
 
In the main in vitro models, simulated saliva consists of a simplified version of this 
complex biological fluid, containing electrolytes (KCl, KSCN, NaH2PO4, NaSO4, NaCl and 
NaHCO3), urea and α-amylase (Gil-Izquierdo et al., 2002), whereas other models also uses 
uric acid and mucin (Versantvoort et al., 2005). Generally, the pH value used in this fluid is 
around 6.8. However, salivary digestion is omitted in some in vitro models, as the TIM-1 
dynamic gastrointestinal model (Minekus et al., 1995), because it is considered that it 
does not represent great changes in matrices or components of interest. 
 
3.1.2 Gastric juices 
The gastric phase is activated when the acid secretion begins and finishes when the 
stomach contents reach the duodenum to start the intestinal phase. Gastric juice is 
secreted by the gastric glands of the stomach, and its production is regulated through 
specific neural and hormonal pathways, by the eating act and by the presence of food in 
the stomach. In the adult human, the stomach typically secretes about 2-3 liters of gastric 
juice per day. The three major constituents of gastric juice are the mucus, the enzymes 
and the aqueous component, the production of hydrochloric acid being a key factor as 
produces a significant drop in pH values (Forte, 1996). 
Gastric mucin is a large glycoprotein which is thought to play, together with NaHCO3 
secretion, a major role in the protection of the gastrointestinal tract from acid, proteases, 
pathogenic microorganisms, and mechanical trauma. 
 
The main enzyme in gastric juice is pepsin, although other enzymes like the gastric lipase 
are also present. Pepsin is actually a heterogeneous group of endoproteases responsible 
for the proteolytic activity of gastric juice (Forte, 1996). Gastric juice lowers the pH of the 
gastric content, due to secretion of hydrochloric acid. Gastric pH values have been 
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reported between 1 and 3 (Allen and Flemström, 2005; Jolliffe et al., 2009; Kong and 
Singh, 2009), while during digestion the pH can increase up to 7.5 (Kong and Singh, 
2009). This pH change is important for the activation of pepsinogens precursors (Vertzoni 
et al., 2005) and to stabilize pepsin that has optimal proteolytic activity in the same pH 
range (i.e., pH 1-3). 
 
When gastric juice is neutralized as it passes into the duodenum, pepsin is denatured and 
thus eliminated from further digestive function. The lipids are emulsified and micellizated 
in the stomach and the small intestine, respectively (Carey et al., 1983). The acidic pH 
optimum for lipolysis is from 3.5 to 6.0 and lipase activity achieves a wide range of pH 
which allows the enzyme to act in the stomach where the postprandial pH is from 4.5 to 
5.5. In the small intestine the pH range is between 5.0 and 6.5 and lipase activity is 
proportional to the bile concentration after ingestion (Liao et al., 1984).  
 
In the in vitro models, gastric juice is often simulated only with a strong decrease of the 
pH, but more complete systems include gastric juices containing pepsin (Gil-Izquierdo et 
al., 2002), and also several electrolytes (NaCl, KCl, CaCl2, NaHCO3), a lipase and bovine 
trypsin (Versantvoort et al., 2005). The gastric juice used in the TIM-1 dynamic 
gastrointestinal model (Minekus et al., 1995), one of the more complete, includes pepsin, 
mucin, glucose, glucuronic acid, urea, glucoseamine hydrochloride, BSA and several salts 
(NaCl, NaH2PO4, KCl, CaCl2·2H2O, NH4Cl and HCl).  
 
The pH value of the gastric juice during the in vitro GI simulation varies between models. 
In some cases the pH is a constant value, usually low (1.3-2) (Gil-Izquierdo et al., 2002; 
Versantvoort et al., 2004), but in other models pH values decrease during simulation from 
higher values (7-5) to lower values at the end (3-2), in a gradual or discontinuous way 
(Döll et al., 2004; Minekus et al., 1995). The gastric pH value is a crucial factor in the 
bioaccessibility determination as it is essential for the activity of pepsin, enzyme that can 
contribute to the release of hidden mycotoxins from proteins of the food matrix (Dall’Asta 
et al., 2009). However, some conjugated mycotoxins, as the DON-3-glucoside are 
resistant to acidic conditions, thus it is extremely unlikely that this compound can be 
hydrolyzed into DON in the stomach (Berthiller et al., 2011). 
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3.1.3 Intestinal juices 
Following gastric digestion, the stomach releases food into the duodenum through the 
pyloric sphincter. Duodenum receives pancreatic enzymes from the pancreas and bile from 
the liver and gallbladder. These fluids are important in aiding digestion and absorption. 
Peristalsis also aids digestion and absorption by churning up food and mixing it with 
intestinal secretions. The rest of the small intestine, located below the duodenum, consists 
of the jejunum and the ileum. These parts of the small intestine are largely responsible for 
the absorption of fats and other nutrients. The intestinal wall releases mucus, which 
lubricates the intestinal contents, and water, which helps dissolve the digested fragments. 
The main components of all the biological fluids implied in the intestinal digestion of food 
are: 
 
- The exocrine pancreatic secretions, which mainly contain pancreatic enzymes as 
proteases (in zymogenic form, including trypsinogen, chymotrypsinogen, 
procarboxypeptidase), lipases (that degrade triglycerides into fatty acids and glycerol), 
cholesterol esterase, phospholipase, nucleases and amylase. 
- The liver secretes bile and bicarbonate into the small intestine. The bile secretion 
contains bile salts, lecithin, cholesterol and bilirubin. 
- The small intestine secretes watery mucus (that protects the intestinal mucosa from 
auto-digestion by proteases and acid) and hormones (like secretin, somastotin, motilin, 
cholecystokinin and the gastric inhibitory peptide). In the small intestine there are 
numerous "brush border" enzymes whose function is to further cleave the already-broken-
down products of digestion into absorbable particles. Some of these enzymes include: 
sucrose, lactase, maltase and other disaccharides. 
- The large intestine secretes mucus (for lubrication and mechanical protection), and 
bicarbonate and potassium ions (for protection from bacterial acid). 
 
Given this high number of chemical compounds forming part of the intestinal secretions, it 
is understandable that in vitro models must simplify the components of the intestinal tract 
to the main components, especially those related with enzymatic properties. Thus in vitro 
small intestine simulation basically includes the main duodenal electrolytes (among which 
the calcium salts are very important), pancreatin (a mixture of several digestive enzymes 
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produced by the exocrine cells of the pancreas: amylase, lipase and protease) and bile 
salts (Gil-Izquierdo et al., 2002; Minekus et al., 1995). Complementarily, some models add 
other components as mucin, lipases, BSA and urea (Versantvoort et al., 2005). 
 
Calcium ion (Ca2+) acts as a co-factor required for enzymatic activity at a low 
concentration, as 40 mM is enough to make, for example, lipolysis to increase (Brownlee 
et al., 2010; Kimura et al., 1982). This ion is usually added in simulated intestine digestion 
systems as CaCl2, at concentrations ranging from 0.3 to 22.2 g/L (see Table 1). 
 
Gastrointestinal enzymes generally have a greater resistance to irreversible denaturation, 
but in the different parts of the intestine of healthy subjects there can be a broad pH 
range, which can vary from pH 5.9 to pH 9 (Brownlee et al., 2010). pH values employed 
for the in vitro intestinal fluids used with mycotoxins have ranged from 6 to 8.2. 
 
Bile salts have a severe impact on bioaccessibility, as they have the capacity of surfacting 
and decreasing the surface tension, consequently, creating an apolar environment in the 
interior of bile salt micelles for hydrophobic contaminants and thereby increase their 
solubility (Oomen et al., 2004). 
 
3.1.4 M icrobial interactions 
The interaction of digestive microbiota with mycotoxins has been predominantly studied in 
models simulating the rumen of ruminants. Thus, in vitro metabolism of different 
mycotoxins (AFB1, AFG2, DON, diacetoxyscirpenol and T-2 toxin) by bacterial, protozoal 
and ovine ruminal fluid preparations has been determined by Westlake et al. (1989). 
Mobashar et al. (2012) have recently studied the contribution of the different microbial 
populations of rumen on OTA degradation using the in vitro Hohenheim gas incubator 
system. Authors have found that in contrast to the opinions in many publications, the 
bacterial (and not the protozoal) community played the dominant role in ruminal OTA 
degradation. Similarly, in vitro ruminal degradation of AFB1 has been described (Jiang et 
al., 2012). However, the most commonly in vitro models used for determination of 
bioaccessibility of mycotoxins in human or monogastric systems ignore what happen in the 
large intestine, as it is in the small intestine where absorption of mycotoxins occurs. 
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Besides, simulation of the large intestine, for its implications in fermentation processes 
that take place on this location, necessarily involves the use of microbiota of human or 
animal origin, under anaerobic conditions, making more difficult the operating procedure. 
 
Laboratory systems to simulate the large intestine have been used successfully (Minekus, 
2005), but they generally do not combine physiological concentrations of metabolites with 
physiological numbers of fecal microorganisms. The TIM-2 large intestinal system 
developed at the TNO Nutrition and Food Research Center (The Netherlands) simulates 
human and monogastric large intestine, and use a complex, metabolic active microbiota of 
human origin. The fecal inoculum used contains a mixture of total anaerobes, facultative 
anaerobes and methanogenic bacteria, as well as Enterobacteriaceae, Bacteroides, 
Bifidobacterium and Lactobacillus. This model is kept always under anaerobic conditions 
by flushing with nitrogen (Minekus et al., 1999). At the moment, and to our knowledge, 
this system has not been used with mycotoxins, unlike what happened with its brother 
system, the TIM-1, which simulates the small intestine. 
 
The effect of different probiotic bacteria on the bioaccessibility of AFB1 and OTA (Kabak et 
al., 2009) and the main four AFs (Kabak and Ozbey, 2012b) has been studied using the in 
vitro model developed by Versantvoort et al. (2005), but in this case the bacteria used 
(different Lactobacillus and Bifidobacterium strains) were employed as mycotoxin 
adsorbents in a system that only simulates the stomach and small intestine. Thus no 
physiological interactions were expected and anaerobic conditions were not employed. 
 
3.1.5 Other factors: temperature, peristalsis and transit (incubation) time 
Temperature used for in vitro bioaccessibility assays of mycotoxins always simulates the 
physiological temperature of the human being, so 37 ºC has been the selected 
temperature for all the studies. Regarding gastrointestinal movements, the mechanical 
action and hydrodynamic flow created by the contraction waves of the stomach muscles 
also play a critical role in gastric digestion. Movements in the stomach are agitation 
mechanics that help to mix the food with the components of gastric juice to obtain a 
homogeneous bolo. Stomach contractions generate a fluid flow of the gastric contents that 
cause a shearing effect on the food surface. Similarly, in the small intestine peristaltic 
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waves not only move food along the intestine, but also mix the food chyme to help in the 
digestive process. In the in vitro models usually used with mycotoxins these physiological 
movements are simulated in different ways, as the use of orbital shakers (Gil-Izquierdo et 
al., 2002), head-over-heels rotation (Versantvoort et al., 2004), movement of tubes in a 
water bath (Döll et al., 2004) or the employment of peristaltic valve pumps (Minekus et 
al., 1995). The influence of the movement system selected has not been properly 
evaluated in the bioaccessibility assays conducted with mycotoxins. 
 
The gastric emptying is regulated by different factors as the volume of the meal, its 
osmotic pressure and the caloric content of the food. Gastric emptying is also the final 
expression of complex hormonal interactions and digestive electrical signal driven by the 
neuronal net and juice secretions. The half-emptying time in healthy subjects occurred 
around 90 minutes (in a range from 60 to 277 minutes), although there are great 
differences between solid and fluid meals (Versantvoort et al., 2004). However, after a 
heavy meal completely emptying of the stomach can take up to 16 hours (Davenport, 
1984). Incubation time in the stomach conditions usually used in in vitro models ranged 
from 2 to 4 hours. With regard to residence time in the small intestine, the mean transit 
time is of the order of 3 hours (range 1 to 6 hours), 2-3 hours being the time usually 
employed in the in vitro models. 
 
3.2 In vitro models used in bioaccessibility or absorption studies on mycotox ins 
Related to mycotoxins, one of the sequential discontinuous models most frequently used 
has been that developed by Gil-Izquierdo et al. (2002), a modification of a previous 
method described by Miller et al. (1981) to study iron bioavailability. This method, with 
slight modifications (Meca et al., 2012ab; Raiola et al., 2012ab), consists of two sequential 
steps: an initial saliva/pepsin/HCl digestion for 2h at 37 ºC to simulate the mouth and the 
gastric conditions, and a second digestion with bile salts/pancreatin for 2.5h at 37ºC to 
simulate duodenal digestion. 
 
Similarly, the method proposed by Versantvoort et al. (2004), and known as RIVM model, 
has been widely used. This system comprises a three-step procedure simulating digestive 
processes in mouth, stomach and small intestine. In each compartment digestion takes 
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place after addition of simulated physiological juices and incubation at 37 ºC for a time 
relevant for the considered compartment. The system has been employed mainly to 
simulate human GI tract (Brandon et al., 2006; De Nijs et al., 2012; Kabak et al., 2009, 
2012ab; Motta and Scott, 2009; Versantvoort et al., 2004, 2005). A very similar 
compartmentalized approach, but simpler in terms of composition of simulated 
physiological juices, has been described by Gawlik-Dziki et al. (2009), and has been used 
for AFB1 bioaccessibility calculations (Simla et al., 2009). 
Döll et al. (2004) developed an in vitro model to simulate the effect of the GI tract on DON 
and ZEA and some potential detoxifying agents. The in vivo conditions (pH, temperature 
and transit time) mimic the porcine GI tract as reviewed by Dänicke et al. (1999) and 
Clemens et al. (1999). The system consists in a sequential incubation of the mycotoxins in 
(0.1 M, , pH 5) phosphate-citrate buffer during 2 h followed by a pH decrease to 3.0 using 
300 µL of ortho-phosphoric acid (85%), pH value that is maintained during 2 h (4 h in all, 
simulates gastric digestion). Thereafter, the pH is increased to 6.0 by adding 600 µL NaOH 
(12 M) and incubation for 3 h after adjusting the pH to 7.0 with 400 µL NaOh (12 M). All 
the incubations are carried out in a water bath regulated at 37 ºC. 
 
The dynamic in vitro gastrointestinal model developed at the TNO, known as TIM model 
has been widely used in the determination of absorption of mycotoxins and other 
contaminants (Minekus, 1998; Minekus et al, 1995, 1999). TIM model is a multi 
compartmental, continuous, dynamic, computer-controlled system which closely simulates 
the in vivo conditions of the stomach and small intestine (TIM-1) and large intestine (TIM-
2) of humans and monogastric animals. The system simulates the peristaltic movements in 
the GI tract, mixing and moving the contents gradually through the stomach and the 
intestine. This system allows the simulation of the gastric emptying and intestinal transit 
times, and a computer-controlled system introduces the simulated salivary, gastric, biliary 
and pancreatic secretions at the appropriate moment. Absorption of water and digested 
food compounds from the small intestinal compartment is achieved by the use of hollow 
fiber membrane systems that are hooked up at the middle and end part of the small 
intestine simulating the jejunum and ileum (Zeijdner et al., 2004). In the large intestinal 
model (TIM-2) a complex metabolic active microbiota of human origin performs the 
fermentation of undigested food components (Minekus, 2005). The system has been used 
simulating the human situation for babies, young adults and elderly people (Dominy et al., 
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2004; Minekus, 1998; Oomen et al., 2002) and, on the other hand, the dog, pig and 
calves situation (Avantaggiato et al., 2003, 2004, 2005, 2007; Minekus, 1998; Smeets-
Peeter et al., 1998, 1999). This system seems to be one of the more complete and 
realistic of those available, but it has also some limitations as there are no mucosal cells 
inside the model, there is no immune system and there are no real feed back mechanisms, 
except for pH and intestinal water absorption (Zeijdner et al., 2004). Table 1 shows the 
main methods used to evaluate the bioaccessibility or absorption of mycotoxins, as well as 
their main characteristics. 
 
4. In vitro bioaccessibility/absorption data of mycotoxins 
Although simulated gastric and intestinal fluids have been used extensively in the 
evaluation of the stability of the adsorbent-mycotoxin union (Ramos, 1996a; Scheideler, 
1989), it was not until the development of the in vitro GI models described previously that 
effective evaluation of the bioaccessibility/absorption of mycotoxins in different food 
matrices has begun. In the next sections, available data on bioaccessibility or absorption 
of mycotoxins, calculated using the in vitro models previously explained, will be described 
(Tables 2 and 3). 
 
4.1 Aflatox ins 
In 2003, Zeijdner et al. using the TIM-1 GI in vitro model tested the absorption of AFB1 in 
an experiment designed for the evaluation of the efficacy of a natural magnesium smectite 
in pig GI tract. Considering only the data from the control, without adsorbent, it could be 
observed that in a contaminated feed with 20 µg/kg AFB1 (65% natural contamination),
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Table 1.- In vitro digestion models used for mycotoxin bioaccessibility determination. 
  TIM-1 Döll RIVM Gil-Izquierdo 
      
General Type model Dynamic Static Static Static 
First time 
assayed with 
mycotoxins 
2003 2004 2004 2012 
Matrix/Food 
assayed 
Wheat/Corn Phosphate-citrate 
buffer 0.1M, pH5 
Peanut 
slurry/Buckwheat 
Crispy bread/Apple 
derivatives/Italian 
pasta 
Mycotoxin 
assayed over 
time 
ZEA, AFB1, DON, 
NIV, FBs, OTA 
DON, ZEA AFB1, OTA ENs/BEA/PAT/DON 
Simulated 
physiology 
Pig Pig Human Human 
Temperature of 
assay 
37 ºC 37 ºC 37 ºC 37 ºC 
Juice movement Peristaltic valve 
pumps 
Tubes in a water 
bath 
Head-over-heels 
rotation at 55 rpm 
Stomacher/Orbital 
shaker 
Computer Yes No No No 
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assisted 
Mouth 
simulation 
 No Yes Yes Yes 
Saliva 
composition 
-- Phosphate-citrate 
buffer 
10 mL KCl 89.6 g/L, 
10 mL KSCN 20 g/L, 
10 mL NaH2PO4 88.8 
g/L, 10 mL NaSO4 57 
g/L, 1.7 mL NaCl 
175.3 g/L, 20 mL 
NaHCO3 84.7 g/L, 8 
mL urea 25 g/L, 290 
mg α-amylase, 15 
mg uric acid, 25 mg 
mucin 
KCl 89.6 g/L, KSCN 
20 g/L, NaH2PO4 
88.8 g/L, NaSO4 57 
g/L, NaCl 175.3 g/L, 
NaHCO3 84.7 g/L, 
urea 25 g/L, 290 mg 
α-amylase 
pH -- 5.0 6.8 6.8 
Incubation time -- 2 hours 5 minutes 30 seconds 
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Table 1. Continued. 
  TIM-1 Döll RIVM Gil-Izquierdo 
Stomach 
simulation 
 Yes Yes Yes Yes 
Gastric juice 
composition 
NaCl 3.1 g/L, KCl 1.1 
g/L, CaCl2 0.15 g/L, 
NaHCO3 0.6 g/L, 
porcine pepsin, 
fungal lipase, bovine 
trypsin  
Only pH adjustment 
to pH 3 with ortho-
phosphoric acid 85% 
15.7 mL NaCl 175.3 
g/L, 3.0 mL NaH2PO4 
88 g/L, 9.2 KCl 89.6 
g/L, 18 mL 
CaCl2·2H2O 22.2 g/L, 
10 mL NH4Cl 30.6 
g/L, 6.5 mL HCl 37% 
g/g, 10 mL glucose 
65 g/L, 10 mL 
glucuronic acid 2g/L, 
3.4 mL urea 25 g/L, 
10 mL glucosamine 
hydrochloride 33 g/L, 
1 g BSA, 2.5 g 
pepsin, 3 g mucin   
Pepsin (14,800U in 
HCl 0.1 N) 
pH Gradually decreasing 
from 7 to 2 
5 (2h) + 3 (2h) 1.30 2.0 
Incubation time  4 hours 2 hours 2 hours 
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Small  
intestine 
simulation 
 Yes Yes Yes Yes 
Small intestine 
juice composition 
Duodenal electrolyte 
solution: NaCl 5.0 
g/L, KCl 0.6 g/L, 
CaCl2 0.3 g/L. 
Pancreatin solution 
at 7%  
Porcine bile exttract 
at 4% 
Only pH adjustment 
to pH 6 with a 12 M 
NaOH 
Duodenal juice: 
40 mL NaCl 175.3 
g/L, 40 mL NaHCO3 
84.7 g/L, 10 mL 
KH2PO4 8 g/L, 6.3 
mL KCl 89.6 g/L, 10 
mL MgCl2 5 g/L, 180 
µL HCl 37% g/g, 4 
mL urea 25 g/L, 9 
mL CaCl2·2H2O 22.2 
g/L, 1g BSA, 9 g 
pancreatin, 1.5 g 
lipase 
 
Pancreatin 
(8mg/mL), bile salts 
(50 mg/mL) 
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Table 1. Continued  
  TIM-1 Döll RIVM Gil-Izquierdo 
Small  
intestine 
simulation 
   Bile juice: 
30 mL NaCl 175.3 
g/L, 68.3 mL 
NaHCO3 84.7 g/L, 
4.2 mL KCl 89.6 g/L, 
150 µL HCl 37% g/g, 
10 mL urea 25 g/L, 
10 mL CaCl2·2H2O 
22.2 g/L, 1.8 g BSA, 
30 g bile 
 
pH 6.5 (duodenum), 6.7 
(jejunum), 7.2 
(ileum) 
6 8.1 (duodenal juice), 
8.2 (bile juice) 
6.5 
Incubation time  3 hours 2 hours 2 hours 
Large 
intestine 
simulation 
 No Yes No No 
Large intestine 
juices 
composition 
Optionally, a TIM-2 
large intestinal 
system for 
microbiological 
Only pH adjustment 
to pH 7 with a 12 M 
NaOH 
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studies is available. 
Not evaluated with 
mycotoxins 
pH  7   
Incubation time  3 hours   
Incubation time  3 hours   
      
Output Specific 
treatment 
Dialysis through 
hollow fiber 
membranes with a 
cut-off of approx. 
5000D 
No No No 
Sample 
centrifugation 
Yes 2100 g - 10 min 2750 g - 5 min 4000 rpm - 10 min to 
1 h 
Sample filtration Yes No No No 
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Table 1. Continued. 
  TIM-1 Döll RIVM Gil-Izquierdo 
Output Observations Total digestion time 
6 h 
More information in 
Avantaggiato et al. 
(2003) 
More information in 
Döll et al. (2004) 
More information in 
Versantvoort et al. 
(2004, 2005) 
More information in 
Meca et al. (2012a) 
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 the amount of mycotoxin absorbed was of 47% (Zeijdner et al., 2003, 2004). This result 
was confirmed by Avantaggiato et al. (2007), using the same in vitro model trying to 
assess the efficacy of a carbon/aluminosilicate-based product on a multicontaminated feed 
containing AFB1, FB1, FB2, DON, ZEA and OTA, as a 46% absorption for AFB1 was 
observed, although the initial level of contamination was almost 10-fold higher (193 
µg/kg). The AFB1 absorption occurred mainly (approx. 75%) at the upper part of the 
system (simulating jejunum) and less at the ileum. 
 
Shortly after, Versantvoort et al. (2004), in the first document where the term 
“bioaccessibility” is applied in the field of mycotoxins, described the bioaccessibility of AFB1 
from peanut slurries using the RIVM model for GI human tract simulation. Data obtained 
using a low amount of AFB1 (3 ng AFB1, from 0.5 g of a peanut slurry contaminated at 6 
µg/kg) or a higher amount (27 ng AFB1, from 4.5 g of a peanut slurry containing 6 µg/kg) 
showed similar results of bioaccessibility, ranging between 80 and 81%, considerably 
higher than the previous works. The bioaccessibility of AFB1 from 9 peanut slurries ranging 
from 0.6 to 14 µg/kg in the chyme (1.5 to 36 µg/kg contamination level of peanuts) was 
determined and it was observed that a more or less constant bioaccessibility percentage of 
90% at each contamination level was found. The bioaccessibility rose to 104-111% when 
AFB1 was in a food mix containing a standard meal plus the peanut slurry (1 and 3 ng 
AFB1 in the digestion model). To test the robustness of the digestion model, some 
changes were applied, as the decrease of the pH in the small intestinal compartment, the 
prolongation of the incubation time in the small intestine section (4h instead 2h), or 
doubling the bile concentration, but none of these variations affected the bioaccessibility 
of AFB1 from the food mix. This data were confirmed with very slight modifications (83-
84% bioaccessibility in peanut slurries, 108-115% in food mix) shortly thereafter by the 
same authors (Versantvoort et al., 2005), and by Simla et al. (2009) in ground corn (92.5-
98.1% bioaccessibility) and peanut (91.2-97.0% bioaccessibility).  
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Table 2. GI in vitro models used for bioaccessibility or absorption determination of aflatoxins. 
Mycotoxin Matrix Contami-
nation 
Matrix 
contamination 
range 
Bioaccessibility
/Absorption 
In vitro model 
used 
Reference 
AFB1 Feed S 20 µg/kg 47% TIM-1* Zeijdner et al., 2003 
Peanut 
slurries 
N 0.6-14 µg/kg around 90% RIVM Versantvoort et al., 2004 
Peanut 
slurries 
N 6 µg/kg 80-81% RIVM Versantvoort et al., 2004 
Food mix N 0.5 µg/kg 104-111% RIVM Versantvoort et al., 2004 
Peanut 
slurries 
N 6 µg/kg 83-84% RIVM Versantvoort et al., 2005 
Food mix N 0.2-0.4 µg/kg 108-115% RIVM Versantvoort et al., 2005 
Corn feed S 193 µg/kg 46% 
(35% jejunum; 
11% ileum) 
TIM-1* Avantaggiato et al., 2007 
Ground corn S 1-20 mg/kg 93-98% Gawlik-Dziki et 
al., 2009 
Simla et al., 2009 
 Peanut 
slurries 
S 1-20 mg/kg 91-97% Gawlik-Dziki et 
al., 2009 
Simla et al., 2009 
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Pistachio 
nuts 
N 109.1 µg/kg 86% RIVM Kabak et al., 2009 
Infant food S 1.76-3.75 µg/kg 88-94% RIVM Kabak et al., 2009 
Peanut S 1.86-9.62 µg/kg 90-95% RIVM Kabak et al., 2012b 
Pistachio S 1.89-9.66 µg/kg 90-96% RIVM Kabak et al., 2012b 
Hazelnut S 1.84-9.54 µg/kg 89-95% RIVM Kabak et al., 2012b 
Dried figs S 1.87-9.71 µg/kg 91-99% RIVM Kabak et al., 2012b 
Paprika S 1.83-9.44 µg/kg 86-94% RIVM Kabak et al., 2012b 
Wheat S 1.87-9.49 µg/kg 85-90% RIVM Kabak et al., 2012b 
Corn S 1.88-9.43 µg/kg 88-93% RIVM Kabak et al., 2012b 
AFB2 Peanut S 0.53-2.78 µg/kg 86-92% RIVM Kabak et al., 2012b 
Pistachio S 0.54-2.81 µg/kg 88-92% RIVM Kabak et al., 2012b 
Hazelnut S 0.53-2.75 µg/kg 86-90% RIVM Kabak et al., 2012b 
Dried figs S 0.54-2.78 µg/kg 88-90% RIVM Kabak et al., 2012b 
Paprika S 0.53-2.72 µg/kg 84-85% RIVM Kabak et al., 2012b 
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Table 2. Continued. 
Mycotoxin Matrix Contami-
nation 
Matrix 
contamination 
range 
Bioaccessibility
/Absorption 
In vitro model 
used 
Reference 
AFB2 Wheat S 0.52-2.63 µg/kg 83-85% RIVM Kabak et al., 2012b 
Corn S 0.52-2.65 µg/kg 84-88% RIVM Kabak et al., 2012b 
AFG1 Peanut S 1.81-9.57 µg/kg 89-93% RIVM Kabak et al., 2012b 
Pistachio S 1.84-9.61 µg/kg 91-95% RIVM Kabak et al., 2012b 
Hazelnut S 1.83-9.51 µg/kg 91-94% RIVM Kabak et al., 2012b 
Dried figs S 1.85-9.50 µg/kg 91-94% RIVM Kabak et al., 2012b 
Paprika S 1.81-9.37 µg/kg 85-91% RIVM Kabak et al., 2012b 
Wheat S 1.83-9.43 µg/kg 88-89% RIVM Kabak et al., 2012b 
Corn S 1.87-9.40 µg/kg 87-92% RIVM Kabak et al., 2012b 
AFG2 Peanut S 0.52-2.70 µg/kg 84-87% RIVM Kabak et al., 2012b 
Pistachio S 0.53-2.75 µg/kg 87-88% RIVM Kabak et al., 2012b 
Hazelnut S 0.52-2.73 µg/kg 84-86% RIVM Kabak et al., 2012b 
Dried figs S 0.53-2.77 µg/kg 87-91% RIVM Kabak et al., 2012b 
Paprika S 0.51-2.70 µg/kg 81-86% RIVM Kabak et al., 2012b 
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AFG2 Wheat S 0.50-2.61 µg/kg 81-84% RIVM Kabak et al., 2012b 
Corn S 0.51-2.63 µg/kg 82-85% RIVM Kabak et al., 2012b 
AFM1 UHT milk N/S 0.011-0.939 µg/L 81-86% RIVM Kabak et al., 2012a 
N: natural, S: spiked. *TIM-1 model determines in vitro intestinal absorption of the bioaccessible mycotoxin.
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Kabak et al. (2009), who also used the RIVM in vitro model found similar data, with an 
AFB1 bioaccessibility that ranged from the 86% in naturally contaminated pistachio nuts, 
to the 88-94% in artificially contaminated infant food. These authors also found that the 
bioaccessibility of AFB1 could be reduced in a 37% by the addition of a probiotic bacteria 
(Lactobacillus acidophilus NCC12). Although other probiotics were used (from Lactobacillus 
and Bifidobacterium genera), results were not conclusive when the standard deviations 
were taken into account. 
 
These authors extended their studies on AFs bioaccessibility to the four main Aflatoxins 
(Kabak and Ozbey, 2012) and to AFM1 (Kabak and Ozbey, 2012a). In the first case, a wide 
range of artificially contaminated food matrices were assayed (peanut, pistachio, hazelnut, 
dried figs, paprika, wheat and corn) finding bioaccessibilities that ranged from 85.1-98.1% 
for AFB1, 83.3-91.8% for AFB2, 85.3-95.1 for AFG1 and 80.7-91.2% for AFG2. The 
bioaccessibilities of all four toxins were independent of the 3 spiking levels (2, 5 and 10 
µg/kg for AFB1 and AFG1, and 0.6, 1.5 and 3 µg/kg for AFB2 and AFG2) and the 7 different 
food matrices assayed. The highest AFB1 bioaccessibility value was reported in dried figs 
(average 94.4%), whereas the lowest was detected in wheat samples (average 87.2%). 
Again, these authors studied the effect of the addition of probiotic bacteria (from 
Lactobacillus and Bifidobacterium genera), finding a bioaccessibility reduction that could 
reach in the best situation a 35.6% reduction. 
 
With regard to AFM1, results found in spiked and naturally contaminated UHT milk, with 
contamination levels ranging from 0.011 to 0.939 µg/L, showed bioaccessibilities around 
80.5-86.3% (Kabak et al., 2012a). There were no significant differences among the spiked 
and naturally contaminated milk samples. Assuming that the bioaccessibility of AFs, 
including AFM1, would be around 80-90%, depending on the matrices and contamination 
levels considered; it can be concluded that AFs are almost completely released from the 
food matrices during digestion, implying a high toxicological risk. 
 
4.2 Ochratox in A 
At present, there are few studies on the bioaccessibility of OTA and its relation to different 
food matrices. Versantvoort et al. (2004), using the RIVM model, determined the OTA 
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bioaccessibility in two lots of buckwheat, finding that a considerable amount of OTA, 
above 45%, was released from the food matrix. Bioaccessibilities seemed to be not 
dependent of the amount of food in the digestion model, the presence of other 
components in the food matrix or some variations in parameters of the in vitro model (as 
lowering the intestinal pH, prolongation of the transit time or doubling the bile 
concentration). Values obtained ranged from 45% (in a buckwheat batch contaminated at 
20 µg/kg) to 84% (in a buckwheat batch contaminated at 7 µg/kg). However, in 2005, the 
same authors using the same experimental design reported bioaccessibilities of OTA 
considerably higher. Thus, values ranging from 86 to 116% were described, although in 
this second report the amount of mycotoxin used in the digestion model was lower 
(Versantvoort et al., 2005). Those data agree with the results later reported by 
Avantaggiato et al. (2007) who found, using the TIM-1 model with an artificially OTA 
contaminated corn feed, absorptions near 88%. Most of the OTA was released from the 
food matrix in the jejunal dialysate, showing a high absorption in the upper part of the 
small intestine, whereas in the ileal dialysate absorption of the ingested OTA was limited 
to approximately 15%. 
 
However, Kabak et al. described again in 2009 much lower values for OTA bioaccessibility 
(22-32%) using the RIVM model with naturally OTA contaminated buckwheat or with low- 
and high-contaminated spiked infant foods. Bioaccessibilities found seemed not to be 
contamination level dependent, but it seemed that bioaccessibility increased if spiked 
contamination was employed, as in this case the toxin may not be tightly bound to the 
food matrix. Besides, the authors suggested that the difference found between the 
bioaccessibility of AFB1 and OTA (AFB1:OTA ratio at 3:1, according to their data) should be 
taken into account in risk assessment, as AFB1 presents a higher toxicological risk.  
It seems obvious that more data are required to more accurately assess OTA 
bioaccessibility. The effect that OTA contamination level, type of contamination (natural 
vs. spiked) and food matrix exerts in bioaccessibility must be more profoundly studied in 
this mycotoxin. 
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4.3 Patulin 
Raiola et al. (2012a) determined the bioaccessibility of PAT in apple juices and purees by 
using an in vitro model based on the sequential steps of GI digestion defined by Gil-
Izquierdo et al. (2002) (gastric and duodenal digestion), pepsin, pancreatin and bile 
extract used were demineralised using a Chelex-100 resin, as described by Jovaní et al. 
(2004). Unlike the original Gil-Izquierdo method, a brief salivary digestion was added and 
no dialysis of the pepsin digest was carried out. Commercial PAT-free apple products were 
contaminated with 50 µg PAT/L (juices) or 25 µg PAT/kg (purees) and digested. A higher 
bioaccessibility was observed in apple juices with pulp (67.3-70.9%), followed by puree 
samples (55.7-58.2%). Apple and pear nectar (38.9%) and clarified apple juices (25.3-
28.6%) showed much lower bioaccessibilities. The authors suggested that these data 
should be taken into account in the risk assessment of this toxin, as high bioaccessibilities 
could be found in apple juices, frequently ingested by children over 3 years. 
 
Similar high PAT bioaccessibilities were found by Brandon et al. (2012) in apple products 
using the RIVM digestion model. The bioaccessibility of PAT was assayed using two 
different amounts of food per digestion tube (2.0 and 4.5 g, representing half a meal and 
a normal amount of dinner). Home-made apple sauce made from apples contaminated 
with Penicillium expansum, and spiked apple sauce and baby fruit were assayed alone or 
in combination with other foods as yoghurt, biscuits or a standard Dutch dinner. Level of 
PAT contamination ranged from 99.8 (spiked foods) to 110-485 µg/kg (naturally 
contaminated). Results showed that bioaccessibility was similar for the two amounts of 
food and that bioaccessibility values were high, ranging between 55 and 100%. 
 
4.4 Fusarium  mycotoxins 
4.4.1 Zearalenone 
Avantaggiato et al. (2003) using the TIM-1 model that simulates the porcine 
gastrointestinal tract determined the GI absorption of ZEA. Contaminated feed (820 µg 
ZEA/kg), containing in its composition artificially contaminated wheat, was pumped into 
the GI-model. Intestinal absorption of the food-released ZEA was measured analysing the 
dialysates at the jejunal and ileal locations of the system. A 32% absorption was observed 
at the jejunal+ileal compartment, although absorption occurred mainly in the jejunal part 
 211 
of the model (22%). Absorption at the stomach+duodenal compartment was considerably 
lower (4%). Authors considered that almost all the ZEA released from the food matrix 
during digestion was rapidly absorbed, a result consistent with the in vivo data obtained 
by Ramos et al. (1996b) in rats that showed a high rate of ZEA absorption through the 
intestinal lumen by a passive process. These results were confirmed by Zeijdner et al. 
(2004) using a naturally contaminated feed (100 µg ZEA/kg). Feed was digested in a TIM-
1 model during six hours, obtaining again a 22% of absorption in the jejunal compartment 
and a 10% in the ileal compartment. Avantaggiato et al. (2007) reported an absorption of 
25% (16% jejunum; 9% ileum) using a naturally contaminated feed containing 1.3 mg 
ZEA/kg. The authors concluded that neither the level of ZEA in the feed nor the origin of 
contamination (natural or spiked) has an effect on the intestinal absorption of ZEA, setting 
an average value of 28% of the matrix-released mycotoxin. On the other hand, absorption 
of ZEA in the TIM-1 model was lower and slower than the observed for other mycotoxins 
as FBs, DON, OTA or AFB1. Consequently, ZEA absorption took place in the distal part of 
the small intestine, with a higher absorption in the ileum compartment compared with the 
rest of mycotoxins. 
 
4.4.2 Deoxynivalenol and nivalenol 
Simultaneous absorption of DON and NIV was evaluated using the porcine TIM-1 model by 
Avantaggiato et al. (2004). A meal containing DON and NIV spiked ground wheat was 
employed for absorption determination. Contamination level of the meal was 560 µg 
DON/kg and 760 µg NIV/kg. Results showed that both toxins were simultaneously 
absorbed in the small intestine, DON absorption being 2.4 times higher that NIV uptake. A 
total absorption of 51% was observed for DON, 44% of which takes place in the jejunum 
and the rest in the ileum compartment. On the other hand, NIV showed a 21% 
absorption, 18% of which corresponding to jejunum. The authors suggested that the 
higher absorption of DON with regard to NIV (ratio 5:2) may be due to its higher 
hydrophobicity. However, using the same in vitro model, higher values for DON absorption 
(68% at jejunum; 6% at ileum) were found later using 10-fold naturally contaminated 
grains (Avantaggiato et al., 2007). 
 
212 
Table 3.- GI in vitro models used for bioaccessibility or absorption determination of OTA, PAT and Fusarium mycotoxins. 
Mycotoxin Matrix Contami-
nation 
Matrix 
contaminati
on range 
Bioaccessibility/ 
Absorption 
In vitro model 
used 
Reference 
OTA Buckwheat N 7-20 µg/kg 45-84% RIVM Versantvoort et al., 2004 
Food mix N 3.3-3.5 µg/kg 60-62% RIVM Versantvoort et al., 2004 
Buckwheat N 11-11.3 
µg/kg 
86-100% RIVM Versantvoort et al., 2005 
Food mix N 1.83-2.0 
µg/kg 
114-116% RIVM Versantvoort et al., 2005 
Corn feed S 11 µg/kg 88% 
(73% jejunum; 
15% ileum) 
TIM-1* Avantaggiato et al., 2007 
Buckwheat N 24.9 µg/kg 22% RIVM Kabak et al., 2009 
Infant food S 3.2-13.1 
µg/kg 
29-32% RIVM Kabak et al., 2009 
PAT Cloudy 
apple juice  
S 50 µg/L 67-71% Gil-Izquierdo et al., 
2002 and Jovaní et 
al., 2004 
Raiola et al., 2012a 
Apple S 25 µg/kg 56-58% Gil-Izquierdo et al., Raiola et al., 2012a 
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puree 2002 
and Jovaní et al., 
2004 
Apple and 
pear nectar 
S 50 µg/L 39% Gil-Izquierdo et al., 
2002 
and Jovaní et al., 
2004 
Raiola et al., 2012a 
Clarified 
apple juice 
S 50 µg/L 25-29% Gil-Izquierdo et al., 
2002 
and Jovaní et al., 
2004 
Raiola et al., 2012a 
Apple 
derived 
products 
N-S 99.8-485 
µg/kg 
55-100% RIVM Brandon et al., 2012 
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Table 3. Continued.  
Mycotoxin Matrix Contami-
nation 
Matrix 
contaminati
on range 
Bioaccessibility/ 
Absorption 
In vitro model 
used 
Reference 
ZEA Feed meal S 820 µg/kg 32% total 
(22% jejunum; 
10% ileum) 
TIM-1* Avantaggiato et al., 2003 
Feed N 100 µg/kg 32% total 
(22% jejunum; 
10% ileum) 
TIM-1* Zeijdner et al., 2004  
Grain N 1300 µg/kg 25% 
(16% jejunum; 
9% ileum) 
TIM-1* Avantaggiato et al., 2007 
DON Feed meal S 560 µg/kg 51% total 
(44% jejunum; 7% 
ileum) 
TIM-1* Avantaggiato et al., 2004 
Grain N 5600 µg/kg 74% total 
(68% jejunum; 6% 
ileum) 
TIM-1* Avantaggiato et al., 2007 
Pasta  N 73.8-387 Child: 20% gastric; Gil-Izquierdo et al., Raiola et al., 2012b 
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µg/kg 10% duodenal 
Adult: 42%% gastric; 
24% duodenal 
2002 
Infant 
formula 
S 2222 µg/kg 65% RIVM De Nijs et al., 2012 
DON-3-G Infant 
formula 
S 2778 µg/kg 55% RIVM De Nijs et al., 2012 
NIV Feed meal  S 760 µg/kg 21% total 
(18% jejunum; 3% 
ileum) 
TIM-1* Avantaggiato et al., 2004 
FBs Grain N 19900 µg 
FB1/kg 
 
 
5900 µg 
FB2/kg 
104% total FB1 
(87% jejunum; 17% 
ileum) 
89% total FB2 
(75% jejunum; 14% 
ileum) 
TIM-1* Avantaggiato et al., 2007 
TB FB1 Corn flakes N 92 µg/kg 51% RIVM Motta and Scott, 2009 
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Table 3. Continued. 
Mycotoxin Matrix Contami-
nation 
Matrix 
contaminati
on range 
Bioaccessibility/ 
Absorption 
In vitro model 
used 
Reference 
ENNs Crispy 
bread 
S 1.5 and 3.0 
µmol/g 
85-91% ENA 
69-73% ENA1 
69-82% ENB 
74-84%ENB1 
Gil-Izquierdo et al., 
2002 
Meca et al., 2012a 
BEA Wheat 
crispy 
bread 
S 5 and 25 
mg/kg 
around 40%  duodenal 
digestion around 30% 
duodenal+colonic 
digestion 
Gil-Izquierdo et al., 
2002 modified 
Meca et al., 2012b 
N: natural, S: spiked *TIM-1 model determines in vitro intestinal absorption of bioaccessible mycotoxin. 
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Recently, Raiola et al. (2012b) determined the bioaccessibility of DON in pasta samples 
using the human in vitro model described by Gil-Izquierdo et al. (2002), slightly modified. 
In most of the samples, the in vitro model was adjusted to simulate child digestion (higher 
gastric pH, reduced amount of pepsin, pancreatin and bile salts) and in this case the mean 
value for DON bioaccessibility was 19.5% (ranging from 2.12% to 38.41%) for the gastric 
compartment and 9.7% for the duodenal compartment (range 1.11-17.91%). In one 
sample where adult digestion was simulated, the bioaccessibilities found were considerably 
higher (32.81% average; 41.49% for gastric and 24.13% for duodenal compartments). 
Although bioaccessibilities found in the adult model were higher, authors postulate that, 
considering the small dimension of the child intestinal tract, the released DON present in 
this place could probably produce more damage to the intestinal enterocytes respect to 
that in an adult. 
 
Regarding masked mycotoxins, a conjugated form of DON, the DON-3-ß-D-glucoside 
(DON-3-G) could be present in DON-contaminated plants, as glucosylation represents a 
major route to detoxify xenobiotics for plants. In fact, it has been proven that in some 
cases mean DON-3-G contamination exceeded the DON contamination (Sasanya et al., 
2008). A major concern is the hydrolysis of the DON-3-G conjugate back to its toxic 
precursor DON during gastrointestinal passage. This fact could clearly influence the real 
bioaccessibility value of this toxin in a food from which only DON contamination is known. 
For this reason DON reversion from DON-3-G was determined using an in vitro experiment 
that mimics the digestion conditions at the GI tract (acid hydrolysis of DON-3-G using 
0.02-0.2 M HCl, pH 1.7-0.7; artificial stomach juice containing pepsin; artificial non-
microbial gut juice containing pancreatin) (Berthiller et al., 2011). Results showed that 
neither the acidic hydrolysis nor the GI enzymatic simulations resulted in DON 
regeneration. However, metabolic activity of some usual GI bacteria could produce the 
hydrolysis of DON-3-G to DON. Several Enterococcus species (E. durans, E. faecium and E. 
mundtii), but also Enterobacter cloacae, Lactobacillus plantarum and Bifidobacterium 
adolescentis were able to cleave DON-3-G in the semi-anaerobic conditions assayed, 
releasing up to values from 6 to 62% of DON after 8h, depending of the considered 
species. Similarly the hydrolytic enzyme cellobiase produces a 73% DON-3-G hydrolysis in 
18h, suggesting that DON- 3-G could be cleaved and DON released in the GI tract of 
plant-based cellulose-foraging ruminants (Berthiller et al., 2011). 
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Once the possibility of a GI reversion of DON-3-G was stated, De Nijs et al. (2012) 
calculated the possible transformation of this masked mycotoxin to DON using the RIVM in 
vitro digestion model. Thus, an infant formula with 2778 µg DON-3-G/kg was introduced 
into the system, but DON was not detected in the chyme of the digested samples (this 
means that, in theory, less than 5% of DON-3-G was hydrolysed to DON). The level of 
DON-3-G detected after digestion was 55% (that is, the bioaccessible fraction). When 
samples were only spiked with DON (2222 µg/kg) the amount of DON detected after 
digestion was 65%, and DON-3-G was not detected. These results confirm the previous 
data, but as this model does not consider the existence of intestinal microbiota, the 
question of whether the DON-3-G hydrolysis at this location would lead to an increase in 
the DON uptake remains unanswered. 
 
4.4.3 Fumonisins 
Absorption of FB1 and FB2 were determined by Avantaggiato et al. (2007) in a naturally 
contaminated blend of grains by using the TIM-1 in vitro model. Absorption of both 
mycotoxins takes place mainly in the simulated jejunum (87% FB1, 75% FB2) and in a 
lesser extent in the ileum (17.3% FB1, 13.9% FB2). Thus, average intestinal absorption 
was 104% for FB1 and 89% for FB2, indicating that release of FBs from the food matrix 
and, consequently, absorption in the simulated intestinal tract is an almost complete fact 
and that absorption of bioaccessible fumonisins would take place mainly in the upper part 
of the small intestine. On the other hand, maximum absorption occurred in the first 2 
hours of digestion. These results do not agree with those from in vivo experiments, as it is 
known that FB1 has very species-specific toxicity and a very low bioavailability when 
administered orally, resulting from low uptake coupled with efficient biliary excretion 
(Shier, 2000). Low oral FB1 bioavailability has been demonstrated in swine (3-6%) 
(Prelusky et al., 1994) and laying hens (0.7%) (Vudathala et al., 1994), whereas in cows 
no FB1 or known metabolites were found in the plasma of orally administered cows, 
indicating no or very limited bioavailability in ruminants (Prelusky et al., 1995). These 
discrepancies between the results obtained in vitro and highlight the limitations of in vitro 
models. 
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It has been hypothesized that the totally hydrolyzed FB1 metabolite HFB1 is the real 
molecule involved in fumonisin toxicity, is more polar than FB1 and in vivo studies 
demonstrated its higher absorption in rats (Hopmans et al., 1997). However, recent in vivo 
studies wih piglets have shown that FB1 hydrolysis strongly reduces its toxicity both in the 
GI tract and the liver (Grenier et al., 2012) these findings suggest that HFB1, rather than 
being the molecule implicated in FB1 toxicity, represents a mechanism for detoxification. 
Effects of HFB1 on the intestine have been poorly studied, and most of the data have 
been obtained from in vitro studies with intestinal cell lines. 
 
It has been demonstrated that although HFB1 could be absorbed in a dose-dependent 
manner by the human colon adenocarcinoma Caco-2 cells, while FB1 was not absorbed by 
human colon adenocarcinoma Caco-2 monolayer of cells. In spite of this, HFB1 was not 
accumalated inside the cells, and no viability alterations or barrier damage was observed 
(De Angelis et al., 2005). Similarly, in vivo HFB1 ingestion assays showed that this 
compound did not induce toxic effect in the piglet intestine, as intestinal integrity was not 
altered and intestinal immunity was not compromised (Grenier et al., 2012). 
Dall’Asta et al. (2009) addressed the problem created by the presence of hidden (masked) 
FBs in the food matrix, as we explained before regarding DON-3-G. 
 
With regard to extractable FBs (expressed as the sum of FB1, FB2 and FB3) an increase of 
30-50% in FB concentration was observed after in vitro digestion of naturally 
contaminated corn flours using the RIVM model, which greatly affects the bioaccessibility 
determination. The authors suggested that the binding mechanism of FBs in raw corn is 
mainly due to an association with macromolecules such as starch and proteins. 
Additionally, no hydrolyzed or partially hydrolyzed FBs were found in the chyme. Besides, 
the total FBs found after digestion are slightly higher than those obtained after an alkaline 
hydrolysis, suggesting that masked FBs are native forms, which can be released under 
conditions found in the GI tract. As a clear example of how the presence of masked 
mycotoxins could affect bioaccessibility measurements, in a reference material with a 
declared FBs contamination of 3036 µg/kg, an amount of 8010 µg/kg of free FBs was 
detected after the in vitro digestion (Dall’Asta et al., 2009). 
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Similarly, Motta and Scott (2009) studied the bioaccessibility of total bound FB1 (TB FB1) in 
naturally contaminated corn flakes using the RIVM model. Corn flake samples assayed had 
a low level (23 µg/kg TB FB1) or high level (92 µg/kg TB FB1) of contamination. Results 
showed that in the case of the high level contaminated corn flakes a 51% (range 37-64%) 
bioaccessibility of TB FB1 was found, showing that masked mycotoxins could be 
bioaccessible for absorption at the small intestine. In addition, authors suggested that TB 
FB1 could be a substrate for the intestinal bacteria and could be also hydrolyzed to 
regenerate the FB1 or to create other hydrolyzed metabolites, increasing the possibility of 
exposure to this group of toxins after ingestion. 
 
4.4.4 Emerging Fusarium mycotox ins 
Fusarium species are also responsible for the production of another group of bioactive 
compounds considered as “minor” mycotoxins. This group includes enniatins (ENA, ENA1, 
ENB and ENB1), fusaproliferin and beauvericin (Meca et al., 2010). All of these toxins 
belong to the group of “emerging” mycotoxins, which are neither routinely determined, 
nor legislatively regulated; however, the evidence of their incidence is rapidly increasing. 
Enniatins represent an emerging food safety issue because of their extensive incidence, 
documented in recent decades, in various small grain cereals (Santini et al., 2012). 
Bioaccessibility of ENNs has been evaluated by the in vitro method of Gil-Izquierdo et al. 
(2002) on spiked wheat crispy breads (Meca et al., 2012a). Thus, breads were 
contaminated with ENA, ENA1, ENB and ENB1 at two concentrations each (1.5 and 3.0 
µmol/g) and gastric and duodenal bioaccessibilities were calculated. At the gastric 
compartment, bioaccessibility ranged between 69.0% (ENA1 at 1.5 µmol/g) and 91.0% 
(ENA at 3 µmol/g), whereas at duodenal compartment the range was between 68.6% 
(ENB at 1.5 µmol/g) and 87.3% (ENA at 3 µmol/g). The enniatin that showed the highest 
bioaccessibilities was the ENA, and the mean bioaccessibility considering the four 
compounds analyzed resulted in 80%. Given the fact that cereals are frequently 
contaminated, that it has been demonstrated that ENs can exert toxic activity at low 
micromolar concentrations in mammalian cells (Meca et al., 2011), and that high 
bioaccessibilities were found these data must be taken into account in future legislative 
actions. 
 
 221 
A similar study was conducted by the same group with beauvericin (Meca et al., 2012b). 
BEA has also shown to be toxic in in vitro studies with human cell lines, including the 
intestinal Caco-2 cells (Prosperini et al., 2012). Gil-Izquierdo et al. (2002) model was used, 
with slight modifications; a simulation of the large intestine (colonic digestion) was 
employed introducing a high inoculum (1014 cfu/mL) of several characteristic bacteria of 
the GI tract after the duodenal digestion. Wheat crispy breads were spiked with 5 or 25 
mg BEA/kg; bioaccessibility was around 40% until duodenal digestion and around 30% 
until duodenal+colonic digestion, with higher bioaccessibilities at the lower BEA dose 
employed. When crispy breads were produced with different concentrations of soluble 
alimentary dietary fibers, bioaccessibilities were drastically reduced at the duodenal 
digestion, but results were quite variable when considered the joint duodenal+colonic 
digestion. Thus, some fibers as chitosan medium MW and galattomannan considerably 
reduced BEA bioaccessibility when used at 5%. On the contrary, the use of 
fructooligosaccharides, inulin or pectin increases the BEA bioaccessibility after 
duodenal+colonic digestion, mainly at low BEA levels (5 mg/kg). 
 
5. Conclusions 
According to the reviewed studies, it can be concluded that bioaccessibility of mycotoxins 
greatly depends on the considered toxin, as well as on the food matrix in which 
experiments are carried out. As a general rule it can be established that bioaccessibility of 
AFs, FBs and ENNs shows high values, generally ranging between 70 and 100%, while 
PAT, DON and BEA show intermediate values, around 30-70%, and ZEA presents lower 
values. The bioaccessibility of OTA has proven to be very variable, with values near 100% 
in some cases but below 30% in others. 
 
The great variability of results between different mycotoxins and, for the same mycotoxin 
among the different studied matrices, highlights the need for further studies on 
bioaccessibility of these fungal metabolites, increasing the number and types of studied 
foods. The true knowledge of the percentage of mycotoxin that can be absorbed in the 
small intestine, from the initially present in food, would enable a more accurate risk 
assessment. 
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It is also necessary to increase the number of studies with naturally contaminated foods, 
as the mycotoxin-matrix binding has shown to be stronger, which could affect the 
bioaccessibility values. On the other hand, when working with spiked samples it is 
necessary that the mycotoxin contamination level fits the natural contamination found in 
foods. In the same sense, a special attention has to be paid to masked mycotoxins, as an 
overestimation of bioaccessibility could occur due to an incorrect estimation of the 
bioaccessible toxin after the digestive process, in relation to the initially known amount of 
toxin. 
 
Determination of the internal exposure is a good approach to improve the risk assessment 
of a mycotoxin. In vitro methods offer an appealing alternative to human and animal 
studies. They can be rapid, simple and reasonably low in cost, can be used to perform 
simplified experiments under uniform and well-controlled conditions, and may provide 
insights not achievable in whole animal studies, but they are not free of some weaknesses. 
In one hand, in many cases they do not take into account important physiological factors 
as the lack of intestinal mucosa, enterohepatic cycling, and immune system and, in most 
cases they do not take into account the existence of an intestinal microbiota which 
possesses enzymatic capabilities that can decisively influence the release of the mycotoxin 
from the food matrix or the bioconversion of these toxins in the GI tract. On the other 
hand, these models usually do not take the large intestine into account, as absorption of 
toxins mainly takes place in the small intestine. 
 
Combined use of these in vitro digestion models with other techniques that employ 
intestinal cell lines, as in vitro intestinal absorption models that use Caco-2 cells (De Nijs et 
al., 2012), conducting for instance transepithelial transport studies (Meca et al., 2012a, 
Prosperini et al., 2012) may offer a more complete picture of what happens in the 
intestinal tract during intestinal digestion. 
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Composition of digestive juices  
Table 1. Composition of digestive juices for the in vitro digestion model.  
Solutions§ Saliva Gastric jucie Duodenal juice Bile juice 
Inorganic 
solution 
10 mL KCl 89.6 g/L 
10 mL KSCN 20 g/L 
10 mL NaH2PO4 88.8 g/L 
10 mL NaSO4 57 g/L 
1.7 mL NaCl 175.3 g/L 
20 mL NaHCO3 84.7 g/L 
15.7 mL NaCl 175.3 g/L 
3.0 mL NaH2PO4 88.8 g/L 
9.2 mL KCl 89.6 g/L 
18 mL CaCl2 19.1 g/L 
10 mL NH4Cl 30.6 g/L 
6.5 mL HCl 37% g/g 
40 mL NaCl 175.3 g/L 
40 mL NaHCO3 84.7 g/L 
10 mL KH2PO4 8 g/L 
6.3 mL KCl 89.6 g/L 
10 mL MgCl2 5 g/L 
180 µL HCl 37% g/g 
30 mL NaCl 175.3 g/L 
68.3 mL NaHCO3 84.7 
g/L 
4.2 mL KCl 89.6 g/L 
150 µL HCl 37% g/g 
Organic solution 8 mL urea 25 g/L 
 
10 mL glucose 65 g/L 
10 mL glucuronic acid 2 g/L 
3.4 mL urea 25g/L 
10 mL glucosamine 
hydrochloride 33 g/L 
4 mL urea 25 g/L 
 
10 mL urea 25 g/L 
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Table 1. continued.  
Solutions§ Saliva Gastric jucie Duodenal juice Bile juice 
Add to mixture 
organic + 
inorganic 
solution 
 
290 mg α-amylase 
15 mg uric acid  
25 mg mucin 
1 gr BSA 
2.5 gr pepsin 
3 g mucin 
9 mL CaCl2 19.1 g/L 
1gr BSA 
9 g pancreatin 
1.5 g lipase 
10 mL CaCl2 19.1 g/L 
1,8 g BSA 
30 g bile 
 
pH 6.8 ± 0.2 1.30 ± 0.02 8.1 ± 0.2 8.2 ± 0.2 
§The inorganic and organic solutions are filled up to 500 mL with distilled water. After mixing the inorganic and organic solutions, 
some further constituents are added and dissolved. If necessary, the pH of the juices is adjusted to the appropriate value.  
Adapted from Versantvoort et al. (2014). 
 
 
 
